



(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 35/00 (2006.01)

A61K 31/437 (2006.01) A61P 37/00 (2006.01)

A61P 31/18 (2006.01)

(21) International Application Number:

PCT/GB2022/051167

(22) International Filing Date:

06 May 2022 (06.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2106486.0 06 May 2021 (06.05.2021) GB

(71) Applicant: **EXSCIENCIA AI LIMITED** [GB/GB]; The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB).

(72) Inventors: **RAY, Peter**; c/o Exscientia Limited, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB). **BRADLEY, Anthony**; c/o Exscientia Limited, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB). **RICHARDS, Simon**; c/o Exscientia Limited, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB). **SANTOS, Catarina**; c/o Exscientia Limited, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB). **BESNARD, Jeremy**; c/o Exscientia Limited, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB). **MENEYROL, Jérôme**; c/o Exscientia Limited, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB). **SUCHAUD, Virginie**; c/o Exscientia Limited, The Schrödinger Building, Oxford Science Park, Oxford OX4 4GE (GB).

(74) Agent: **CARPMAELS & RANSFORD LLP** et al.; One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,


AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PKC-THETA MODULATORS



(57) Abstract: Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of PKC-theta. Such compounds are represented by Formula I, wherein the variables are defined herein. I

PKC-theta Modulators

TECHNICAL FIELD

5

The present disclosure relates to novel compounds capable of modulating PKC-theta phosphorylation activity. Such phosphorylation activity may be inhibited by the compounds described herein. The present invention further describes the synthesis of the compounds and their uses as medicaments in diseases or disorders where PKC-theta modulation may be

10 beneficial.

BACKGROUND

Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a variety of signal transduction processes within the cell (see Hardie, G and Hanks, S. The Protein Kinase Facts Book, I and II, Academic Press, San Diego, CA: 1995).

15

The connection between abnormal protein phosphorylation and disease is well known. Accordingly, protein kinases are an important group of drug targets (see, for example, Cohen, Nature, vol. 1 (2002), pp 309-315, Gaestel et al. Curr. Med. Chem, 2007, pp 2214-223; Griminger et al. Nat. Rev. Drug Disc. vol. 9(12), 2010, pp 956-970).

20

Protein kinase C (hereafter PKC) is a family of serine- and threonine-specific protein kinases. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signalling pathways. Each member of the PKC family has a specific expression profile and is believed to have a distinct role.

25

The PKC members can be classified into three groups. Group I (Ca²⁺ and DAG (diacylglycerol) dependent): PKC- α , PKC- β I, PKC- β II and PKC- γ , Group II (Ca²⁺ independent): PKC- δ (hereafter PKC- δ), PKC- ϵ , PKC- η (or PKC- ϵ) and PKC- θ (hereafter PKC-theta). Group III (Ca²⁺ and DAG independent): PKC- ι , PKC- ζ and PKC- μ (Brezar et al 2015 Frontiers Immunol).

30

The expression of the PKC-theta isoform of PKC is enriched in T lymphocytes and plays an important role in the T-cell receptor (TCR)-triggered activation of T-cells. PKC-theta signals through transcription factors, including NF- κ B, NFAT and AP-1, leading to the release of cytokines such as IL-2 and IFN- γ , and subsequently T-cell proliferation, differentiation and survival (Brezar et al 2015 Front Immunol). Unlike broader biimmunosuppressive mechanisms,

35

including those displayed by the calcineurin inhibitors, PKC-theta inhibition has demonstrated a selective effect on the immune system (Brezar et al 2015 Front Immunol 6:530). Antiviral responses remain intact in mice lacking PKC-theta activity (Zhang et al Adv Pharm. 2013 ; 66: 267–31). In regulatory T-cells (Tregs), PKC-theta signalling is not absolutely required for
5 activation and function (Zhang et al. Adv Pharmacol. 2013 ; 66: 267–31). *Prkcd*^{-/-} mice have a reduced but significant proportion of circulating Tregs and Tregs isolated from *Prkcd*^{-/-} mice retain suppressive activity (Gupta, et al., 2008). Pharmacological inhibition of PKC-theta protected Tregs from inactivation by TNF α and enhanced protection of mice from inflammatory colitis (Zanin-Zhorov, et al., 2010). Indeed, evidence has emerged that PKC-theta is a negative
10 regulator of Tregs function (Zhang et al Adv Pharm. 2013 ; 66: 267–31).

In human disease, associations of the *Prkcd* locus specific single nucleotide polymorphisms (SNP) have been identified with type 1 diabetes (T1D), rheumatoid arthritis (RA), and celiac disease by genome-wide association studies (GWAS; Brezar et al 2015 Front Immunol 6:530).
15 Further, pharmacological inhibition of PKC θ rescued the defective activity of Tregs from rheumatoid arthritis patients (Zanin-Zhorov, et al., 2010).

PKC-theta activity is critically important in Th2 (allergic disease) and Th17 (autoimmune disease) responses and differentiation (Zhang et al Adv Pharm. 2013 ; 66: 267–31).). The *Prkcd*^{-/-} mouse
20 is protected in Th2 models of allergic lung inflammation and parasite infection. Likewise, lack of PKC-theta activity is protective in Th17-driven mouse models such as experimental autoimmune encephalomyelitis (EAE), adjuvant-induced arthritis, and colitis.

PKC-theta is also implicated in various types of cancers and the PKC-theta-mediated signalling events controlling cancer initiation and progression. In these types of cancers, the high PKC-
25 theta expression leads to aberrant cell proliferation, migration and invasion resulting in malignant phenotype (Nicolle, A et al., Biomolecules, 2021, 11, 221. Inhibition of PKC-theta may also benefit the treatment for cancers in which PKC-theta has been implicated.

30 Small molecule inhibitors of PKC-theta are known, for example inhibitors based on a pyrazolopyrimidine scaffold are described in WO 2011/139273, and WO 2015/095679 describes PKC-theta inhibitors based on a diaminopyrimidine core.


To date there is no effective and approved medical treatment available which is based on the
35 inhibition of PKC-theta, largely due to the difficulties of securing potent inhibition alongside suitable selectivity for the PKC-theta isoform over other isoforms, particularly PKC-delta in the PKC family (Group 2), and other kinases.

The present invention has been devised with the above observations in mind.

SUMMARY OF THE INVENTION

5

In one aspect of the invention there is provided a compound of Formula I:



10

I

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers, tautomer, or isotopic form, or pharmaceutically active metabolite thereof, or combinations thereof, wherein:

15 A is selected from the group consisting of: N, C-R^a, where R^a is selected from hydrogen, halogen, C1-3 alkyl and CN;

G is selected from the group consisting of: CR₁R₂; O and NR₁;

20 R₁ and R₂ are independently selected from the group consisting of: hydrogen, halogen, C1-3 alkyl; C3-7 cycloalkyl (e.g. CH₂^oPr); C1-3 alkoxy (e.g. OMe); C2-6 cycloalkoxy (e.g. O^oPr); C2-6 alkyl alkoxy (e.g. CH₂OMe), hydroxyl, C1-3 alkyl hydroxyl (e.g. CH₂OH), amino, C1-3 alkyl amino (e.g. CH₂NH₂); C1-4 amino alkyl (e.g. NHMe or N(Me)₂), C2-7 alkyl amino alkyl (e.g. CH₂NHMe or CH₂N(Me)₂); and C1-3 haloalkyl; or

25 R₁ and R₂ together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring; particularly a 4-5 membered optionally substituted carbocyclic or heterocyclic spiro ring; wherein in embodiments the carbocyclic or heterocyclic spiro ring is unsubstituted; wherein in alternative embodiments the carbocyclic or heterocyclic spiro ring is substituted with

one or more substituents selected from the group consisting of: C1-2 alkyl, halogen; C1-2 haloalkyl; hydroxy; and C1-2 alkoxy;


B is selected from the group consisting of: N; C-H and C-halogen (e.g. C-F, C-Cl, C-Br);

D is selected from the group consisting of: N and C-R3;

- 5 R3 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me, Et); C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃); C1-3 alkoxy (e.g. OMe); C2-5 alkyl alkoxy (e.g. CH₂OMe); and halogen (e.g. F, Cl, Br); and

R4 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃); OMe and halogen; or

- 10 wherein when D is C-R3, R3 and R4 together are joined to form an optionally substituted aryl or heteroaryl ring having the structure selected from the group consisting of:



wherein;

R7 is selected from the group consisting of: hydrogen and halogen;

- 15 R8 is selected from the group consisting of: hydrogen and halogen;

R9 is selected from the group consisting of: hydrogen; C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃) and halogen;

R10 is selected from the group consisting of: hydrogen; halogen; C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃); and C1-3 haloalkoxy (e.g. OCF₂H, OCF₃); and wherein:


- 20 n is selected from the group consisting of: 0 and 1;

E is selected from the group consisting of: C-H; and C-R^a, where R^a is selected from halogen; C1-3 alkyl; C1-3 alkyl hydroxyl (e.g. CH₂OH); C1-3 haloalkyl (e.g. CH₂F); C2-6 alkyl alkoxy (e.g. CH₂OMe) and C2-4 alkyl nitrile (e.g. CH₂CN);

R5 and R6 are joined together to form an optionally substituted, optionally bridged, 4-8-membered, suitably 5-7-membered, saturated carbocyclic or heterocyclic ring.

In embodiments, the compound according to the disclosure has the structural Formula II:


5



II

10


In embodiments, the compound according to the disclosure has the structural Formula IIa:



IIa

15

wherein, R17 is selected from the group consisting of:



wherein

- R11 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;
- 5 R12 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxyl; and C1-2 alkyl nitrile;
- R13 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;
- R14 is selected from the group consisting of: hydrogen and C1-2 alkyl;
- R15 is selected from the group consisting of: hydrogen and C1-2 alkyl;
- 10 R16 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxy; and C1-3 alkyl alkoxy;
- n is selected from the group consisting of: 0 and 1;
- p is selected from the group consisting of: 1 and 2;
- X is selected from the group consisting of: CH₂ and O;
- 15 Y is selected from the group consisting of: CH₂; O; NH and NMe.

In embodiments:

- R1 is selected from the group consisting of: hydrogen, Me, Et, OMe, OEt, OH, NH₂, NHMe and NHET;
- 20 R2 is selected from the group consisting of: hydrogen, Me and Et; or


- R1 and R2 together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring; particularly a 4-5 membered optionally substituted carbocyclic or heterocyclic spiro ring; wherein in embodiments the carbocyclic or heterocyclic spiro ring is unsubstituted; wherein in alternative embodiments the carbocyclic or heterocyclic spiro ring is substituted with
- 5 one or more substituents selected from the group consisting of: C1-2 alkyl, halogen; C1-2 haloalkyl; hydroxyl; and C1-2 alkoxy;

A is selected from the group consisting of: C-H; C-F; C-Cl and C-Br;

B is selected from the group consisting of: N; C-H, C-F; C-Cl and C-Br;

R17 is selected from the group consisting of:


10



wherein:

- R18 is selected from the group consisting of: hydrogen; and halogen;
- 15 R19 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxy;
- m is selected from the group consisting of: 0 and 1;
- R20 is selected from the group consisting of: hydrogen; halogen;
- X is selected from the group consisting of: CH₂ and O;
- 20 R21 and R22 are each independently selected from the group consisting of: hydrogen and C1-3 alkyl;
- Y is selected from the group consisting of: CH₂; O and NH;
- R23 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl.

In embodiments, the compound according to the disclosure has the structural Formula III:



III

5

wherein;


D is selected from the group consisting of: N; C-H and C-R3;

R3 is selected from the group consisting of: C1-3 alkyl; C2-5 alkyl alkoxy; C1-3 haloalkyl and halogen;


10 R4 is selected from the group consisting of: hydrogen; C1-3 alkyl; C2-5 alkyl alkoxy; C1-3 haloalkyl and halogen.

In embodiments, the compound according to the disclosure has the structural Formula IIIa, IIIb or IIIc:


15



IIIa



IIIb




IIIc

5

wherein,

R17 is selected from the group consisting of:



wherein

10

R11 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;

R12 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxyl; and C1-2 alkyl nitrile;

R13 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;

R14 is selected from the group consisting of: hydrogen and C1-2 alkyl;

R15 is selected from the group consisting of: hydrogen and C1-2 alkyl;

R16 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-

5 3 alkyl hydroxyl; and C1-3 alkyl alkoxy;

n is selected from the group consisting of: 0 and 1;

p is selected from the group consisting of: 1 and 2;

X is selected from the group consisting of: CH₂ and O;

Y is selected from the group consisting of: CH₂, O, NH and NMe.

10

In embodiments,

R1 is selected from the group consisting of: hydrogen, Me, Et, OMe, OH, NH₂, and NHMe;

15


R2 is selected from the group consisting of: hydrogen; Me; and Et; or

R1 and R2 together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring;

A is selected from the group consisting of: C-H, C-F, C-Cl and C-Br;

R17 is selected from the group consisting of:

20



wherein:

R18 is selected from the group consisting of: hydrogen and halogen;

R19 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl and hydroxyl;

m is selected from the group consisting of: 0 and 1;

R20 is selected from the group consisting of: hydrogen and halogen;

5 X is selected from the group consisting of: CH₂; and O;

R21 and R22 are each independently selected from the group consisting of: hydrogen and C1-3 alkyl;

Y is selected from the group consisting of: CH₂; O and NH;

R23 is selected from the group consisting of: hydrogen; C1-3 alkyl; and C1-3 haloalkyl.

10

In another aspect the invention provides a pharmaceutical composition comprising a compound according to this disclosure or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers, tautomer, or isotopic form, or pharmaceutically active metabolite thereof, or combinations thereof, and one or more pharmaceutically acceptable carrier.

15

In another aspect the invention provides the compound according to this disclosure or the pharmaceutical composition according to this disclosure for use in the treatment of a disorder or disease selected from autoimmune disorders and/or inflammatory diseases and/or oncologic disease and/or cancers and/or HIV infection and replication. Suitably, the disorder or disease is selected from the group consisting of: rheumatoid arthritis, multiple sclerosis, psoriasis, atopic dermatitis.

20

In embodiments, the compound or pharmaceutical composition for use according to this disclosure is an inhibitor of PKC- θ .

25

In embodiments, the use is in a method comprising administering the compound orally, topically, by inhalation, by intranasal administration, or systemically by intravenous, intraperitoneal, subcutaneous, or intramuscular injection. In embodiments, the use is in a method comprising administering the compound according to this disclosure in combination with one or more additional therapeutic agents. In embodiments, the administering comprises administering the compound according to this disclosure simultaneously, sequentially or separately from the one or more additional therapeutic agent.

30

In embodiments, the use comprises administering to a subject an effective amount of the compound according to this disclosure, wherein the effective amount is between about 5 nM and about 10 μ M in the blood of the subject.

35

In another aspect of the invention there is provided a method of treating or preventing PKC-theta mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta. In embodiments, the disease may be a disease associated with autoimmunity, inflammatory disease, cancer and/or oncologic disease and/or oncologic disease and/or cancers
5 and/or HIV infection and replication (particularly autoimmune disorders and inflammatory diseases) in a subject in need thereof. Suitably, the disorder or disease is selected from the group consisting of: rheumatoid arthritis, multiple sclerosis, psoriasis, atopic dermatitis.

In embodiments, the method comprises administering a compound according to this disclosure
10 or a pharmaceutical composition according to this disclosure. Suitably the compound is, or the pharmaceutical composition comprises, an inhibitor of PKC-theta.

In embodiments, the method comprises administering the compound or pharmaceutical composition orally, topically, by inhalation, by intranasal administration, or systemically by
15 intravenous, intraperitoneal, subcutaneous, or intramuscular injection. In embodiments, method comprises administering the compound according to this disclosure or pharmaceutical composition according to this disclosure in combination with one or more additional therapeutic agents. In embodiments, the administering comprises administering the compound according to this disclosure or pharmaceutical composition according to this disclosure simultaneously,
20 sequentially or separately from the one or more additional therapeutic agent.

In embodiments, the method comprises administering to a subject an effective amount of the compound according to this disclosure, wherein the effective amount is between about 5 nM and about 10 μ M in the blood of the subject.

25 Within the scope of this application, it is expressly intended that the various aspects, embodiments, examples and alternatives set out in the preceding paragraphs, in the claims and/or in the following description and drawings, and in particular the individual features thereof, may be taken independently or in any combination. That is, all embodiments and/or features of
30 any embodiment can be combined in any way and/or combination, unless such features are incompatible. More particularly, it is specifically intended that any embodiment of any aspect may form an embodiment of any other aspect, and all such combinations are encompassed within the scope of the invention. The applicant reserves the right to change any originally filed claim or file any new claim, accordingly, including the right to amend any originally filed claim to depend on
35 and/or incorporate any feature of any other claim although not originally claimed in that manner.

DETAILED DESCRIPTION

Described herein are compounds and compositions (e.g., organic molecules, research tools, pharmaceutical formulations and therapeutics); uses for the compounds and compositions of the disclosure (*in vitro* and *in vivo*); as well as corresponding methods, whether diagnostic, therapeutic or for research applications. The chemical synthesis and biological testing of the compounds of the disclosure are also described. Beneficially, the compounds, compositions, uses and methods have utility in research towards and/or the treatment of diseases or disorders in animals, such as humans. Diseases or disorders which may benefit from PKC-theta modulation include, for example, autoimmune disorder, inflammatory disease, cancer and/or oncologic disease and/or HIV infection and replication, such as rheumatoid arthritis, multiple sclerosis, psoriasis, asthma, atopic dermatitis and Crohn's disease.

The compounds may also or alternatively be useful as lead molecules for the selection, screening and development of further derivatives that may have one or more improved beneficial drug property, as desired. Such further selection and screening may be carried out using the proprietary computational evolutionary algorithm described e.g. in the Applicant's earlier published patent application WO 2011/061548, which is hereby incorporated by reference in its entirety.

The disclosure also encompasses salts, solvates and functional derivatives of the compounds described herein. These compounds may be useful in the treatment of diseases or disorders which may benefit from PKC-theta modulation, such as the autoimmune disorders, inflammatory diseases, cancers and/or oncologic diseases and/or HIV infection and replication identified herein.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g. in organic, physical or theoretical chemistry; biochemistry and molecular biology).

Unless otherwise indicated, the practice of the present invention employs conventional techniques in chemistry and chemical methods, biochemistry, molecular biology, pharmaceutical formulation, and delivery and treatment regimens for patients, which are within the capabilities of a person of ordinary skill in the art. Such techniques are also described in the literature cited herein. All documents cited in this disclosure are herein incorporated by reference in their entirety.

Prior to setting forth the detailed description of the invention, a number of definitions are provided that will assist in the understanding of the disclosure.

5 In accordance with this disclosure, the terms 'molecule' or 'molecules' are used interchangeably with the terms 'compound' or 'compounds', and sometimes the term 'chemical structure'. The term 'drug' is typically used in the context of a pharmaceutical, pharmaceutical composition, medicament or the like, which has a known or predicted physiological or *in vitro* activity of medical significance; but such characteristics and qualities are not excluded in a molecule or compound of the disclosure. The term 'drug' is therefore used interchangeably with the alternative terms and
10 phrases 'therapeutic (agent)', 'pharmaceutical (agent)', and 'active (agent)'. Therapeutics according to the disclosure also encompass compositions and pharmaceutical formulations comprising the compounds of the disclosure.

Prodrugs and solvates of the compounds of the disclosure are also encompassed within the
15 scope of the disclosure. The term 'prodrug' means a compound (e.g. a drug precursor) that is transformed *in vivo* to yield a compound of the disclosure or a pharmaceutically acceptable salt, solvate or ester of the compound. The transformation may occur by various mechanisms (e.g. by metabolic or chemical processes), such as by hydrolysis of a hydrolysable bond, e.g. in blood (see Higuchi & Stella (1987), "Pro-drugs as Novel Delivery Systems", vol. 14 of the A.C.S.
20 Symposium Series; (1987), "Bioreversible Carriers in Drug Design", Roche, ed., American Pharmaceutical Association and Pergamon Press). The compositions and medicaments of the disclosure therefore may comprise prodrugs of the compounds of the disclosure. In some aspects and embodiments the compounds of the disclosure are themselves prodrugs which may be metabolised *in vivo* to give the therapeutically effective compound.

25 The invention also includes various deuterated forms of the compounds of any of the Formulas disclosed herein, including Formulas (I), (II), or (III) (inc. corresponding subgeneric formulas defined herein), respectively, or a pharmaceutically acceptable salt and/or a corresponding tautomer form thereof (including subgeneric formulas, as defined above) of the present invention.
30 Each available hydrogen atom attached to a carbon atom may be independently replaced with a deuterium atom. A person of ordinary skill in the art will know how to synthesize deuterated forms of the compounds of any of the Formulas disclosed herein, including Formulas (I), (II), or (III) (inc. corresponding subgeneric formulas defined herein), respectively, or a pharmaceutically acceptable salt and/or a corresponding tautomer form thereof (including subgeneric formulas, as
35 defined above) of the present invention. For example, deuterated materials, such as alkyl groups may be prepared by conventional techniques (see for example: methyl-d₃ -amine available from Aldrich Chemical Co., Milwaukee, WI, Cat. No.489,689-2).

The subject invention also includes isotopically-labelled compounds which are identical to those recited in any of the Formulas disclosed herein, including Formulas (I), (II), or (III) (inc. corresponding subgeneric formulas defined herein), respectively, or a pharmaceutically acceptable salt and/or a corresponding tautomer form thereof (including subgeneric formulas, as defined above) of the present invention but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, iodine and chlorine such as ^3H , ^{11}C , ^{14}C , ^{18}F , ^{123}I or ^{125}I . Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically labelled compounds of the present invention, for example those into which radioactive isotopes such as ^3H or ^{14}C have been incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e. ^3H , and carbon-14, i.e. ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. ^{11}C and ^{18}F isotopes are particularly useful in PET (positron emission tomography).

In the context of the present disclosure, the terms 'individual', 'subject', or 'patient' are used interchangeably to indicate an animal that may be suffering from a medical (pathological) condition and may be responsive to a molecule, pharmaceutical drug, medical treatment or therapeutic treatment regimen of the disclosure. The animal is suitably a mammal, such as a human, cow, sheep, pig, dog, cat, bat, mouse or rat. In particular, the subject may be a human.

The term 'alkyl' refers to a monovalent, optionally substituted, saturated aliphatic hydrocarbon radical. Any number of carbon atoms may be present, but typically the number of carbon atoms in the alkyl group may be from 1 to about 20, from 1 to about 12, from 1 to about 6 or from 1 to about 4. Usefully, the number of carbon atoms is indicated, for example, a C_{1-12} alkyl (or C_{1-12} alkyl) refers to any alkyl group containing 1 to 12 carbon atoms in the chain. An alkyl group may be a straight chain (i.e. linear), branched chain, or cyclic. 'Lower alkyl' refers to an alkyl of 1 to 6 carbon atoms in the chain, and may have from 1 to 4 carbon atoms, or 1 to 2 carbon atoms. Thus, representative examples of lower alkyl radicals include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, isopentyl, amyl (C_5H_{11}), sec-butyl, tert-butyl, sec-amyl, tert-pentyl, 2-ethylbutyl, 2,3-dimethylbutyl, and the like. 'Higher alkyl' refers to alkyls of 7 carbons and above, including n-heptyl, n-octyl, n-nonyl, n-decyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, n-eicosyl, and the like, along with branched variations thereof. A linear carbon chain of say 4 to 6 carbons would refer to the chain length not including any carbons residing on a

branch, whereas in a branched chain it would refer to the total number. Optional substituents for alkyl and other groups are described below.

The term 'substituted' means that one or more hydrogen atoms (attached to a carbon or heteroatom) is replaced with a selection from the indicated group of substituents, provided that the designated atom's normal valency under the existing circumstances is not exceeded. The group may be optionally substituted with particular substituents at positions that do not significantly interfere with the preparation of compounds falling within the scope of this invention and on the understanding that the substitution(s) does not significantly adversely affect the biological activity or structural stability of the compound. Combinations of substituents are permissible only if such combinations result in stable compounds. By 'stable compound' or 'stable structure', it is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and/or formulation into an efficacious therapeutic agent. By 'optionally substituted' it is meant that the group concerned is either unsubstituted, or at least one hydrogen atom is replaced with one of the specified substituent groups, radicals or moieties.

Any radical / group / moiety described herein that may be substituted (or optionally substituted) may be substituted with one or more (e.g. one, two, three, four or five) substituents, which are independently selected from the designated group of substituents. Thus, substituents may be selected from the group: halogen (or 'halo', e.g. F, Cl and Br), hydroxyl (-OH), amino or aminyl (-NH₂), thiol (-SH), cyano (-CN), (lower) alkyl, (lower) alkoxy, (lower) alkenyl, (lower) alkynyl, aryl, heteroaryl, (lower) alkylthio, oxo, haloalkyl, hydroxyalkyl, nitro (-NO₂), phosphate, azido (-N₃), alkoxycarbonyl, carboxy, alkylcarboxy, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, thioalkyl, alkylsulfonyl, arylsulfinyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, alkylcarbonylamino, arylcarbonylamino, cycloalkyl, heterocycloalkyl, unless otherwise indicated. Alternatively, where the substituents are on an aryl or other cyclic ring system, two adjacent atoms may be substituted with a methylenedioxy or ethylenedioxy group. More suitably, the substituents are selected from: halogen, hydroxy, amino, thiol, cyano, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkenyl, (C₁-C₆)alkynyl, aryl, aryl(C₁-C₆)alkyl, aryl(C₁-C₆)alkoxy, heteroaryl, (C₁-C₆)alkylthio, oxo, halo(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, nitro, phosphate, azido, (C₁-C₆)alkoxycarbonyl, carboxy, (C₁-C₆)alkylcarboxy, (C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, amino(C₁-C₆)alkyl, (C₁-C₆)alkylamino(C₁-C₆)alkyl, di(C₁-C₆)alkylamino(C₁-C₆)alkyl, thio(C₁-C₆)alkyl, (C₁-C₆)alkylsulfonyl, arylsulfinyl, (C₁-C₆)alkylaminosulfonyl, arylaminosulfonyl, (C₁-C₆)alkylsulfonylamino, arylsulfonylamino, carbamoyl, (C₁-C₆)alkylcarbamoyl, di(C₁-C₆)alkylcarbamoyl, arylcarbamoyl, (C₁-C₆)alkylcarbonylamino, arylcarbonylamino, (C₁-C₆)cycloalkyl, and heterocycloalkyl. Still more suitably, the substituents are selected from one or

more of: fluoro, chloro, bromo, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)alkoxy, (C₅-C₆)aryl, a 5- or 6-membered heteroaryl, (C₄-C₆)cycloalkyl, a 4- to 6-membered heterocycloalkyl, cyano, (C₁-C₆)alkylthio, amino, -NH(alkyl), -NH((C₁-C₆)cycloalkyl), -N((C₁-C₆)alkyl)₂, -OC(O)-(C₁-C₆)alkyl, -OC(O)-(C₅-C₆)aryl, -OC(O)-(C₁-C₆)cycloalkyl, carboxy and -C(O)O-(C₁-C₆)alkyl. Most suitably, the substituents are selected from one or more of: fluoro, chloro, bromo, hydroxy, amino, (C₁-C₆)alkyl and (C₁-C₆)alkoxy, wherein alkyl and alkoxy are optionally substituted by one or more chloro. Particularly preferred substituents are: chloro, methyl, ethyl, methoxy and ethoxy.

The term 'halo' or 'halogen' refers to a monovalent halogen radical chosen from chloro, bromo, iodo, and fluoro. A 'halogenated' compound is one substituted with one or more halo substituent. Preferred halo groups are F, Cl and Br, and most preferred is F.

When used herein, the term 'independently', in reference to the substitution of a parent moiety with one or more substituents, means that the parent moiety may be substituted with any of the listed substituents, either individually or in combination, and any number of chemically possible substituents may be used. In any of the embodiments, where a group is substituted, it may contain up to 5, up to 4, up to 3, or 1 and 2 substituents. As a non-limiting example, useful substituents include: phenyl or pyridine, independently substituted with one or more lower alkyl, lower alkoxy or halo substituents, such as: chlorophenyl, dichlorophenyl, trichlorophenyl, tolyl, xylyl, 2-chloro-3-methylphenyl, 2,3-dichloro-4-methylphenyl, etc.

As used herein, the term 'alkylene' or 'alkylenyl' means a difunctional group obtained by removal of a hydrogen atom from an alkyl group as defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene. 'Lower alkylene' means an alkylene having from 1 to 6 carbon atoms in the chain, and may be straight or branched. Alkylene groups are optionally substituted.

The term 'alkenyl' refers to a monovalent, optionally substituted, unsaturated aliphatic hydrocarbon radical. Therefore, an alkenyl has at least one carbon-carbon double bond (C=C). The number of carbon atoms in the alkenyl group may be indicated, such as from 2 to about 20. For example, a C₂₋₁₂ alkenyl (or C₂₋₁₂ alkenyl) refers to an alkenyl group containing 2 to 12 carbon atoms in the structure. Alkenyl groups may be straight (i.e. linear), branched chain, or cyclic. 'Lower alkenyl' refers to an alkenyl of 1 to 6 carbon atoms, and may have from 1 to 4 carbon atoms, or 1 to 2 carbon atoms. Representative examples of lower alkenyl radicals include ethenyl, 1-propenyl, 1-butenyl, 1-pentenyl, 1-hexenyl, isopropenyl, isobutenyl, and the like. Higher alkenyl refers to alkenyls of seven carbons and above, such as 1-heptenyl, 1-octenyl, 1-nonenyl, 1-decenyl, 1-dodecenyl, 1-tetradecenyl, 1-hexadecenyl, 1-octadecenyl, 1-eicosenyl,

and the like, along with branched variations thereof. Optional substituents include are described elsewhere.

5 'Alkenylene' means a difunctional group obtained by removal of a hydrogen from an alkenyl group that is defined above. Non-limiting examples of alkenylene include -CH=CH-, -C(CH₃)=CH-, and -CH=CHCH₂-

'Alkynyl' and 'lower alkynyl' is defined similarly to the term 'alkenyl', except that it includes at least one carbon-carbon triple bond.

10

The term 'alkoxy' refers to a monovalent radical of the formula RO-, where R is any alkyl, alkenyl or alkynyl as defined herein. Alkoxy groups may be optionally substituted by any of the optional substituents described herein. 'Lower alkoxy' has the formula RO-, where the R group is a lower alkyl, alkenyl or alkynyl. Representative alkoxy radicals include methoxy, ethoxy, n-propoxy, n-butoxy, n-pentyloxy, n-hexyloxy, isopropoxy, isobutoxy, isopentyloxy, amyloxy, sec-butoxy, tert-butoxy, tert-pentyloxy, and the like. Preferred alkoxy groups are methoxy and ethoxy.

15

The term 'aryl' as used herein refers to a substituted or unsubstituted aromatic carbocyclic radical containing from 5 to about 15 carbon atoms; and preferably 5 or 6 carbon atoms. An aryl group may have only one individual carbon ring, or may comprise one or more fused rings in which at least one ring is aromatic in nature. A 'phenyl' is a radical formed by removal of a hydrogen atom from a benzene ring, and may be substituted or unsubstituted. A 'phenoxy' group, therefore, is a radical of the formula RO-, wherein R is a phenyl radical. 'Benzyl' is a radical of the formula R-CH₂-, wherein R is phenyl, and 'benzyloxy' is a radical of the formula RO-, wherein R is benzyl.

20 Non-limiting examples of aryl radicals include, phenyl, naphthyl, benzyl, biphenyl, furanyl, pyridinyl, indanyl, anthraquinolyl, tetrahydronaphthyl, a benzoic acid radical, a furan-2-carboxylic acid radical, and the like.

25

A 'heteroaryl' group is herein defined as a substituted or unsubstituted 'aryl' group in which one or more carbon atoms in the ring structure has been replaced with a heteroatom, such as nitrogen, oxygen or sulphur. Generally, the heteroaryl group contains one or two heteroatoms. A preferred heteroatom is N. Exemplary heteroaryl groups include: furan, benzofuran, isobenzofuran, pyrrole, indole, isoindole, thiophene, benzothiophene, benzo[c]thiophene, imidazole, benzimidazole, purine, pyrazole, indazole, oxazole, benzoxazole, isoxazole, benzisoxazole, thiazole, benzothiazole, pyridine, quinoline, isoquinoline, pyrazine, quinoxaline, acridine, pyrimidine, quinazoline, pyridazine and cinnoline.


30
35

The terms 'heterocycle' or 'heterocyclic' group as used herein refer to a monovalent radical of from about 4- to about 15- ring atoms, and preferably 4-, 5- or 6,7- ring members. Generally the heterocyclic group contains one, two or three heteroatoms, selected independently from nitrogen, oxygen and sulphur. A preferred heteroatom is N. A heterocyclic group may have only one individual ring or may comprise one or more fused rings in which at least one ring contains a heteroatom. It may be fully saturated or partially saturated and may be substituted or unsubstituted as in the case of aryl and heteroaryl groups. Representative examples of unsaturated 5-membered heterocycles with only one heteroatom include 2- or 3-pyrrolyl, 2- or 3-furanyl, and 2- or 3-thiophenyl. Corresponding partially saturated or fully saturated radicals include 3-pyrrolin-2-yl, 2- or 3-pyrrolindinyl, 2- or 3-tetrahydrofuranyl, and 2- or 3-tetrahydrothiophenyl. Representative unsaturated 5-membered heterocyclic radicals having two heteroatoms include imidazolyl, oxazolyl, thiazolyl, pyrazolyl, and the like. The corresponding fully saturated and partially saturated radicals are also included. Representative examples of unsaturated 6-membered heterocycles with only one heteroatom include 2-, 3-, or 4-pyridinyl, 2H-pyran-2-yl, and 4H-pyran-2-yl. Corresponding partially saturated or fully saturated radicals include 2-, 3-, or 4-piperidinyl, 2-, 3-, or 4-tetrahydropyran-2-yl and the like. Representative unsaturated 6-membered heterocyclic radicals having two heteroatoms include 3- or 4-pyridazinyl, 2-, 4-, or 5-pyrimidinyl, 2-pyrazinyl, morpholino, and the like. The corresponding fully saturated and partially saturated radicals are also included, e.g. 2-piperazine. The heterocyclic radical is bonded through an available carbon atom or heteroatom in the heterocyclic ring directly to the entity or through a linker such as an alkylene such as methylene or ethylene.

Unless defined otherwise, 'room temperature' is intended to mean a temperature of from about 18 to 28°C, typically between about 18 and 25°C, and more typically between about 18 and 22°C. As used herein, the phrase 'room temperature' may be shortened to 'rt' or 'RT'.

Molecules and Compounds

Disclosed herein is a compound having the structural Formula I:



5

I

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers, tautomer, or isotopic form, or pharmaceutically active metabolite thereof, or combinations thereof, wherein:

A is selected from the group consisting of: N, C-R^a, where R^a is selected from hydrogen, halogen, C1-3 alkyl and CN;

G is selected from the group consisting of: CR¹R²; O and NR¹;

R¹ and R² are independently selected from the group consisting of: hydrogen, halogen, C1-3 alkyl; C3-7 cycloalkyl (e.g. CH₂^oPr); C1-3 alkoxy (e.g. OMe); C2-6 cycloalkoxy (e.g. O^oPr); C2-6 alkyl alkoxy (e.g. CH₂OMe), hydroxyl, C1-3 alkyl hydroxyl (e.g. CH₂OH), amino, C1-3 alkyl amino (e.g. CH₂NH₂); C1-4 amino alkyl (e.g. NHMe or N(Me)₂), C2-7 alkyl amino alkyl (e.g. CH₂NHMe or CH₂N(Me)₂); C1-3 haloalkyl; or

R¹ and R² together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring; particularly a 4-5 membered optionally substituted carbocyclic or heterocyclic spiro ring; wherein in embodiments the carbocyclic or heterocyclic spiro ring is unsubstituted; wherein in alternative embodiments the carbocyclic or heterocyclic spiro ring is substituted with one or more substituents selected from the group consisting of: C1-2 alkyl, halogen; C1-2 haloalkyl; hydroxyl and C1-2 alkoxy;


B is selected from the group consisting of: N; C-H and C-halogen (e.g. C-F, C-Cl, C-Br);

D is selected from the group consisting of: N and C-R³;

R3 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me, Et); C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃); C1-3 alkoxy (e.g. OMe); C2-5 alkyl alkoxy (e.g. CH₂OMe); and halogen (e.g. F, Cl, Br); and

- R4 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃); OMe and halogen; or

wherein when D is C-R3, R3 and R4 together are joined to form an optionally substituted aryl or heteroaryl ring having the structure selected from the group consisting of:



wherein;

- 10 R7 is selected from the group consisting of: hydrogen and halogen;
R8 is selected from the group consisting of: hydrogen and halogen;
R9 is selected from the group consisting of: hydrogen; C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃) and halogen;

- R10 is selected from the group consisting of: hydrogen; halogen; C1-3 halo alkyl (e.g. CF₂H, CF₃; CH₂CF₃); C1-3 haloalkoxy (e.g. OCFH₂, OCF₂H, OCF₃); and


wherein:

n is selected from the group consisting of: 0 and 1;

- E is selected from the group consisting of: C-H; and C-R^a, where R^a is selected from halogen; C1-3 alkyl; C1-3 alkyl hydroxy (e.g. CH₂OH); C1-3 haloalkyl (e.g. CH₂F); C2-6 alkyl alkoxy (e.g. CH₂OMe) and C2-4 alkyl nitrile (e.g. CH₂CN);


R5 and R6 are joined together to form an optionally substituted, optionally bridged, 4-8-membered, suitably 5-7-membered, saturated carbocyclic or heterocyclic ring.

In specific embodiments of Formula I, D is C-R3, and R3 and R4 together are joined to form an optionally substituted aryl ring having the structure:



i.e. compounds of the general Formula II:


5



II

10 wherein, A, B, E, G, R1, R2, R5, R6, R7, R8, R9, R10 and n are defined as for Formula I.


In specific embodiments of Formula II, compounds have the structure of Formula IIa:



IIa

wherein, A, B, E, R1, R2, R5, R6, R7, R8, R9, R10 and n are defined as for Formula I;

5 R17 is selected from the group consisting of:



wherein

R11 is selected from the group consisting of: hydrogen; halogen (e.g. F) and C1-2 alkyl (e.g. Me);

10

R12 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me); C1-3 haloalkyl (e.g. CH₂F); C1-3 alkyl hydroxy (e.g. CH₂OH); and C1-2 alkyl nitrile (e.g. CH₂CN);

R13 is selected from the group consisting of: hydrogen; halogen (e.g. F) and C1-2 alkyl (e.g. Me);

5 R14 is selected from the group consisting of: hydrogen and C1-2 alkyl (e.g. Me);

R15 is selected from the group consisting of: hydrogen and C1-2 alkyl (e.g. Me);

R16 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me); C1-3 haloalkyl (e.g. -CH₂CH₂F, CH₂CHF₂, CH₂CF₃); C1-3 alkyl hydroxy (e.g. CH₂OH); and C1-3 alkyl alkoxy (e.g. CH₂OMe);

10 n is selected from the group consisting of: 0 and 1;

p is selected from the group consisting of: 1 and 2;

X is selected from the group consisting of: CH₂ and O;

Y is selected from the group consisting of: CH₂, O, NH and NMe.

15

In specific embodiments of Formula IIa, E, R5, R6, R7, R8, R9 and R10 are as for Formula I;

R1 is selected from the group consisting of: hydrogen, Me, Et, OMe, OEt, OH, NH₂, NHMe and NHEt; and

R2 is selected from the group consisting of: hydrogen, Me and Et; or

20

R1 and R2 together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring; particularly a 4-5 membered optionally substituted carbocyclic or heterocyclic spiro ring; wherein in embodiments the carbocyclic or heterocyclic spiro ring is unsubstituted; wherein in alternative embodiments the carbocyclic or heterocyclic spiro ring is substituted with one or more substituents selected from the group consisting of: C1-2 alkyl, halogen; C1-2 haloalkyl; hydroxyl; and C1-2 alkoxy;


25

A is selected from the group consisting of: C-H; C-F; C-Cl and C-Br;

B is selected from the group consisting of: N; C-H and C-halogen (e.g. C-F; C-Cl and C-Br);

R17 is selected from the group consisting of:

30



wherein:

R18 is selected from the group consisting of: hydrogen and halogen (e.g. F);

R19 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me); C1-3

5 haloalkyl (e.g. CH_2F); C1-3 alkyl hydroxyl (e.g. CH_2OH);

m is selected from the group consisting of: 0 and 1;

R20 is selected from the group consisting of: hydrogen and halogen (e.g. F);

X is selected from the group consisting of: CH_2 and O;

R21 and R22 are each independently selected from the group consisting of: hydrogen;


10 and C1-3 alkyl (e.g. Me);

Y is selected from the group consisting of: CH_2 , O and NH;

R23 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me) and C1-3

haloalkyl (e.g. $-\text{CH}_2\text{CH}_2\text{F}$, CH_2CHF_2 , CH_2CF_3).

15 In alternative embodiments of Formula I, compounds have the general Formula III:



III

wherein, A, B, E, G, R1, R2, R5, R6 and n are defined as for Formula I, II, or IIa;

5 D is selected from the group consisting of: N; C-H and C-R3;




R3 is selected from the group consisting of: C1-3 alkyl; C2-5 alkyl alkoxy (e.g. OMe); C1-3 haloalkyl (e.g. CF₃) and halogen;

R4 is selected from the group consisting of: hydrogen; C1-3 alkyl; C2-5 alkyl alkoxy (e.g. OMe); C1-3 haloalkyl (e.g. CF₃) and halogen.

10


In specific embodiments of Formula III, G is CR₁R₂ and one of B or D is N, the other being C-H; or B and D are C-H, i.e. compounds having the structure of Formula IIIa, IIIb or IIIc:

15



5

wherein, A, R1, R2, R3, R4, E, R5, R6 and n are defined as for Formula III;
 R17 is selected from the group consisting of:



wherein

R11 is selected from the group consisting of: hydrogen; halogen (e.g. F) and C1-2 alkyl (e.g. Me);

5 R12 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me); C1-3 haloalkyl (e.g. CH₂F); C1-3 alkyl hydroxy (e.g. CH₂OH); and C1-2 alkyl nitrile (e.g. CH₂CN)

R13 is selected from the group consisting of: hydrogen; halogen (e.g. F) and C1-2 alkyl (e.g. Me);

R14 is selected from the group consisting of: hydrogen and C1-2 alkyl (e.g. Me);

10 R15 is selected from the group consisting of: hydrogen and C1-2 alkyl (e.g. Me);

R16 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me); C1-3 haloalkyl (e.g. -CH₂CH₂F, CH₂CHF₂, CH₂CF₃); C1-3 alkyl hydroxyl (e.g. CH₂OH); and C1-3 alkyl alkoxyl (e.g. CH₂OMe);

n is selected from the group consisting of: 0 and 1;

15 p is selected from the group consisting of: 1 and 2;

X is selected from the group consisting of: CH₂ and O;

Y is selected from the group consisting of: CH₂, O, NH and NMe.

20 In specific embodiments of Formula IIIa, IIIb and IIIc, A and n are as for Formula III, and

R1 is selected from the group consisting of: hydrogen, Me, Et, OMe, OH, NH₂, and NHMe; and


R2 is selected from the group consisting of: hydrogen; Me; and Et; or

- R1 and R2 together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring; particularly a 4-5 membered optionally substituted carbocyclic or heterocyclic spiro ring (e.g. cyclobutene, cyclopentane, tetrahydrofuran); wherein in embodiments the carbocyclic or heterocyclic spiro ring is unsubstituted; wherein in alternative embodiments the carbocyclic or heterocyclic spiro ring is substituted with one or more substituents selected from the group consisting of: C1-2 alkyl, halogen; C1-2 haloalkyl; hydroxy; and C1-2 alkoxy;

A is selected from the group consisting of: C-H, C-F, C-Cl and C-Br;

R17 is selected from the group consisting of:

10







wherein:



- R18 is selected from the group consisting of: hydrogen and halogen (e.g. F);
- 15 R19 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me); C1-3 haloalkyl (e.g. CH₂F); and C1-3 alkyl hydroxy (e.g. CH₂OH);
- m is selected from the group consisting of: 0 and 1;
- R20 is selected from the group consisting of: hydrogen and halogen (e.g. F);
- X is selected from the group consisting of: CH₂ and O;
- 20 R21 and R22 are each independently selected from the group consisting of: hydrogen and C1-3 alkyl (e.g. Me);
- Y is selected from the group consisting of: CH₂; O and NH;
- R23 is selected from the group consisting of: hydrogen; C1-3 alkyl (e.g. Me) and C1-3 haloalkyl (e.g. -CH₂CH₂F, CH₂CHF₂, CH₂CF₃).



In another aspect the invention provides a pharmaceutical composition comprising a compound according to this disclosure.



- 5 The compounds of the invention may have the structure as described below:



Example no.	Structure	Synthesis route	M+H	NMR
1		pyrazole	285.2	¹ H NMR (DMSO-d ₆ , 500 MHz): δ (ppm) 11.52 (br d, J = 1.7 Hz, 1H), 10.95 (s, 1H), 8.78-9.19 (m, 2H), 8.51 (s, 1H), 8.18 (s, 1H), 7.86 (d, J = 5.6 Hz, 1H), 7.25 (d, J = 5.6 Hz, 1H), 4.53 (tt, J = 10.8, 4.1 Hz, 1H), 3.96 (br s, 1H), 3.40 (br d, J = 13.0 Hz, 2H), 3.07-3.16 (m, 2H), 2.25-2.33 (m, 2H), 2.13-2.24 (m, 2H)
2		pyrazole	299.3	¹ H NMR (DMSO-d ₆ , 500 MHz): δ (ppm) 11.45 (br s, 1H), 10.85 (br s, 1H), 9.07 (br s, 1H), 8.77 (br s, 1H), 8.05 (s, 1H), 7.88 (d, J = 5.6 Hz, 1H), 6.99 (d, J = 5.6 Hz, 1H), 4.39-4.47 (m, 1H), 4.22 (br s, 1H), 3.40 (br d, J = 13.0 Hz, 2H), 3.03-3.15 (m, 2H), 2.29 (s, 3H), 2.12-2.27 (m, 4H)



3		pyrrole	284.2	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.77 (br s, 1H), 10.97 (br s, 1H), 9.08 (br s, 1H), 8.89 (br s, 1H), 7.82 (d, J = 5.9 Hz, 1H), 7.64 (s, 1H), 7.22 (d, J = 5.9 Hz, 1H), 7.00 (t, J = 2.2 Hz, 1H), 6.70 (br s, 1H), 4.28 (tt, J = 11.4, 3.6 Hz, 1H), 3.53 (br s, 1H), 3.36-3.46 (m, 2H), 3.05 (q, J = 12.1 Hz, 2H), 2.23 (br d, J = 12.5 Hz, 2H), 2.06-2.18 (m, 2H)
4		pyrrole	328.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.24 (s, 1H), 10.76 (br s, 1H), 7.78 (d, J = 5.6 Hz, 1H), 7.69 (d, J = 1.9 Hz, 1H), 7.10 (d, J = 5.6 Hz, 1H), 6.62 (d, J = 1.9 Hz, 1H), 4.40 (s, 2H), 4.06 (tt, J = 11.7, 4.0 Hz, 1H), 3.22 (s, 3H), 3.06-3.16 (m, 2H), 2.65 (br t, J = 11.7 Hz, 2H), 2.68 (br s, 1H), 1.89-1.99 (m, 2H), 1.84 (br d, J = 10.0 Hz, 2H)



5		pyrrole	297.1	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.18 (br s, 1H), 8.64-9.16 (m, 2H), 7.96 (d, J = 5.9 Hz, 1H), 7.50 (s, 1H), 7.15 (br d, J = 5.6 Hz, 1H), 6.98 (t, J = 2.4 Hz, 1H), 6.59 (br s, 1H), 4.31 (tt, J = 11.6, 4.0 Hz, 1H), 3.97 (q, J = 8.1 Hz, 1H), 3.83 (br s, 1H), 3.40 (br d, J = 12.7 Hz, 2H), 2.97-3.10 (m, 2H), 2.18-2.24 (m, 2H), 2.11 (br s, 2H), 1.27 (d, J = 7.3 Hz, 3H)
6		pyrrole	311.1	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.95 (s, 1H), 8.45-8.94 (m, 2H), 7.97 (d, J = 5.6 Hz, 1H), 7.15 (t, J = 2.0 Hz, 1H), 6.96 (t, J = 2.4 Hz, 1H), 6.91 (d, J = 5.6 Hz, 1H), 6.34-6.36 (m, 1H), 4.33 (tt, J = 11.6, 3.8 Hz, 1H), 3.41 (br d, J = 12.7 Hz, 2H), 3.35 (br s, 1H), 2.97-3.09 (m, 2H), 2.20 (br d, J = 12.2 Hz, 2H), 1.97-2.13 (m, 2H), 1.30 (s, 6H)



7		indole	361.1	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.09 (s, 1H), 8.55-9.02 (m, 2H), 8.11 (d, J = 5.4 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.51 (s, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.26 (td, J = 7.6, 1.0 Hz, 1H), 7.10 (td, J = 7.3, 0.5 Hz, 1H), 6.92 (d, J = 5.4 Hz, 1H), 4.85 (tt, J = 11.5, 4.7 Hz, 1H), 3.48 (br d, J = 13.4 Hz, 3H), 3.10-3.23 (m, 2H), 2.17-2.29 (m, 4H), 1.13 (s, 6H)
8		pyrazole	312.1	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.06 (s, 1H), 8.62-9.21 (m, 2H), 8.08 (d, J = 5.6 Hz, 1H), 7.93 (d, J = 2.4 Hz, 1H), 7.25 (d, J = 5.6 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 4.59 (tt, J = 10.3, 5.0 Hz, 1H), 4.25 (br s, 1H), 3.43 (br d, J = 13.0 Hz, 2H), 3.02-3.14 (m, 2H), 2.13-2.29 (m, 4H), 1.48 (s, 6H)



9		Indazole 1	362	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.14 (s, 1H), 8.61-9.12 (m, 2H), 8.23 (d, J = 5.4 Hz, 1H), 7.87-7.89 (m, 1H), 7.85-7.86 (m, 1H), 7.47-7.61 (m, 1H), 7.34 (d, J = 5.4 Hz, 1H), 7.26-7.31 (m, 1H), 5.13 (tt, J = 11.5, 3.8 Hz, 1H), 4.64 (s, 1H), 3.05-3.65 (m, 4H), 2.12-2.43 (m, 4H), 1.38 (s, 6H)
10		indole	347.1	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.11 (s, 1H), 9.28-9.87 (m, 2H), 8.10 (d, J = 5.4 Hz, 1H), 7.78 (s, 1H), 7.65 (d, J = 8.3 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.27 (td, J = 7.7, 1.0 Hz, 1H), 7.08-7.13 (m, 1H), 6.88 (d, J = 5.4 Hz, 1H), 5.48 (quin, J = 7.3 Hz, 1H), 4.38 (br s, 1H), 3.74-3.88 (m, 1H), 3.40-3.55 (m, 2H), 3.27-3.38 (m, 1H), 2.52-2.61 (m, 1H), 2.32 (dq, J = 13.2, 7.8 Hz, 1H), 1.12 (d, J = 4.6 Hz, 6H)



11		pyrrole	313	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.96 (br s, 1H), 8.62-9.06 (m, 2H), 7.96 (d, J = 5.9 Hz, 1H), 7.86 (t, J = 1.8 Hz, 1H), 7.15 (d, J = 5.9 Hz, 1H), 6.94 (t, J = 2.4 Hz, 1H), 6.81 (dd, J = 2.6, 1.8 Hz, 1H), 4.31 (ddt, J = 11.5, 7.7, 4.0 Hz, 2H), 4.05 (br s, 1H), 3.41 (br d, J = 12.5 Hz, 2H), 2.98-3.13 (m, 2H), 2.19 (br d, J = 12.0 Hz, 2H), 1.98-2.13 (m, 2H), 1.38 (s, 3H)
12		indole	363	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.98 (s, 1H), 8.62-9.09 (m, 2H), 8.47 (s, 1H), 8.13 (d, J = 5.6 Hz, 1H), 7.87 (d, J = 8.1 Hz, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.35 (d, J = 5.6 Hz, 1H), 7.26-7.31 (m, 1H), 7.18-7.22 (m, 1H), 6.49 (br s, 1H), 4.76-4.93 (m, 1H), 4.17 (br s, 1H), 3.40-3.54 (m, 2H), 3.12-3.27 (m, 2H), 2.17-2.28 (m, 3H), 2.07-2.17 (m, 1H), 1.24 (s, 3H)



13		pyrazole	314	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.03 (s, 1H), 8.63-9.12 (m, 2H), 8.11 (d, J = 5.6 Hz, 1H), 7.98 (d, J = 2.3 Hz, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.18 (d, J = 2.5 Hz, 1H), 6.30 (br s, 1H), 4.63 (tt, J = 11.1, 4.2 Hz, 1H), 3.99 (br s, 1H), 3.39-3.49 (m, 2H), 3.04-3.12 (m, 2H), 2.09-2.31 (m, 4H), 1.43 (s, 3H)
14		pyrazole	326	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.05 (s, 1H), 8.07 (br d, J = 5.4 Hz, 1H), 8.03 (br s, 3H), 7.91 (d, J = 2.4 Hz, 1H), 7.23 (d, J = 5.6 Hz, 1H), 6.81 (d, J = 2.2 Hz, 1H), 5.00 (br s, 1H), 4.24-4.32 (m, 1H), 3.05 (s, 1H), 2.13-2.22 (m, 2H), 2.10 (br d, J = 12.0 Hz, 2H), 1.81-1.94 (m, J = 12.7, 12.7, 12.7, 2.8 Hz, 2H), 1.51-1.63 (m, 2H), 1.48 (s, 6H)



15		Indazole 2	348	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.15 (s, 1 H) 8.97 - 9.68 (m, 2 H) 8.23 (d, J=5.43 Hz, 1 H) 7.84 - 7.89 (m, 1 H) 7.77 - 7.82 (m, 1 H) 7.50 - 7.61 (m, 1 H) 7.28 - 7.34 (m, 1 H) 7.26 (d, J=5.43 Hz, 1 H) 5.53 - 5.93 (m, 1 H) 3.54 - 3.93 (m, 2 H) 3.40 - 3.53 (m, 2 H) 2.55 - 2.64 (m, 1 H) 2.34 - 2.46 (m, 1 H) 1.32 (s, 6 H)
16		Indazole 2	348	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.14 (br s, 1H), 8.23 (d, J = 5.4 Hz, 1H), 7.87 (d, J = 8.6 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.53 (t, J = 7.7 Hz, 1H), 7.28 (q, J = 4.8 Hz, 2H), 5.60 (s, 1H), 3.51-3.72 (m, 2H), 3.37 (br s, 4H), 2.44-2.48 (m, 1H), 2.33 (br d, J = 5.9 Hz, 1H), 1.91 (s, 1H), 1.36 (s, 3H), 1.31 (s, 3H)



17		indole	349	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.97 (s, 1H), 9.49 (br s, 2H), 8.45 (s, 1H), 8.14 (dd, J = 5.6, 2.0 Hz, 1H), 7.85 (dd, J = 7.9, 4.0 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.28-7.34 (m, 2H), 7.19-7.25 (m, 1H), 5.42 (dt, J = 19.1, 7.2 Hz, 1H), 3.99 (br s, 2H), 3.18-3.60 (m, 4H), 2.53-2.65 (m, 1H), 2.27-2.42 (m, 1H), 1.27 (s, 1.5H), 1.24 (s, 1.5H)
18		indole	349	¹H NMR (DMSO-d₆, 500MHz): Shift (ppm) 10.97 (s, 1H), 9.49 (br s, 2H), 8.45 (s, 1H), 8.14 (dd, J=5.6, 2.0 Hz, 1H), 7.85 (dd, J=7.9, 4.3 Hz, 1H), 7.69 (d, J=8.3 Hz, 1H), 7.28-7.33 (m, 2H), 7.22 (t, J=7.5 Hz, 1H), 5.59-7.00 (br s, 1H), 5.37-5.47 (m, 1H), 3.75-3.83 (m, 1H), 3.69 (br dd, J=17.0, 5.3 Hz, 1H), 3.52 (dq, J=11.9, 5.7 Hz, 1H), 3.28-3.47 (m, 1H), 3.24-3.35 (m, 1H), 2.54-2.64 (m, 1H), 2.31-2.42 (m, 1H), 1.25 (d, J=13.7 Hz, 3H)



19		Indazole 1	362	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.16 (s, 1H), 9.18-9.50 (m, 2H), 8.23 (d, J = 5.4 Hz, 1H), 7.83 (dd, J = 17.5, 8.4 Hz, 2H), 7.50-7.66 (m, 1H), 7.23-7.36 (m, 2H), 5.22 (tt, J = 11.3, 3.9 Hz, 1H), 3.62 (br d, J = 11.5 Hz, 1H), 3.20-3.45 (m, 2H), 2.95-3.15 (m, 1H), 2.12-2.34 (m, 2H), 2.03 (br dd, J = 6.7, 4.0 Hz, 2H), 1.28-1.45 (m, 6H)
20		Indazole 1	362	¹H NMR (600 MHz, DMSO-d₆) δ ppm 1.23 - 1.43 (m, 6 H), 1.93 - 2.09 (m, 2 H), 2.13 - 2.30 (m, 2 H), 2.97 - 3.10 (m, 1 H), 3.23 - 3.35 (m, 1 H), 3.36 - 3.41 (m, 1 H), 3.59 - 3.62 (m, 1 H), 5.12 - 5.30 (m, 1 H), 7.25 - 7.35 (m, 2 H), 7.57 (m, J=1.00 Hz, 1 H), 7.76 - 7.90 (m, 2 H), 8.23 (d, J=5.43 Hz, 1 H), 9.17 - 9.45 (m, 2 H), 11.15 (s, 1 H)



21		Specific Indole 1	371	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.04 (s, 1H), 8.09 (d, J = 5.4 Hz, 1H), 7.43 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.21 (td, J = 7.7, 1.0 Hz, 1H), 7.07-7.12 (m, 1H), 6.89 (d, J = 5.3 Hz, 1H), 3.46 (s, 2H), 2.72-2.81 (m, 2H), 2.58-2.66 (m, 2H), 2.13-2.26 (m, 1H), 1.92-2.03 (m, 1H), 1.15 (s, 6H)
22		Indazole 3	372	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.11 (s, 1H), 8.22 (d, J = 5.4 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.68 (dt, J = 8.5, 0.9 Hz, 1H), 7.49 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H), 7.32 (d, J = 5.4 Hz, 1H), 7.30 (ddd, J = 8.1, 7.0, 0.6 Hz, 1H), 3.49 (s, 2H), 2.90-2.98 (m, 2H), 2.62-2.68 (m, 2H), 2.19-2.25 (m, 1H), 1.95-2.04 (m, 1H), 1.37 (s, 6H)



23		Indazole 5	378	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.13 (s, 1 H), 8.86 - 9.79 (m, 2 H), 8.23 (d, J=5.43 Hz, 1 H), 7.85 (d, J=9.24 Hz, 2 H), 7.46 - 7.54 (m, 1 H), 7.28 - 7.32 (m, 1 H), 7.25 - 7.28 (m, 1 H), 5.39 - 5.57 (m, 1 H), 4.10 - 4.29 (m, 1 H), 3.79 - 4.05 (m, 3 H), 3.35 - 3.52 (m, 2 H), 2.70 - 3.06 (m, 2 H), 1.15 - 1.47 (m, 6 H)
24		Specific Indole 1	373	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.98 (s, 1H), 8.44 (s, 1H), 8.13 (d, J = 5.6 Hz, 1H), 7.83-7.94 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 5.9 Hz, 1H), 7.14-7.29 (m, 2H), 3.85-5.57 (m, 1H), 3.31-3.54 (m, 2H), 2.57-2.85 (m, 4H), 2.13-2.30 (m, 1H), 1.88-2.06 (m, 1H), 1.29 (s, 3H)



25		Indazole 3	374.2	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.09 (br s, 1H), 8.27 (d, J = 5.4 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H), 7.54 (ddd, J = 8.4, 7.2, 1.0 Hz, 1H), 7.51 (d, J = 5.6 Hz, 1H), 7.36 (dd, J = 7.8, 6.8 Hz, 1H), 5.98 (s, 1H), 3.49 (d, J = 2.2 Hz, 2H), 2.79-3.05 (m, 2H), 2.64 (ddd, J = 12.2, 8.9, 2.7 Hz, 2H), 1.93-2.30 (m, 2H), 1.48 (s, 3H)
26		Indazole 1	364	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.12 (s, 1H), 8.96 (br s, 1H), 8.72 (br s, 1H), 8.27 (d, J = 5.6 Hz, 1H), 8.06 (d, J = 8.3 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.59 (ddd, J = 8.3, 7.1, 0.7 Hz, 1H), 7.50 (d, J = 5.6 Hz, 1H), 7.33-7.37 (m, 1H), 5.95 (br s, 1H), 5.18 (tt, J = 11.2, 4.0 Hz, 1H), 3.85 (br s, 1H), 3.47-3.59 (m, 2H), 3.11-3.27 (m, 2H), 2.13-2.40 (m, 4H), 1.46 (s, 3H)



27		Indazole 1 (using compound II' obtained from OHMe isomer 1)	364	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.12 (s, 1H), 8.62-9.07 (m, 2H), 8.27 (d, J = 5.4 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.7 Hz, 1H), 7.59 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.49 (d, J = 5.6 Hz, 1H), 7.33-7.37 (m, 1H), 5.94 (br s, 1H), 5.18 (tt, J = 11.3, 4.0 Hz, 1H), 4.15 (br s, 1H), 3.49-3.56 (m, 2H), 3.12-3.23 (m, 2H), 2.17-2.37 (m, 4H), 1.46 (s, 3H)
28		Indazole 1 (using compound II' obtained from OHMe isomer 2)	364	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.12 (s, 1H), 8.57-9.03 (m, 2H), 8.27 (d, J = 5.4 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.6 Hz, 1H), 7.56-7.62 (m, 1H), 7.50 (d, J = 5.4 Hz, 1H), 7.32-7.38 (m, 1H), 5.95 (br s, 1H), 5.17 (tt, J = 11.2, 3.9 Hz, 1H), 4.36 (br s, 1H), 3.06-3.69 (m, 4H), 2.12-2.42 (m, 4H), 1.46 (s, 3H)



29		Indazole 1 (using compound II' obtained from OHMe isomer 1)	378	¹H NMR (600 MHz, DMSO-d₆, 300K) δ ppm 11.09 (s, 1 H), 8.69 - 8.95 (m, 1 H), 8.36 - 8.51 (m, 1 H), 8.26 (d, J=5.4 Hz, 1 H), 8.03 (d, J=8.2 Hz, 1 H), 7.89 (d, J=8.7 Hz, 1 H), 7.55 (ddd, J=8.4, 7.0, 0.9 Hz, 1 H), 7.46 (d, J=5.6 Hz, 1 H), 7.32 (ddd, J=8.0, 7.1, 0.6 Hz, 1 H), 4.46 - 4.59 (m, 2 H), 3.21 - 3.30 (m, 2 H), 2.75 - 2.90 (m, 2 H), 2.27 (dtt, J=14.8, 7.4, 7.4, 3.5, 3.5 Hz, 1 H), 1.73 (br t, J=13.2 Hz, 2 H), 1.41 - 1.50 (m, 5 H)
30		Indazole 1	376	¹H NMR (600 MHz, DMSO-d₆, 300K) δ ppm 11.12 (s, 1 H), 8.64 - 8.82 (m, 1 H), 8.31 - 8.51 (m, 1 H), 8.22 (d, J=5.4 Hz, 1 H), 7.80 - 7.87 (m, 2 H), 7.51 (ddd, J=8.3, 7.1, 0.9 Hz, 1 H), 7.30 (d, J=5.4 Hz, 1 H), 7.25 - 7.28 (m, 1 H), 4.49 (d, J=7.0 Hz, 2 H), 3.27 (br d, J=12.8 Hz, 2 H), 2.75 - 2.89 (m, 2 H), 2.31 (ddd, J=11.0, 7.4, 3.7 Hz, 1 H), 1.72 (br d, J=12.5 Hz, 2 H), 1.41 - 1.55 (m, 2 H), 1.37 (s, 6 H)



31		Indazole 4	392.1	¹H NMR (600 MHz, DMSO-d₆) δ 11.10 (br s, 1H), 8.21 (d, J = 5.4 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.29 (d, J = 5.4 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 4.69 (d, J = 14.4 Hz, 1H), 4.53 (d, J = 14.4 Hz, 1H), 3.64 (s, 1H), 3.58 (d, J = 11.0 Hz, 1H), 3.49 (br t, J = 8.0 Hz, 1H), 3.29 – 3.27 (m, 1H), 3.10 (br s, 1H), 2.74 (br d, J = 13.6 Hz, 1H), 2.36 – 2.15 (m, 1H), 1.36 (s, 6H), 0.94 (s, 3H)
32		Indazole 1	380	¹H NMR(DMSO-d₆, 500 MHz): δ (ppm) 11.18 (s, 1H), 9.02 (d, J=10.8 Hz, 1H), 8.76 (d, J=9.9 Hz, 1H), 8.24 (d, J=5.4 Hz, 1H), 7.65 (d, J=8.2 Hz, 1H), 7.38 (dd, J=12.5, 7.6 Hz, 1H), 7.31 – 7.21 (m, 2H), 5.13 (td, J=10.8, 5.2 Hz, 1H), 3.49 (d, J=12.9 Hz, 2H), 3.23 (q, J=11.8 Hz, 2H), 2.42 – 2.29 (m, 4H), 1.35 (s, 6H)



33		Indazole 1	380	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.16 (s, 1H), 8.66-9.16 (m, 2H), 8.23 (d, J = 5.4 Hz, 1H), 7.87 (dd, J = 9.0, 5.1 Hz, 1H), 7.78 (dd, J = 9.8, 2.2 Hz, 1H), 7.31 (d, J = 5.4 Hz, 1H), 7.16 (td, J = 9.0, 2.2 Hz, 1H), 5.07 (tt, J = 11.4, 3.9 Hz, 1H), 4.02 (br s, 2H), 3.51 (br d, J = 13.0 Hz, 2H), 3.06-3.21 (m, 2H), 2.28-2.39 (m, 2H), 2.21 (br d, J = 12.2 Hz, 2H), 1.36 (s, 6H)
34		Indazole 1	381.9	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.13 (d, J = 12.0 Hz, 1H), 8.72-9.75 (m, 2H), 8.28 (dd, J = 5.4, 4.3 Hz, 1H), 8.07-8.20 (m, 1H), 7.96 (dd, J = 8.7, 3.5 Hz, 1H), 7.61-7.67 (m, 1H), 7.49-7.60 (m, 1H), 7.35-7.44 (m, 1H), 5.90-6.25 (m, 1H), 5.41-5.59 (m, 1H), 5.15-5.39 (m, 1H), 3.40-3.82 (m, 3H), 3.20-3.30 (m, 1H), 2.71-2.95 (m, 1H), 2.27 (br d, J = 13.1 Hz, 1H), 1.30-1.50 (m, 3H)



35		Indazole 1	382	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.12 (s, 1H), 9.52-9.68 (m, 1H), 9.27 (br d, J = 1.0 Hz, 1H), 8.28 (d, J = 5.6 Hz, 1H), 8.02 (t, J = 8.9 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.56-7.66 (m, 1H), 7.43-7.52 (m, 1H), 7.29-7.40 (m, 1H), 5.93 (br s, 1H), 5.38-5.53 (m, 1H), 5.12-5.36 (m, 1H), 3.75-4.07 (m, 1H), 3.48-3.56 (m, 1H), 3.25-3.36 (m, 1H), 3.14-3.24 (m, 1H), 2.30-2.57 (m, 2H), 1.41-1.56 (m, 3H)
36		Indazole 1	380	¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.16 (s, 1 H); 8.97 - 10.01 (m, 2 H), 8.24 (d, J=5.38 Hz, 1 H); 7.84 (dd, J=8.31, 5.62 Hz, 2 H), 7.50 - 7.59 (m, 1 H), 7.34 (d, J=5.62 Hz, 1 H), 7.27 - 7.32 (m, 1 H), 5.37 - 5.48 (m, 1 H), 5.19 - 5.37 (m, 1 H); 3.85 (br s, 1 H); 3.46 - 3.54 (m, 1 H), 3.24 - 3.34 (m, 1 H), 3.13 - 3.24 (m, 1 H), 2.29 - 2.49 (m, 2 H), 1.36 (d, J=13.20 Hz, 6 H)



37		Indazole 1	380	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.14 (s, 1H), 8.51-9.66 (m, 2H), 8.23 (d, J = 5.4 Hz, 1H), 7.91 (dd, J = 16.2, 8.4 Hz, 2H), 7.56 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H), 7.27-7.40 (m, 2H), 5.35-5.49 (m, 1H), 5.18-5.35 (m, 1H), 3.54-3.80 (m, 3H), 3.19-3.29 (m, 1H), 2.97 (br dd, J = 13.0, 3.9 Hz, 1H), 2.20-2.32 (m, 1H), 1.42 (s, 3H), 1.32 (s, 3H)
38		Indazole 1	394	¹H NMR (500 MHz, DMSO-d₆): δ ppm 11.15 (s, 1H), 8.56 - 9.22 (m, 2H), 8.23 (d, J=5.38 Hz, 1H), 7.72 - 7.90 (m, 2H), 7.44 - 7.57 (m, 1H), 7.31 (d, J=5.38 Hz, 1H), 7.25 - 7.30 (m, 1H), 4.90 - 4.98 (m, 2H), 3.24 - 3.33 (m, 2H), 2.90 - 3.04 (m, 2H), 1.85 - 2.22 (m, 4H), 1.37 (s, 6H)



39		Indazole 1 (using specific indazole 2 as compound II)	396.1	¹H NMR (600 MHz, DMSO-d₆): δ ppm 11.10 (d, J=4.84 Hz, 1 H), 8.36 - 8.62 (m, 3 H), 8.26 (dd, J=5.43, 1.76 Hz, 1 H), 8.01 - 8.07 (m, 1 H), 7.98 (d, J=8.66 Hz, 1 H), 7.53 - 7.59 (m, 1 H), 7.44 - 7.51 (m, 1 H), 7.30 - 7.38 (m, 1 H), 5.31 - 6.78 (m, 1 H), 4.99 - 5.09 (m, 1 H), 4.83 - 4.98 (m, 1 H), 3.42 - 3.51 (m, 1 H), 2.56 - 2.70 (m, 1 H), 1.88 - 2.35 (m, 4 H), 1.60 - 1.79 (m, 1 H), 1.45 (m, J=14.20 Hz, 3 H)
40		Indazole 3 (using compound II' obtained from OHMe isomer 1)	374.2	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.09 (s, 1H), 8.27 (d, J = 5.6 Hz, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.52-7.56 (m, 1H), 7.50 (d, J = 5.4 Hz, 1H), 7.36 (ddd, J = 8.1, 7.0, 0.7 Hz, 1H), 5.98 (s, 1H), 3.41-3.56 (m, 2H), 2.84-3.05 (m, 2H), 2.61-2.69 (m, 2H), 2.17-2.30 (m, 1H), 1.96-2.05 (m, 1H), 1.48 (s, 3H)



41		Indazole 1 (using specific indazole 2 as compound II)	376	¹H NMR (600 MHz, DMSO-d₆): δ ppm 11.11 (s, 1 H), 8.22 (d, J=5.43 Hz, 1 H), 7.98 - 8.10 (m, 3 H), 7.91 (d, J=8.66 Hz, 1 H), 7.81 - 7.86 (m, 1 H), 7.44 - 7.53 (m, 1 H), 7.33 (d, J=5.43 Hz, 1 H), 7.22 - 7.28 (m, 1 H), 4.71 - 4.85 (m, 1 H), 3.11 - 3.30 (m, 1 H), 2.10 - 2.19 (m, 4 H), 1.97 - 2.08 (m, 2 H), 1.61 - 1.75 (m, 2 H), 1.37 (s, 6 H)
42		Indazole 1 (using compound II' obtained from OHMe isomer 1)	432.2	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.13 (s, 1H), 8.62-9.09 (m, 2H), 8.43 (s, 1H), 8.28 (d, J = 5.4 Hz, 1H), 8.19 (d, J = 8.7 Hz, 1H), 7.58 (dd, J = 8.7, 1.3 Hz, 1H), 7.42 (d, J = 5.4 Hz, 1H), 5.83 (br s, 1H), 5.27-5.37 (m, 1H), 4.32 (br s, 1H), 3.53 (br d, J = 12.3 Hz, 2H), 3.10-3.20 (m, 2H), 2.17-2.37 (m, 4H), 1.50 (s, 3H)



43		indazole 2 (using compound II' obtained from OHMe isomer 1 and specific Indazole 1 as compound II)	430	¹H NMR (500 MHz, DMSO-d₆) protonated form Shift 11.11 (s, 1H), 9.01 (br s, 1H), 8.73 (s, 1H), 8.71 (br s, 1H), 8.27 (d, J=5.62 Hz, 1H), 7.80 (dd, J=0.98, 7.83 Hz, 1H), 7.47 (s, 1H), 7.28-7.37 (m, 2H), 7.27-7.64 (m, 1H), 5.38-6.19 (m, 1H), 5.20- 5.29 (m, 1H), 3.45-3.58 (m, 2H), 3.11-3.20 (m, 2H), 2.25-2.38 (m, 4H), 1.51 (s, 3H)
44		Indazole 1	394	¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.15 (s, 1 H), 8.40 - 9.59 (m, 2 H), 8.24 (d, J=5.38 Hz, 1 H), 7.84 (m, J=8.30, 4.90 Hz, 2 H), 7.48 - 7.62 (m, 1 H), 7.31 (d, J=5.38 Hz, 1 H), 7.28 (d, J=7.09 Hz, 1 H), 4.73 - 5.02 (m, 2 H), 3.28 - 3.42 (m, 2 H), 3.21 (m, J=12.00 Hz, 1 H), 2.76 - 2.99 (m, 1 H), 1.83 - 2.06 (m, 2 H), 1.68 - 1.82 (m, 2 H), 1.29 - 1.45 (m, 6 H)



45		Indazole 3	374	¹H NMR (600 MHz, DMSO-d₆): δ ppm 11.02 (s, 1 H), 8.24 (d, J=5.28 Hz, 1 H), 7.88 (d, J=8.36 Hz, 1 H), 7.58 - 7.67 (m, 1 H), 7.50 - 7.56 (m, 1 H), 7.31 - 7.39 (m, 1 H), 7.28 - 7.31 (m, 1 H), 4.90 - 5.41 (m, 4 H), 3.72 (s, 2 H), 1.33 (s, 6 H)
46		Indazole 3	373	¹H NMR (500 MHz, DMSO-d₆): Shift 11.18 (s, 1H), 9.74 (br s, 1H), 9.34 (br s, 1H), 8.25 (d, J=5.38 Hz, 1H), 7.90 (d, J=8.07 Hz, 1H), 7.77 (d, J=8.56 Hz, 1H), 7.59 (t, J=7.65 Hz, 1H), 7.38 (t, J=7.48 Hz, 1H), 7.28 (d, J=5.38 Hz, 1H), 4.81-4.88 (m, 2H), 4.61-4.67 (m, 2H), 3.79-3.88 (m, 2H), 1.35 (s, 6H)



47		Indazole 1 (using compound II' obtained from OHMe isomer 1)	396	¹ H NMR (500 MHz, DMSO-d ₆) δ ppm 11.09 (s, 1 H), 8.57 - 9.23 (m, 2 H), 8.27 (d, J=5.38 Hz, 1 H), 7.95 - 8.11 (m, 1 H), 7.78 - 7.90 (m, 1 H), 7.52 - 7.60 (m, 1 H), 7.46 (d, J=5.38 Hz, 1 H), 7.30 - 7.36 (m, 1 H), 5.89 (s, 1 H), 4.85 - 5.10 (m, 2 H), 3.21 - 3.36 (m, 2 H), 2.82 - 3.11 (m, 2 H), 1.82 - 2.22 (m, 4 H), 1.52 (s, 3 H)
48		Indazole 3 (using compound II' obtained from OHMe isomer 1)	376	¹ H NMR (600 MHz, DMSO-d ₆): δ ppm 13.85 (br s, 1 H), 8.30 (d, J=5.43 Hz, 1 H), 8.06 (d, J=8.36 Hz, 1 H), 7.67 - 7.75 (m, 1 H), 7.59 - 7.66 (m, 1 H), 7.44 - 7.54 (m, 1 H), 7.21 - 7.34 (m, 1 H), 6.60 (br s, 1 H), 5.06 - 5.30 (m, 2 H), 4.60 - 4.75 (m, 2 H), 3.48 - 3.51 (m, 2 H), 1.50 (s, 3 H)



49		Indazole 3 (using compound II' obtained from OHMe isomer 1)	375	¹ H NMR (DMSO-d ₆ , 500 MHz): δ (ppm) 11.10 (s, 1H), 9.94 (br s, 1H), 9.44 (br s, 1H), 8.27 (d, J = 5.6 Hz, 1H), 8.03 (d, J = 8.3 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.58 (ddd, J = 8.4, 7.2, 0.9 Hz, 1H), 7.38 (d, J = 5.6 Hz, 1H), 7.35-7.41 (m, 1H), 5.17-6.26 (m, 1H), 4.79-4.95 (m, 2H), 4.56-4.67 (m, 2H), 4.28-4.34 (m, 1H), 3.83 (d, J = 3.4 Hz, 2H), 1.51 (s, 3H)
50		Indazole 1 (using compound II' obtained from OHMe isomer 1)	382	¹ H NMR (600 MHz, DMSO-d ₆) δ ppm 11.12 (s, 1H), 8.74 - 9.59 (m, 2H), 8.28 (m, J=5.40, 4.30 Hz, 1H), 8.06 - 8.19 (m, 1H), 7.90 - 7.98 (m, 1H), 7.61 - 7.67 (m, 1H), 7.50 - 7.60 (m, 1H), 7.40 (d, J=7.63 Hz, 1H), 5.85 - 6.31 (m, 1H), 5.40 - 5.59 (m, 1H), 5.22 - 5.38 (m, 1H), 3.70 - 3.85 (m, 1H), 3.48 - 3.66 (m, 3H), 3.17 - 3.28 (m, 1H), 2.76 - 2.91 (m, 1H), 2.22 - 2.33 (m, 1H), 1.42 (s, 3H)



51		Indazole 1 (using specific indazole 3 as compound III)	388.1	¹H NMR (500 MHz, DMSO-d₆) δ ppm 11.13 (br s, 1 H), 8.28 (br d, J=5.14 Hz, 1 H), 8.01 - 8.14 (m, 1 H), 7.66 - 7.76 (m, 1 H), 7.42 - 7.60 (m, 2 H), 7.31 - 7.40 (m, 1 H), 6.01 (s, 1 H), 3.42 - 3.57 (m, 2 H), 2.56 - 3.06 (m, 4 H), 1.79 - 2.30 (m, 4 H), 0.38 - 0.58 (m, 3 H)
52		Indazole 1	394	¹H NMR (600 MHz, DMSO-d₆): δ ppm 11.15 (s, 1 H), 8.60 - 9.67 (m, 2 H), 8.24 (d, J=5.43 Hz, 1 H), 7.89 - 7.94 (m, 1 H), 7.84 - 7.89 (m, 1 H), 7.56 (t, J=7.70 Hz, 1 H), 7.27 - 7.39 (m, 2 H), 5.34 - 5.47 (m, 1 H), 5.17 - 5.34 (m, 1 H), 3.58 - 3.79 (m, 2 H), 3.49 - 3.55 (m, 1 H), 3.19 - 3.25 (m, 1 H), 2.86 - 3.03 (m, 1 H), 2.21 - 2.31 (m, 1 H), 1.57 - 2.15 (m, 2 H), 1.32 - 1.50 (m, 3 H), 0.28 - 0.44 (m, 3 H)



53		Indazole 2	362	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.20 (s, 1H), 9.32-9.71 (m, 2H), 8.24 (dd, J = 5.4, 1.5 Hz, 1H), 7.87 (d, J = 8.6 Hz, 1H), 7.75-7.80 (m, 1H), 7.56 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H), 7.27-7.33 (m, 1H), 7.25 (dd, J = 5.5, 1.3 Hz, 1H), 5.73 (quin, J = 6.5 Hz, 1H), 3.80-3.93 (m, 1H), 3.40-3.60 (m, 3H), 2.53-2.63 (m, 1H), 2.33-2.47 (m, 1H), 1.62-1.90 (m, 2H), 1.26-1.43 (m, 3H), 0.31-0.49 (m, 3H)
54		Indazole 4	392.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.10 (s, 1H), 8.21 (d, J = 5.4 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.49 (ddd, J = 8.3, 7.0, 1.0 Hz, 1H), 7.29 (d, J = 5.4 Hz, 1H), 7.22-7.26 (m, 1H), 4.69 (d, J = 14.5 Hz, 1H), 4.53 (d, J = 14.5 Hz, 1H), 3.65 (dt, J = 10.8, 3.8 Hz, 1H), 3.58 (d, J = 11.2 Hz, 1H), 3.49 (ddd, J = 10.8, 8.3, 2.9 Hz, 1H), 3.28-3.30 (m, 1H), 3.10 (ddd, J = 12.3, 8.6, 3.2 Hz, 1H), 2.71-2.78 (m, 1H), 2.33 (br s, 1H), 1.36 (d, J = 1.6 Hz, 6H), 0.94 (s, 3H)



55		Indazole 5	422.1	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.02 (s, 1H), 9.18-9.66 (m, 2H), 8.19 (d, J = 5.4 Hz, 1H), 7.65-7.84 (m, 2H), 7.17 (td, J = 9.0, 2.1 Hz, 1H), 7.11 (d, J = 5.4 Hz, 1H), 4.10 (dt, J = 12.0, 6.0 Hz, 2H), 3.80-3.97 (m, 3H), 3.40-3.52 (m, 1H), 3.23-3.34 (m, 1H), 2.66-2.93 (m, 2H), 2.10-2.28 (m, 2H), 1.77-1.90 (m, 4H), 1.60 (br d, J = 2.7 Hz, 2H)
56		Indazole 1	396.1	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.15 (m, J=8.40 Hz, 1 H), 8.70 - 9.62 (m, 2 H), 8.29 (dd, J=5.43, 3.81 Hz, 1 H), 8.06 - 8.20 (m, 1 H), 7.91 - 7.98 (m, 1 H), 7.61 - 7.66 (m, 1 H), 7.49 - 7.60 (m, 1 H), 7.36 - 7.43 (m, 1 H), 5.72 - 6.51 (m, 1 H), 5.39 - 5.61 (m, 1 H), 5.20 - 5.38 (m, 1 H), 3.73 - 3.85 (m, 1 H), 3.59 - 3.66 (m, 2 H), 3.18 - 3.32 (m, 1 H), 2.71 - 2.89 (m, 1 H), 2.16 - 2.29 (m, 1 H), 1.78 - 1.99 (m, 2 H), 0.37 - 0.49 (m, 3 H)



57		Indazole 3	388.1	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.30 (s, 1H), 8.30 (d, J = 5.4 Hz, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.48 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H), 7.39 (d, J = 5.4 Hz, 1H), 7.27-7.32 (m, 1H), 3.43 (d, J = 2.7 Hz, 2H), 2.90-3.05 (m, 2H), 2.80 (s, 3H), 2.62 (tt, J = 8.0, 3.9 Hz, 2H), 2.14-2.28 (m, 1H), 1.94-2.03 (m, 1H), 1.59 (s, 3H)
58		Indazole 3 (using compound II' obtained from OHMe isomer 1)	392	¹H NMR (CHLOROFORM-d, 500 MHz): δ (ppm) 8.34 (d, J = 5.6 Hz, 1H), 8.18 (br s, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.51 (d, J = 5.4 Hz, 1H), 7.30-7.36 (m, 1H), 7.24-7.30 (m, 1H), 6.12 (s, 1H), 3.13-3.23 (m, 2H), 2.95-3.13 (m, 2H), 2.67-2.79 (m, 2H), 2.07-2.24 (m, 2H), 1.58 (s, 3H)



59		Indazole 3 (using compound II' obtained from OHMe isomer 1)	392	¹ H NMR (600 MHz, DMSO-d ₆): δ ppm 11.09 (s, 1 H), 8.26 (d, J=5.43 Hz, 1 H), 8.05 - 8.11 (m, 1 H), 7.50 - 7.57 (m, 1 H), 7.44 (d, J=5.58 Hz, 1 H), 7.19 - 7.25 (m, 1 H), 5.88 (s, 1 H), 3.51 (s, 2 H), 2.81 - 3.01 (m, 2 H), 2.59 - 2.67 (m, 2 H), 1.93 - 2.27 (m, 2 H), 1.47 (s, 3 H)
60		Indazole 3 (using compound II' obtained from OHMe isomer 1)	375.1	¹ H NMR (600 MHz, DMSO-d ₆) δ 11.11 (s, 1H), 8.68 (dd, J=1.47, 4.40 Hz, 1H), 8.55 (dd, J=1.47, 8.22 Hz, 1H), 8.27 (d, J=5.43 Hz, 1H), 7.46 (d, J=5.58 Hz, 1H), 7.42 (dd, J=4.40, 8.22 Hz, 1H), 5.88 (s, 1H), 3.56-3.65 (m, 2H), 2.97-3.15 (m, 2H), 2.53- 2.62 (m, 2H), 2.15-2.23 (m, 1H), 1.98-2.04 (m, 1H), 1.50 (s, 3H)



61		Indazole 1	396	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.32 (s, 1H), 9.28-9.59 (m, 1H), 8.76-9.10 (m, 1H), 8.29-8.35 (m, 1H), 7.86 (d, J = 8.1 Hz, 2H), 7.51-7.61 (m, 1H), 7.26-7.45 (m, 2H), 5.02-5.57 (m, 2H), 3.33-3.81 (m, 3H), 3.17-3.32 (m, 1H), 2.89-3.03 (m, 1H), 2.71-2.87 (m, 3H), 2.15-2.31 (m, 1H), 1.44-1.75 (m, 3H)
62		Indazole 1 (using specific indazole 3 as compound III)	387.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.10 (s, 1H), 8.25 (d, J = 5.6 Hz, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.51 (d, J = 5.4 Hz, 1H), 7.48-7.54 (m, 1H), 7.34 (ddd, J = 8.0, 7.1, 0.6 Hz, 1H), 3.45-3.57 (m, 2H), 2.99 (br s, 1H), 2.86-2.96 (m, 2H), 2.64 (ddd, J = 11.7, 8.1, 3.1 Hz, 2H), 2.17-2.29 (m, 1H), 1.94-2.04 (m, 1H), 1.88 (s, 3H), 1.39 (s, 3H)



63		Indazole 4	406	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.39-11.88 (m, 1H), 11.16 (br s, 1H), 8.23 (dd, J = 5.1, 1.7 Hz, 1H), 7.88-8.11 (m, 1H), 7.82 (br t, J = 9.0 Hz, 1H), 7.16-7.71 (m, 3H), 4.72-5.44 (m, 2H), 3.43 (s, 6H), 2.86-3.04 (m, 3H), 1.15-1.62 (m, 9H)
64		Indazole 3 (using compound II' obtained from OHMe isomer 2)	442.1	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.10 (s, 1 H), 8.28 (d, J=5.58 Hz, 1 H), 8.19 - 8.24 (m, 1 H), 8.01 (s, 1 H), 7.55 - 7.66 (m, 1 H), 7.41 (d, J=5.43 Hz, 1 H), 5.77 (s, 1 H), 3.54 (s, 2 H), 2.69 (m, J=9.20, 6.10, 3.20 Hz, 4 H), 1.93 - 2.31 (m, 2 H) 1.50 (s, 3 H)



65		Indazole 2 (using compound II' obtained from MeEt isomer 1)	362.1	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.12 (s, 1 H), 8.18 - 8.27 (m, 1 H), 7.85 (d, J=8.51 Hz, 1 H), 7.79 - 7.83 (m, 1 H), 7.49 (ddd, J=8.36, 7.04, 1.03 Hz, 1 H), 7.28 - 7.34 (m, 1 H), 7.22 - 7.27 (m, 1 H), 5.33 - 5.43 (m, 1 H), 3.36 - 3.40 (m, 1 H), 3.33 - 3.34 (m, 1 H), 3.08 - 3.16 (m, 1 H), 3.02 - 3.06 (m, 1 H), 2.94 - 3.02 (m, 1 H), 2.14 - 2.36 (m, 2 H), 1.64 - 2.04 (m, 2 H), 1.39 (s, 3 H), 0.32 - 0.44 (m, 3 H)
66		Indazole 2 (using compound II' obtained from MeEt isomer 2)	362.1	¹H NMR (600 MHz, DMSO-d₆): δ ppm 11.22 (s, 1 H), 8.23 (d, J=5.43 Hz, 1 H), 7.86 (d, J=8.51 Hz, 1 H), 7.78 (d, J=8.22 Hz, 1 H), 7.51 - 7.56 (m, 1 H), 7.27 - 7.31 (m, 1 H), 7.25 - 7.26 (m, 1 H), 5.56 - 5.69 (m, 1 H), 3.70 - 3.77 (m, 1 H), 3.42 - 3.45 (m, 1 H), 3.38 - 3.40 (m, 2 H), 3.29 - 3.30 (m, 1 H), 2.27 - 2.49 (m, 2 H), 1.68 - 1.94 (m, 2 H), 1.30 - 1.33 (m, 3 H), 0.38 - 0.48 (m, 3 H)



67		Indazole 1	410.1	¹H NMR (600 MHz, DMSO-d₆, 300K) δ ppm 11.34 (d, J=4.4 Hz, 1 H), 9.26 - 9.52 (m, 1 H), 8.46 - 8.85 (m, 1 H), 8.25 - 8.35 (m, 1 H), 7.72 - 7.91 (m, 2 H), 7.46 - 7.60 (m, 1 H), 7.32 - 7.40 (m, 1 H), 7.21 - 7.31 (m, 1 H), 4.60 - 5.12 (m, 2 H), 3.12 - 3.58 (m, 3 H), 2.65 - 2.91 (m, 4 H), 1.55 - 2.16 (m, 7 H)
68		Indazole 1 (using specific indazole 3 as compound III and compound II' obtained from EtOH isomer 1)	388.1	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.12 (s, 1 H), 8.28 (d, J=5.57 Hz, 1 H), 8.07 - 8.17 (m, 1 H), 7.66 - 7.75 (m, 1 H), 7.52 - 7.57 (m, 1 H), 7.49 - 7.52 (m, 1 H), 7.32 - 7.39 (m, 1 H), 6.00 (s, 1 H), 3.39 - 3.57 (m, 2 H), 2.57 - 3.05 (m, 4 H), 2.23 (m, J=11.00 Hz, 1 H), 1.80 - 2.05 (m, 3 H), 0.47 (t, J=1.00 Hz, 3 H)



69		Indazole 1 (using specific indazole 3 as compound III and compound II' obtained from EtOH isomer 2)	388.1	¹ H NMR (500 MHz, DMSO-d ₆) δ 11.13 (s, 1H), 8.28 (d, J=5.62 Hz, 1H), 8.11 (d, J=8.31 Hz, 1H), 7.70 (d, J=8.56 Hz, 1H), 7.54 (ddd, J=0.86, 7.15, 8.38 Hz, 1H), 7.51 (d, J=5.38 Hz, 1H), 7.36 (t, J=7.54 Hz, 1H), 6.01 (s, 1H), 3.44-3.53 (m, 2H), 2.86-3.00 (m, 2H), 2.63 (ddd, J=3.55, 6.11, 9.17 Hz, 2H), 2.19-2.29 (m, 1H), 1.96-2.04 (m, 2H), 1.83-1.91 (m, 1H), 0.47 (t, J=7.46 Hz, 3H)
70		Indazole 2	366.1	¹ H NMR (600 MHz, DMSO-d ₆) δ 11.17 (s, 1H), 9.55 (br s, 1H), 9.42 (br s, 1H), 8.23 (d, J=5.43 Hz, 1H), 7.78-7.82 (m, 2H), 7.23 (d, J=5.43 Hz, 1H), 7.14-7.20 (m, 1H), 5.65-5.70 (m, 1H), 3.84-3.90 (m, 1H), 3.40-3.58 (m, 3H), 2.52-2.61 (m, 1H), 2.40 (qd, J=6.58, 12.82 Hz, 1H), 1.23-1.37 (m, 6H)



71		Indazole 2	382.0; 383.9	¹H NMR (500 MHz, DMSO-d₆) δ 11.18 (s, 1H), 9.40 (br s, 1H), 9.34 (br s, 1H), 8.24 (d, J=5.38 Hz, 1H), 8.11 (d, J=1.47 Hz, 1H), 7.79 (d, J=8.80 Hz, 1H), 7.31 (dd, J=1.83, 8.68 Hz, 1H), 7.23 (d, J=5.38 Hz, 1H), 5.71-5.77 (m, 1H), 3.70-3.90 (m, 1H), 3.47-3.66 (m, 2H), 3.40-3.46 (m, 1H), 2.52-2.61 (m, 1H), 2.36-2.43 (m, 1H), 1.17-1.42 (m, 6H)
72		Indazole 2	366	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.19 (s, 1H), 9.19-9.55 (m, 2H), 8.24 (d, J = 5.4 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.41 (dd, J = 12.5, 7.6 Hz, 1H), 7.25 (td, J = 7.9, 4.3 Hz, 1H), 7.21 (d, J = 5.3 Hz, 1H), 5.70-5.81 (m, 1H), 3.86-3.90 (m, 1H), 3.62 (dq, J = 12.2, 6.1 Hz, 1H), 3.42-3.52 (m, 2H), 2.51-2.65 (m, 2H), 1.21-1.35 (m, 6H)



73		Indazole 2	366.1	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.16 (s, 1 H), 8.99 - 9.97 (m, 2 H), 8.22 (d, J=5.43 Hz, 1 H), 7.91 - 7.99 (m, 1 H), 7.53 - 7.60 (m, 1 H), 7.41 - 7.52 (m, 1 H), 7.22 - 7.31 (m, 1 H), 5.65 - 6.16 (m, 1 H), 3.81 - 3.89 (m, 1 H), 3.37 - 3.58 (m, 3 H), 2.54 - 2.63 (m, 1 H), 2.34 - 2.45 (m, 1 H), 1.31 (s, 6 H)
74		Indazole 2	416.1	¹H NMR (500 MHz, DMSO-d₆, 300 K) δ (ppm) = 11.21 (s, 1H), 9.61 - 9.31 (m, 2H), 8.45 (s, 1H), 8.26 (d, J = 5.4 Hz, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 1.1, 8.7 Hz, 1H), 7.26 (d, J = 5.4 Hz, 1H), 6.06 - 5.79 (m, 1H), 3.98 - 3.83 (m, 1H), 3.58 - 3.40 (m, 3H), 2.68 - 2.53 (m, 1H), 2.42 (td, J = 6.4, 13.3 Hz, 1H), 1.35 (s, 3H), 1.25 (s, 3H)



75		Indazole 1 (using compound II' obtained from OHMe isomer 1)	410.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.32 (s, 1H), 8.55-9.10 (m, 2H), 8.31 (d, J = 5.4 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.51 (ddd, J = 8.4, 7.0, 0.9 Hz, 1H), 7.36 (d, J = 5.3 Hz, 1H), 7.23-7.30 (m, 1H), 4.80-4.95 (m, 2H), 3.21-3.34 (m, 2H), 2.92-3.04 (m, 2H), 2.74 (s, 3H), 1.86-2.17 (m, 4H), 1.68 (s, 3H)
76		Indazole 1 (using compound II' obtained from OHMe isomer 1)	428.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.34 (s, 1H), 8.53-9.00 (m, 2H), 8.31 (d, J = 5.3 Hz, 1H), 7.85 (dd, J = 8.9, 5.1 Hz, 1H), 7.66 (d, J = 9.8 Hz, 1H), 7.33 (d, J = 5.4 Hz, 1H), 7.15 (td, J = 9.0, 2.2 Hz, 1H), 4.74-4.98 (m, 2H), 3.22-3.32 (m, 2H), 2.91-3.04 (m, 2H), 2.75 (s, 3H), 1.86-2.17 (m, 4H), 1.65 (s, 3H)



77		Indazole 5	380.3	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.11 (br s, 1H), 8.22 (d, J = 5.6 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.31 (d, J = 5.4 Hz, 1H), 7.28 (t, J = 7.3 Hz, 1H), 4.63-4.98 (m, 2H), 3.61 (br s, 2H), 2.81-3.17 (m, 3H), 2.63 (tt, J = 8.5, 4.2 Hz, 1H), 2.41-2.48 (m, 1H), 1.37 (s, 3H), 1.31 (s, 3H)
78		Indazole 1 (using compound II' obtained from OHMe isomer 2)	410.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.32 (s, 1H), 8.54-9.01 (m, 2H), 8.31 (d, J = 5.4 Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 8.7 Hz, 1H), 7.51 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.36 (d, J = 5.4 Hz, 1H), 7.27 (td, J = 7.5, 0.7 Hz, 1H), 4.82-4.98 (m, 2H), 3.24-3.33 (m, 2H), 2.93-3.05 (m, 2H), 2.74 (s, 3H), 1.85-2.17 (m, 4H), 1.68 (s, 3H)



79		Indazole 1 (using compound II' obtained from OHMe isomer 2)	428.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.34 (s, 1H), 8.54-8.97 (m, 2H), 8.31 (d, J = 5.4 Hz, 1H), 7.85 (dd, J = 8.9, 5.0 Hz, 1H), 7.66 (d, J = 9.8 Hz, 1H), 7.34 (d, J = 5.4 Hz, 1H), 7.15 (td, J = 9.1, 2.3 Hz, 1H), 4.73-4.99 (m, 2H), 3.23-3.33 (m, 2H), 2.92-3.08 (m, 2H), 2.75 (s, 3H), 1.84-2.15 (m, 4H), 1.65 (s, 3H)
80		Indazole 3 (using compound II' obtained from OHMe isomer 2)	388.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.29 (s, 1H), 8.30 (d, J = 5.4 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.47 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.39 (d, J = 5.4 Hz, 1H), 7.25-7.32 (m, 1H), 3.39-3.48 (m, 2H), 2.90-3.05 (m, 2H), 2.80 (s, 3H), 2.56-2.67 (m, 2H), 2.15-2.27 (m, 1H), 1.93-2.03 (m, 1H), 1.59 (s, 3H)



81		Indazole 3 (using compound II' obtained from OHMe isomer 1)	388.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.29 (s, 1H), 8.30 (d, J = 5.4 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.47 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H), 7.39 (d, J = 5.3 Hz, 1H), 7.24-7.33 (m, 1H), 3.39-3.49 (m, 2H), 2.86-3.07 (m, 2H), 2.80 (s, 3H), 2.55-2.67 (m, 2H), 2.14-2.26 (m, 1H), 1.93-2.04 (m, 1H), 1.59 (s, 3H)
82		Indazole 1 (using compound II' obtained from EtOH isomer 1)	396	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.12 (br s, 1H), 8.28 (d, J = 5.4 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.57 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.55 (d, J = 5.6 Hz, 1H), 7.33-7.42 (m, 1H), 6.18 (s, 1H), 5.09-5.31 (m, 1H), 4.75-5.02 (m, 1H), 3.12-3.25 (m, 2H), 2.95-3.08 (m, 1H), 2.77 (br t, J = 12.4 Hz, 1H), 2.43-2.49 (m, 1H), 2.01 (s, 1H), 1.77-1.97 (m, 3H), 0.42 (t, J = 7.6 Hz, 3H)



83		Indazole 1 (using compound II' obtained from EtOH isomer 1)	396.1	¹ H NMR (DMSO-d ₆ , 600 MHz): δ (ppm) 11.13 (br s, 1H), 8.29 (d, J = 5.6 Hz, 1H), 8.18 (d, J = 8.2 Hz, 1H), 8.00 (d, J = 8.7 Hz, 1H), 7.61 (d, J = 5.4 Hz, 1H), 7.58 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.35-7.41 (m, 1H), 6.36 (s, 1H), 5.13-5.27 (m, 1H), 4.77-4.92 (m, 1H), 3.13-3.25 (m, 2H), 2.94- 3.07 (m, 1H), 2.79 (br t, J = 12.3 Hz, 1H), 2.50 (dt, J = 3.7, 1.8 Hz, 1H), 2.14 (s, 1H), 1.89 (br dd, J = 12.2, 2.5 Hz, 1H), 1.83 (q, J = 7.6 Hz, 2H), 0.43 (t, J = 7.5 Hz, 3H)
84		Indazole 1 (using compound II' obtained from EtOH isomer 2)	396.1	¹ H NMR (DMSO-d ₆ , 600 MHz): δ (ppm) 11.11 (br d, J = 0.6 Hz, 1H), 8.28 (d, J = 5.4 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.57 (ddd, J = 8.4, 7.0, 0.9 Hz, 1H), 7.55 (d, J = 5.4 Hz, 1H), 7.35-7.40 (m, 1H), 6.18 (s, 1H), 5.11-5.23 (m, 1H), 4.81-4.97 (m, 1H), 3.12-3.25 (m, 2H), 2.91-3.07 (m, 1H), 2.77 (br t, J = 12.3 Hz, 1H), 2.40-2.49 (m, 1H), 1.97-2.10 (m, 1H), 1.77-1.97 (m, 3H), 0.42 (t, J = 7.6 Hz, 3H)



85		Indazole 1 (using compound II' obtained from EtOH isomer 2)	396.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.13 (br s, 1H), 8.29 (d, J = 5.6 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.7 Hz, 1H), 7.61 (d, J = 5.4 Hz, 1H), 7.58 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.36-7.40 (m, 1H), 6.36 (s, 1H), 5.08-5.35 (m, 1H), 4.74-4.92 (m, 1H), 3.10-3.24 (m, 2H), 2.90-3.07 (m, 1H), 2.79 (br t, J = 12.5 Hz, 1H), 2.50 (dt, J = 3.7, 1.8 Hz, 1H), 1.89 (br dd, J = 12.5, 2.3 Hz, 1H), 1.83 (q, J = 7.6 Hz, 2H), 0.43 (t, J = 7.5 Hz, 3H)
86		Indazole 4	378.3	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.10 (s, 1H), 8.22 (d, J = 5.4 Hz, 1H), 7.77-7.87 (m, 2H), 7.49 (ddd, J = 8.4, 6.9, 0.8 Hz, 1H), 7.30 (d, J = 5.4 Hz, 1H), 7.22-7.27 (m, 1H), 4.46 (d, J = 5.6 Hz, 2H), 3.53-3.73 (m, 2H), 3.38 (td, J = 10.5, 2.4 Hz, 1H), 3.22-3.30 (m, 3H), 2.64-2.93 (m, 2H), 1.36 (d, J = 16.1 Hz, 6H)



87		Indazole 4	410.4	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.98-11.25 (m, 1H), 8.22 (br d, J = 3.2 Hz, 1H), 7.77-7.87 (m, 1H), 7.72 (br d, J = 9.3 Hz, 1H), 7.27 (br s, 1H), 7.06-7.18 (m, 1H), 4.64 (br d, J = 14.9 Hz, 1H), 4.44-4.56 (m, 1H), 3.40-3.73 (m, 4H), 3.03-3.13 (m, 1H), 2.70-2.82 (m, 1H), 2.16-2.42 (m, 1H), 1.35 (br d, J = 1.5 Hz, 6H), 0.95 (br s, 3H)
88		Indazole 1 (synthesized from racemic and separated in chiral purification with method B, OMe/Et isomer 1)	424.3	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.01-11.60 (m, 1H), 8.30 (d, J = 5.4 Hz, 1H), 7.67-7.83 (m, 2H), 7.42-7.53 (m, 1H), 7.32 (d, J = 5.4 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 4.57-4.84 (m, 2H), 2.61-2.87 (m, 7H), 2.10-2.38 (m, 2H), 1.85-1.99 (m, 1H), 1.49-1.80 (m, 4H), 0.58 (t, J = 7.6 Hz, 3H)



89		Indazole 1 (synthesized from racemic and separated in chiral purification with method B, OMe/Et isomer 2)	424.3	¹ H NMR (DMSO-d ₆ , 500 MHz): δ (ppm) 10.85-11.72 (m, 1H), 8.30 (d, J = 5.4 Hz, 1H), 7.76 (t, J = 8.4 Hz, 2H), 7.47 (t, J = 7.8 Hz, 1H), 7.31 (d, J = 5.4 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 4.58-4.85 (m, 2H), 2.59-2.88 (m, 7H), 2.32 (dd, J = 12.6, 7.7 Hz, 1H), 1.82-2.19 (m, 2H), 1.47-1.81 (m, 4H), 0.58 (t, J = 7.6 Hz, 3H)
90		Indazole 1(using compound II' obtained from OHMe isomer 1)	396.1	¹ H NMR (DMSO-d ₆ , 600 MHz): δ (ppm) 11.23 (br s, 1H), 8.28 (d, J = 5.4 Hz, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.47 (t, J = 7.7 Hz, 1H), 7.30 (d, J = 5.4 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H), 5.02-5.11 (m, 1H), 4.85 (d, J = 51.2 Hz, 1H), 3.13-3.22 (m, 2H), 2.98 (dd, J = 37.6, 13.2 Hz, 1H), 2.84 (s, 3H), 2.69-2.78 (m, 1H), 2.62-2.68 (m, 1H), 2.18 (br s, 1H), 1.84-1.92 (m, 1H), 1.54 (s, 3H)



91		Indazole 1(using compound II' obtained from OHMe isomer 1)	396.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.25 (br s, 1H), 8.29 (d, J = 5.4 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.48 (ddd, J = 8.3, 7.0, 1.0 Hz, 1H), 7.37 (d, J = 5.4 Hz, 1H), 7.27 (ddd, J = 8.0, 7.0, 0.7 Hz, 1H), 5.04-5.14 (m, 1H), 4.86 (d, J = 50.3 Hz, 1H), 3.15-3.22 (m, 2H), 2.98 (dd, J = 37.7, 14.1 Hz, 1H), 2.72-2.79 (m, 1H), 2.70 (s, 3H), 2.63-2.69 (m, 1H), 2.16 (br s, 1H), 1.89 (br dd, J = 12.3, 3.5 Hz, 1H), 1.73 (s, 3H)
92		Indazole 1(using compound II' obtained from OHMe isomer 2)	396	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.25 (br s, 1H), 8.28 (d, J = 5.4 Hz, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.30 (d, J = 5.4 Hz, 1H), 7.26 (t, J = 7.6 Hz, 1H), 5.02-5.11 (m, 1H), 4.89 (d, J = 50.5 Hz, 1H), 3.15-3.27 (m, 2H), 2.98 (dd, J = 37.9, 13.9 Hz, 1H), 2.84 (s, 3H), 2.72-2.78 (m, 1H), 2.60-2.68 (m, 1H), 2.21 (br s, 1H), 1.85-1.91 (m, 1H), 1.54 (s, 3H)



93		Indazole 1 (using compound II' obtained from OHMe isomer 2)	396.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.26 (br s, 1H), 8.29 (d, J = 5.4 Hz, 1H), 7.91 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 8.1 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.37 (d, J = 5.4 Hz, 1H), 7.27 (t, J = 7.6 Hz, 1H), 5.09 (br d, J = 19.8 Hz, 1H), 4.87 (d, J = 50.9 Hz, 1H), 3.15-3.21 (m, 2H), 2.98 (dd, J = 38.6, 15.3 Hz, 1H), 2.72-2.79 (m, 1H), 2.70 (s, 3H), 2.63-2.69 (m, 1H), 2.15 (br s, 1H), 1.89 (br dd, J = 12.5, 3.5 Hz, 1H), 1.73 (s, 3H)
94		Indazole 1 (using specific indazole 3 as compound III and synthesized from racemic and separated in chiral purification with method A, NHMe/Me isomer 2)	387.3	¹H NMR (600 MHz, DMSO-d₆) δ ppm 11.10 (s, 1 H), 0.00 (d, J=5.43 Hz, 1 H), 8.04 - 8.10 (m, 1 H), 7.68 (d, J=8.51 Hz, 1 H), 7.51 (m, J=5.40 Hz, 2 H), 7.31 - 7.38 (m, 1 H), 3.47 - 3.58 (m, 2 H), 2.96 - 3.07 (m, 1 H), 2.86 - 2.95 (m, 2 H), 2.59 - 2.69 (m, 2 H), 1.94 - 2.29 (m, 2 H), 1.88 (s, 3 H), 1.39 (s, 3 H)



95		Indazole 1 (using specific indazole 3 as compound III and synthesized from racemic and separated in chiral purification with method A, NHMe/Me isomer 1)	387.3	¹ H NMR (600 MHz, DMSO-d ₆) δ ppm 11.10 (s, 1 H), 8.25 (d, J=5.58 Hz, 1 H), 8.07 (d, J=8.22 Hz, 1 H), 7.65 - 7.72 (m, 1 H), 7.44 - 7.58 (m, 2 H), 7.29 - 7.37 (m, 1 H), 3.47 - 3.60 (m, 2 H), 2.96 - 3.06 (m, 1 H), 2.84 - 2.96 (m, 2 H), 2.56 - 2.70 (m, 2 H), 1.96 - 2.29 (m, 2 H), 1.88 (s, 3 H), 1.40 (s, 3 H)
96		Indazole 2	380.3	¹ H NMR (500 MHz, DMSO-d ₆) δ 11.14 (s, 1H), 9.83 - 9.17 (m, 2H), 8.23 (d, J = 5.4 Hz, 1H), 7.86 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.54 (t, J = 7.3 Hz, 1H), 7.33 - 7.24 (m, 2H), 5.22 - 5.03 (m, 2H), 3.72 - 3.53 (m, 1H), 3.53 - 3.24 (m, 3H), 2.48 - 2.32 (m, 1H), 2.26 - 2.08 (m, 1H), 1.36 (d, J = 8.3 Hz, 6H)



97		Indazole 1 (using compound II' obtained from MeEt isomer 2)	412.3	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.75-11.39 (m, 1H), 8.21 (d, J = 5.4 Hz, 1H), 8.01 (dd, J = 9.2, 4.3 Hz, 1H), 7.61 (dd, J = 9.0, 2.2 Hz, 1H), 7.43 (td, J = 9.0, 2.2 Hz, 1H), 7.31 (d, J = 5.4 Hz, 1H), 5.06-5.19 (m, 1H), 4.77-4.94 (m, 1H), 3.11-3.26 (m, 2H), 2.92-3.07 (m, 1H), 2.75 (br t, J = 12.5 Hz, 1H), 2.61 (qd, J = 12.3, 3.9 Hz, 1H), 2.28 (br s, 1H), 1.99-2.09 (m, 1H), 1.89 (br d, J = 9.8 Hz, 1H), 1.61-1.71 (m, 1H), 1.45 (s, 3H), 0.34 (t, J = 7.3 Hz, 3H)
98		Indazole 1 (using compound II' obtained from MeEt isomer 1)	412.3	¹H NMR (600 MHz, DMSO-d₆) δ 10.04-11.93 (m, 1H), 8.21 (d, J=5.43 Hz, 1H), 8.00 (dd, J=4.26, 9.24 Hz, 1H), 7.60 (dd, J=2.27, 9.17 Hz, 1H), 7.42 (dt, J=2.35, 9.02 Hz, 1H), 7.30 (d, J=5.43 Hz, 1H), 5.07-5.16 (m, 1H), 4.77-4.93 (m, 1H), 3.11-3.22 (m, 2H), 2.93-3.04 (m, 1H), 2.75 (br t, J=12.25 Hz, 1H), 2.60 (dq, J=4.18, 12.40 Hz, 1H), 1.98-2.06 (m, 1H), 1.95-2.42 (m, 1H), 1.88 (br d, J=9.24 Hz, 1H), 1.61-1.69 (m, 1H), 1.44 (s, 3H), 0.34 (t, J=7.41 Hz, 3H)



99		Indazole 1 (using compound II' obtained from MeEt isomer 2)	412.3	¹ H NMR (600 MHz, DMSO-d ₆) δ 8.21 (d, J=5.43 Hz, 1H), 8.00 (dd, J=4.18, 9.17 Hz, 1H), 7.61 (dd, J=2.35, 9.24 Hz, 1H), 7.42 (dt, J=2.42, 9.06 Hz, 1H), 7.32 (d, J=5.43 Hz, 1H), 5.07-5.17 (m, 1H), 4.77- 4.93 (m, 1H), 3.13-3.25 (m, 4H), 2.92-3.04 (m, 1H), 2.75 (br t, J=12.47 Hz, 1H), 2.55-2.66 (m, 1H), 2.10-2.18 (m, 1H), 1.89 (br d, J=9.68 Hz, 1H), 1.66-1.76 (m, 1H), 1.37 (s, 3H), 0.38 (t, J=7.41 Hz, 3H)
100		Indazole 1 (using compound II' obtained from MeEt isomer 1)	412.3	¹ H NMR (600 MHz, DMSO-d ₆) δ 11.11 (br s, 1H), 8.21 (d, J=5.43 Hz, 1H), 8.00 (dd, J=4.25, 9.10 Hz, 1H), 7.61 (dd, J=2.27, 9.17 Hz, 1H), 7.42 (dt, J=2.42, 9.06 Hz, 1H), 7.32 (d, J=5.43 Hz, 1H), 5.05-5.17 (m, 1H), 4.73-4.92 (m, 1H), 3.15-3.20 (m, 2H), 2.92-3.06 (m, 1H), 2.75 (br t, J=12.32 Hz, 1H), 2.52-2.65 (m, 1H), 1.96-2.35 (m, 2H), 1.89 (br d, J=9.54 Hz, 1H), 1.67-1.74 (m, 1H), 1.34-1.39 (m, 3H), 0.38 (t, J=7.41 Hz, 3H)

101		Indazole 1 (using compound II' obtained from MeEt isomer 1)	412.3	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 8.22 (d, J = 5.4 Hz, 1H), 7.82-7.90 (m, 2H), 7.29 (d, J = 5.4 Hz, 1H), 7.15 (td, J = 9.0, 2.2 Hz, 1H), 4.98-5.10 (m, 1H), 4.77-4.93 (m, 1H), 3.12-3.22 (m, 3H), 2.91-3.06 (m, 2H), 2.69-2.79 (m, 1H), 2.55-2.67 (m, 1H), 1.95-2.05 (m, 1H), 1.87 (br dd, J = 12.5, 2.9 Hz, 1H), 1.64 (dd, J = 13.4, 7.3 Hz, 1H), 1.44 (s, 3H), 0.33 (t, J = 7.5 Hz, 3H)
102		Indazole 1 (using compound II' obtained from MeEt isomer 1)	412.3	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.86-11.42 (m, 1H), 8.22 (d, J = 5.4 Hz, 1H), 7.80-7.93 (m, 2H), 7.31 (d, J = 5.6 Hz, 1H), 7.15 (td, J = 9.1, 2.1 Hz, 1H), 4.96-5.17 (m, 1H), 4.69-4.92 (m, 1H), 3.17 (br d, J = 11.5 Hz, 2H), 2.91-3.06 (m, 1H), 2.70-2.81 (m, 1H), 2.56-2.68 (m, 1H), 2.11 (dd, J = 13.7, 7.1 Hz, 1H), 2.00 (s, 1H), 1.88 (br dd, J = 12.6, 3.1 Hz, 1H), 1.69 (dd, J = 13.4, 7.3 Hz, 1H), 1.36 (s, 3H), 0.38 (t, J = 7.5 Hz, 3H)

103		Indazole 1 (using compound II' obtained from MeEt isomer 2)	412.3	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.83-11.36 (m, 1H), 8.22 (d, J = 5.4 Hz, 1H), 7.84-7.89 (m, 2H), 7.31 (d, J = 5.4 Hz, 1H), 7.15 (td, J = 9.1, 2.1 Hz, 1H), 4.97-5.11 (m, 1H), 4.84 (d, J = 52.8 Hz, 1H), 3.13-3.22 (m, 2H), 2.91-3.06 (m, 1H), 2.69-2.78 (m, 1H), 2.56-2.66 (m, 1H), 2.30 (br s, 1H), 2.08-2.16 (m, 1H), 1.84-1.91 (m, 1H), 1.65-1.74 (m, 1H), 1.36 (s, 3H), 0.38 (t, J = 7.5 Hz, 3H)
104		Indazole 1 (using compound II' obtained from MeEt isomer 2)	412.3	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 8.22 (d, J = 5.4 Hz, 1H), 7.83-7.89 (m, 2H), 7.29 (d, J = 5.4 Hz, 1H), 7.15 (t, J = 8.8 Hz, 1H), 4.98-5.11 (m, 1H), 4.78-4.93 (m, 1H), 3.12-3.23 (m, 3H), 2.93-3.04 (m, 2H), 2.69-2.77 (m, 1H), 2.55-2.67 (m, 1H), 2.00 (dd, J = 13.3, 7.5 Hz, 1H), 1.87 (br dd, J = 12.5, 2.9 Hz, 1H), 1.64 (dd, J = 13.4, 7.3 Hz, 1H), 1.44 (s, 3H), 0.33 (t, J = 7.3 Hz, 3H)

105		Indazole 1 (using compound II' obtained from MeEt isomer 2)	394.3	¹ H NMR (600 MHz, DMSO-d ₆) δ 11.11 (br s, 1H), 8.22 (d, J = 5.4 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 5.4 Hz, 1H), 7.28 (t, J = 7.4 Hz, 1H), 5.15 – 5.05 (m, 1H), 4.85 (d, J = 51.2 Hz, 1H), 3.22 – 2.93 (m, 3H), 2.77 (br t, J = 12.3 Hz, 1H), 2.69 – 2.58 (m, 1H), 2.20 – 2.05 (m, 2H), 1.92 – 1.86 (m, 1H), 1.74 – 1.66 (m, 1H), 1.38 (s, 3H), 0.38 (t, J = 7.4 Hz, 3H)
106		Indazole 1 (using compound II' obtained from MeEt isomer 1)	394.1	¹ H NMR (DMSO-d ₆ , 500 MHz) δ 11.11 (s, 1H), 8.22 (d, J=5.4 Hz, 1H), 7.93 (d, J=8.6 Hz, 1H), 7.85 (d, J=8.3 Hz, 1H), 7.4-7.5 (m, 1H), 7.32 (d, J=5.4 Hz, 1H), 7.28 (t, J=7.6 Hz, 1H), 5.00-5.20 (m, 1H), 4.80-4.90 (m, 1H), 3.10-3.20 (m, 2H), 2.90-3.10 (m, 1H), 2.77 (td, J=1.0, 12.2 Hz, 1H), 2.65 (qd, J=4.2, 12.5 Hz, 1H), 2.1-2.3 (m, 1H), 2.03 (spt, J=7.6 Hz, 1H), 1.80-1.90 (m, 1H), 1.65 (spt, J=7.3 Hz, 1H), 1.46 (s, 3H), 0.33 (t, J=7.5 Hz, 3H)

107		Indazole 1 (using compound II' obtained from MeEt isomer 2)	394.1	¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 11.10 (br s, 1H), 8.22 (d, J = 5.4 Hz, 1H), 7.92 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.49 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.31 (d, J = 5.3 Hz, 1H), 7.27 (td, J = 7.5, 0.7 Hz, 1H), 5.02-5.19 (m, 1H), 4.74-4.95 (m, 1H), 3.09-3.24 (m, 2H), 3.01 (dd, J = 38.7, 14.7 Hz, 1H), 2.76 (br t, J = 12.5 Hz, 1H), 2.59-2.69 (m, 1H), 2.13 (br dd, J = 4.2, 3.3 Hz, 1H), 1.99-2.07 (m, 1H), 1.89 (br dd, J = 12.6, 2.9 Hz, 1H), 1.59-1.70 (m, 1H), 1.45 (s, 3H), 0.33 (t, J = 7.3 Hz, 3H)
108		Indazole 1 (using compound II' obtained from MeEt isomer 1)	394.1	¹H NMR (600 MHz, DMSO-d₆) δ 8.22 (d, J = 5.4 Hz, 1H), 7.92 (d, J = 8.5 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.49 (ddd, J = 8.3, 7.1, 0.9 Hz, 1H), 7.33 (d, J = 5.4 Hz, 1H), 7.28 (ddd, J = 8.0, 7.0, 0.7 Hz, 1H), 5.16-5.05 (m, 1H), 4.85 (d, J = 51.4 Hz, 1H), 3.29-3.27 (m, 1H), 3.22-3.15 (m, 2H), 3.07-2.91 (m, 2H), 2.77 (br t, J = 12.3 Hz, 1H), 2.69-2.60 (m, 1H), 2.18-2.10 (m, 1H), 1.89 (br dd, J = 12.3, 2.8 Hz, 1H), 1.75-1.66 (m, 1H), 1.38 (s, 3H), 0.38 (t, J = 7.3 Hz, 3H)

109		Indazole 4	392.1	¹H NMR (600 MHz, DMSO-d₆) δ 11.10 (br s, 1H), 8.21 (d, J = 5.4 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.29 (d, J = 5.4 Hz, 1H), 7.24 (t, J = 7.6 Hz, 1H), 4.69 (d, J = 14.4 Hz, 1H), 4.53 (d, J = 14.4 Hz, 1H), 3.65 (br d, J = 11.0 Hz, 1H), 3.58 (d, J = 11.2 Hz, 1H), 3.52 – 3.46 (m, 1H), 3.29 – 3.26 (m, 1H), 3.13 – 3.07 (m, 1H), 2.74 (br d, J = 13.6 Hz, 1H), 2.38 (s, 1H), 1.36 (s, 6H), 0.96 – 0.91 (m, 3H)
110		Indazole 4	410.4	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.13 (br s, 1H), 8.22 (d, J = 5.4 Hz, 1H), 7.81 (dd, J = 9.0, 5.1 Hz, 1H), 7.71 (dd, J = 9.9, 2.1 Hz, 1H), 7.26 (d, J = 5.4 Hz, 1H), 7.12 (td, J = 9.0, 2.2 Hz, 1H), 4.64 (d, J = 14.4 Hz, 1H), 4.49 (d, J = 14.4 Hz, 1H), 3.60–3.67 (m, 1H), 3.55 (d, J = 11.2 Hz, 1H), 3.29–3.30 (m, 1H), 3.08 (ddd, J = 12.3, 8.6, 3.1 Hz, 1H), 2.71–2.79 (m, 1H), 2.21–2.39 (m, 1H), 1.35 (s, 6H), 1.06 (t, J = 7.0 Hz, 1H), 0.95 (s, 3H)



111		Indole 1	349	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 10.97 (s, 1H), 9.49 (br s, 2H), 8.45 (s, 1H), 8.14 (dd, J = 5.6, 2.0 Hz, 1H), 7.85 (dd, J = 7.9, 4.0 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.28-7.34 (m, 2H), 7.19-7.25 (m, 1H), 5.42 (dt, J = 19.1, 7.2 Hz, 1H), 3.99 (br s, 2H), 3.18-3.60 (m, 4H), 2.53-2.65 (m, 1H), 2.27-2.42 (m, 1H), 1.27 (s, 1.5H), 1.24 (s, 1.5H)
112		Indazole 1	380	¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.16 (s, 1H), 8.66-9.16 (m, 2H), 8.23 (d, J = 5.4 Hz, 1H), 7.87 (dd, J = 9.0, 5.1 Hz, 1H), 7.78 (dd, J = 9.8, 2.2 Hz, 1H), 7.31 (d, J = 5.4 Hz, 1H), 7.16 (td, J = 9.0, 2.2 Hz, 1H), 5.07 (tt, J = 11.4, 3.9 Hz, 1H), 4.02 (br s, 2H), 3.51 (br d, J = 13.0 Hz, 2H), 3.06-3.21 (m, 2H), 2.28-2.39 (m, 2H), 2.21 (br d, J = 12.2 Hz, 2H), 1.36 (s, 6H)

Table 1: Specific PKC-theta inhibitor compounds of the disclosure.

PKC-theta Activity, Prodrugs and Metabolites of Compounds

5 PKC-theta is selectively expressed in T lymphocytes and plays an important role in the T cell antigen receptor (TCR)-triggered activation of mature T cells, and the subsequent release of cytokines such as IL-2 and T cell proliferation (Isakov and Altman, Annu. Rev. Immunol., 2002, 20, 761-94). Thus, reduction of IL-2 levels is indicative of a desirable response that could provide a treatment of diseases and disorders as described herein, such as autoimmune and oncological disease.

10 Due to its involvement in T-cell activation, selective inhibition of PKC-theta may reduce harmful inflammation mediated by Th17 (mediating autoimmune diseases) or by Th2 (causing allergies) (Madouri et al, Journal of Allergy and Clinical Immunology. 139 (5): 2007, pp 1650–1666). without diminishing the ability of T cells to get rid of viral-infected cells. Inhibitors could be used in T-cell mediated adaptive immune responses. Inhibition of PKC-theta downregulates
15 transcription factors (NF- κ B, NF-AT) and results in lower production of IL-2. It was observed that animals without PKC-theta are resistant to some autoimmune diseases. (Zanin-Zhorov et al., Trends in Immunology. 2011, 32(8): 358–363). PKC-theta is therefore an interesting target for potential cancer and autoimmune therapies.

20 Studies in PKC-theta-deficient mice have demonstrated that while antiviral responses are independent of PKC-theta activity, T cell responses associated with autoimmune diseases are PKC-theta-dependent (Jimenez et al., J. Med. Chem. 2013, 56(5) pp 1799-1810). Thus, potent and selective inhibition of PKC-theta is expected to block autoimmune T cell responses without compromising antiviral immunity. However, the similarity of the PKC isoforms, particularly PKC-
25 delta, and selectivity over other protein kinases represents a challenge to the development of a suitable PKC-inhibitor for clinical use.

In order to address such concerns, in aspects and embodiments, compounds (or 'active agents') of the disclosure may beneficially provide a potent and selective (having a selectivity of greater
30 than 5-fold, preferably greater than 20-fold by a suitable measure, such as pIC50 in a suitable assay) PKC-theta inhibition over other PKC-isoforms, such as PKC-delta, and other kinases.

The active agents or compounds of the present invention may be provided as prodrugs of compounds of the disclosure.

35

The term 'active agent' is typically used to refer to a compound according to the disclosure which has inhibition activity against PKC-theta; especially under physiological conditions. However, it

is often the case that the active agent may be difficult to administer or deliver to the physiological site of relevance, e.g. due to solubility, half-life or many other chemical or biological reasons. Therefore, it is known to use 'prodrugs' of the active agent in order to overcome physiochemical, biological or other barriers in drug efficiency and/or toxicity. Moreover, prodrug strategy may be used to increase the selectivity of drugs for their intended target. In accordance with the disclosure, therefore, prodrugs may be beneficial in targeting the active agent to the biological sites of interest while advantageously bypassing e.g. the stomach (or lungs), where problematic of inconvenient side-effects may be manifested due to localised inhibition of PKC-theta activity.

10 An active agent may be formed from a compound or prodrug of the disclosure by metabolism of the drug *in vivo*, and/or by chemical or enzymatic cleavage of the prodrug *in vivo*. Typically, a prodrug may be a pharmacologically inactive compound that requires chemical or enzymatic transformation to become an effective, active agent inside the body in which it is intended to have its therapeutic effect. On the other hand, since a prodrug may, in some embodiments, have very close structural similarity to the active agent, in some such embodiments, the prodrug may also have activity against the PKC-theta target. This may be particularly the case where the active agent is formed from a compound or prodrug of the disclosure by metabolism or a minor chemical transformation, such that the metabolite is closely related to the parent compound / prodrug. Accordingly, prodrugs of the disclosure may be active inhibitors of PKC-theta. Suitably, however, such prodrugs may be characterised by having lower inhibition activity against PKC-theta than the drug / active agent that is derived from the prodrug of the disclosure.

On the other hand, where the therapeutic effect is derived from the release of the active agent from a larger chemical entity, then the eventual active agent / compound / drug may have significant structural differences compared to the prodrug from which it was derived. In such cases, the prodrug can effectively 'mask' the form(s) of the active agent, and in such cases the prodrug may be completely (or essentially) completely inactive under physiological conditions.

Dosage Forms, Medicaments and Pharmaceuticals

30 The compounds, molecules or agents of the disclosure may be used to treat (e.g. cure, alleviate or prevent) one or more diseases, infections or disorders. Thus, in accordance with the disclosure, the compounds and molecules may be manufactured into medicaments or may be incorporated or formulated into pharmaceutical compositions.

35 The molecules, compounds and compositions of the disclosure may be administered by any convenient route, for example, methods of administration include intradermal, intramuscular,

intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intravaginal, transdermal, rectally, by inhalation, or topically to the skin. Delivery systems are also known to include, for example, encapsulation in liposomes, microgels, microparticles, microcapsules, capsules, etc. Any other suitable delivery system known in the art is also
5 envisioned in use. Administration can be systemic or local. The mode of administration may be left to the discretion of the practitioner.

The dosage administered will, of course, vary depending upon known factors, such as the pharmacodynamic properties of the particular active agent; the chosen mode and route of
10 administration; the age, health and weight of the recipient; the nature of the disease or disorder to be treated; the extent of the symptoms; any simultaneous or concurrent treatments; the frequency of treatment; and the effect desired. In general, a daily dosage of active agent of between about 0.001 and about 1,000 mg/kg of body weight can be expected. For some applications, the dosage may suitably be within the range of about 0.01 to about 100 mg/kg;
15 between about 0.1 to about 25 mg/kg, or between about 0.5 and 10 mg/kg.

Depending on known factors, such as those noted above, the required dosage of the active agent may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of e.g. two, three, or four times daily. Suitably, the therapeutic treatment regime
20 according to the disclosure is devised for a single daily dose or for a divided daily dose of two doses.

Dosage forms of the pharmaceutical compositions of the disclosure suitable for administration may contain from about 1 mg to about 2,000 mg of the active ingredient per unit. Typically, the
25 daily dosage of compounds may be at least about 10 mg and at most about 1,500 mg per human dose; such as between about 25 and 1,250 mg or suitably between about 50 and 1,000 mg. Typically, the daily dosage of compounds may be at most about 1000 mg. In such compositions the compound of the invention will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

30 The 'effective amount' or 'therapeutically effective amount' is meant to describe an amount of compound or a composition of the disclosure that is effective in curing, inhibiting, alleviating, reducing or preventing the adverse effects of the diseases or disorders to be treated, or the amount necessary to achieve a physiological or biochemically-detectable effect. Thus, at the
35 effective amount, the compound or agent is able to produce the desired therapeutic, ameliorative, inhibitory or preventative effect in relation to disease or disorder. Beneficially, an effective amount of the compound or composition of the disclosure may have the effect of inhibiting PKC-theta.

Diseases or disorders which may benefit from PKC-theta inhibition include, for example, autoimmune disorders, inflammatory diseases, cancers and/or oncologic diseases, such as rheumatoid arthritis, multiple sclerosis, psoriasis, Sjogren's syndrome and systemic lupus erythematosus or vasculitic conditions, cancers of hematopoietic origin or solid tumors, including
5 chronic myelogenous leukemia, myeloid leukemia, non-Hodgkin lymphoma and other B cell lymphomas.

For therapeutic applications, the effective amount or therapeutically effective amount of a compound / active agent of the disclosure may be at least about 50 nM or at least about 100 nM;
10 typically at least about 200 nM or at least about 300 nM in the blood of the subject. The effective amount or therapeutically effective amount may be at most about 5 μ M, at most about 3 μ M, suitably at most about 2 μ M and typically at most about 1 μ M in the blood of the subject. For example, the therapeutically effective amount may be at most about 500 nM, such as between about 100 nM and 500 nM. In some embodiments the amount of therapeutic compound is
15 measured in serum of the subject and the above concentrations may then apply to serum concentration of the compounds of the disclosure.

When administered to a subject, a compound of the disclosure is suitably administered as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle.
20 One or more additional pharmaceutical acceptable carrier (such as diluents, adjuvants, excipients or vehicles) may be combined with the compound of the disclosure in a pharmaceutical composition. Suitable pharmaceutical carriers are described in "*Remington's Pharmaceutical Sciences*" by E. W. Martin. Pharmaceutical formulations and compositions of the disclosure are formulated to conform to regulatory standards and according to the chosen route of
25 administration.

Acceptable pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical vehicles can be saline, gum acacia, gelatin, starch
30 paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilising, thickening, lubricating and colouring agents may be used. When administered to a subject, the pharmaceutically acceptable vehicles are generally sterile. Water is a suitable vehicle when the compound is to be administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions.
35 Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The

present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or buffering agents.

5 The medicaments and pharmaceutical compositions of the disclosure can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, powders, gels, capsules (for example, capsules containing liquids or powders), modified-release formulations (such as slow or sustained-release formulations), suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. Other examples of suitable pharmaceutical vehicles are described in Remington's Pharmaceutical Sciences, Alfonso R. Gennaro ed., Mack Publishing Co. Easton, Pa., 19th ed., 1995, see for example pages 1447-1676.

15 Suitably, the therapeutic compositions or medicaments of the disclosure are formulated in accordance with routine procedures as a pharmaceutical composition adapted for oral administration (more suitably for humans). Compositions for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Thus, in one embodiment, the pharmaceutically acceptable vehicle is a capsule, tablet or pill.

20 Orally administered compositions may contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavouring agents such as peppermint, oil of wintergreen, or cherry; colouring agents; and preserving agents, to provide a pharmaceutically palatable preparation. When the composition is in the form of a tablet or pill, the compositions may be coated to delay disintegration and absorption in the gastrointestinal tract, so as to provide a sustained release of active agent over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compositions. In these dosage forms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These dosage forms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such vehicles are preferably of pharmaceutical grade. For oral formulations, the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art is able to prepare formulations that will not dissolve in the stomach yet will release the material in the duodenum or elsewhere in the intestine. Suitably, the release will avoid the deleterious effects of the stomach environment, either by protection of the compound (or composition) or by release of

the compound (or composition) beyond the stomach environment, such as in the intestine. To ensure full gastric resistance a coating impermeable to at least pH 5.0 would be essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, 5 HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac, which may be used as mixed films.

While it can be beneficial to provide therapeutic compositions and/or compounds of the disclosure in a form suitable for oral administration, for example, to improve patient compliance and for ease of administration, in some embodiments compounds or compositions of the disclosure may cause 10 undesirable side-effects, such as intestinal inflammation which may lead to premature termination of a therapeutic treatment regime. Thus, in some embodiments, the therapeutic treatment regime is adapted to accommodate 'treatment holidays', e.g. one or more days of non-administration. For example, treatment regimens and therapeutic methods of the disclosure may 15 comprise a repetitive process comprising administration of the therapeutic composition or compound for a number of consecutive days, followed by a treatment holiday of one or more consecutive days. For example, a treatment regime of the disclosure may comprise a repetitive cycle of administration of the therapeutic composition or compound for between 1 and 49 consecutive days, between 2 and 42 days, between 3 and 35 days, between 4 and 28 days, 20 between 5 and 21 days, between 6 and 14 days, or between 7 and 10 days; followed by a treatment holiday of between 1 and 14 consecutive days, between 1 and 12 days, between 1 and 10 days, or between 1 and 7 days (e.g. 1, 2, 3, 4, 5, 6 or 7 days).

To aid dissolution of the therapeutic agent into the aqueous environment a surfactant might be 25 added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. Potential nonionic detergents that could be included in the formulation as surfactants include: lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol 30 monostearate, polysorbate 20, 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants, when used, could be present in the formulation of the compound or derivative either alone or as a mixture in different ratios.

Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. 35 Where necessary, the compositions may also include a solubilising agent.

Another suitable route of administration for the therapeutic compositions of the disclosure is via pulmonary or nasal delivery.

- 5 Additives may be included to enhance cellular uptake of the therapeutic agent of the disclosure, such as the fatty acids oleic acid, linoleic acid and linolenic acid.

The therapeutic agents of the disclosure may also be formulated into compositions for topical application to the skin of a subject.

- 10 Where the invention provides more than one active compound / agent for use in combination, generally, the agents may be formulated separately or in a single dosage form, depending on the prescribed most suitable administration regime for each of the agents concerned. When the therapeutic agents are formulated separately, the pharmaceutical compositions of the invention may be used in a treatment regime involving simultaneous, separate or sequential administration
15 with the other one or more therapeutic agent. The other therapeutic agent(s) may comprise a compound of the disclosure or a therapeutic agent known in the art).

- The compounds and/or pharmaceutical compositions of the disclosure may be formulated and suitable for administration to the central nervous system (CNS) and/or for crossing the blood-
20 brain barrier (BBB).

The invention will now be described by way of the following non-limiting examples.

25 EXAMPLES

Materials and Methods

Sample preparation: Powders were solubilized in DMSO- d_6 , vortexed vigorously until the solution was clear and transferred to a NMR tube for data acquisition.

30 NMR spectroscopy:

- Liquid-state NMR experiments were recorded on a 600 MHz (14.1 Tesla) Bruker Avance III NMR spectrometer (600 MHz for ^1H , 151 MHz for ^{13}C) using a triple-resonance ^1H , ^{15}N , ^{13}C CP-TCI 5
35 mm cryoprobe (Bruker Biospin, Germany).

Liquid-state NMR experiments were recorded on a 500 MHz (11.75 Tesla) Bruker Avance I NMR spectrometer (500 MHz for ^1H , 125 MHz for ^{13}C) using a Dual Resonance BBI 5 mm probe (Bruker Biospin, Germany).

- 5 Liquid-state NMR experiments were recorded on a 400 MHz (9.4 Tesla) Bruker Avance NEO NMR spectrometer (400 MHz for ^1H , 100 MHz for ^{13}C) using a SEI 5 mm probe (Bruker Biospin, Germany).

- 10 All the experiments used for the resonance assignment procedure and the elucidation of the products structure (1D ^1H , 2D ^1H - ^1H -COSY, 2D ^1H - ^1H -ROESY, 2D ^1H - ^{13}C -HSQC, 2D ^1H - ^{13}C -HMBC) were recorded at 300 K. ^1H chemical shifts are reported in δ (ppm) as s (singlet), d (doublet), t (triplet), q (quartet), dd (double doublet), m (multiplet) or br s (broad singlet)

LCMS chromatography:

15

LCMS chromatography were recorded the following apparatus using:

- Waters HPLC : Alliance 2695, UV : PDA 996, MS : ZQ (simple Quad) ZQ2
- Waters UPLC : Acquity, UV : Acquity PDA, MS : Qda
- Waters UPLC : Acquity, UV : Acquity TUV, MS : Qda
- 20 - Waters UPLC : Acquity, UV : Acquity PDA, MS : QDa, ELSD

- 25 The apparatus was tested using a column Gemini NX-C18 Phenomenex (30 x 2 mm) 3 μm for the Waters HPLC or a CSH C18 Waters (50 x 2.1 mm), 1,7 μm for the UPLC Waters. All of them used a combination of the following eluents: H_2O + 0.05% TFA (v/v) and ACN + 0.035% TFA (v/v) and a positive electrospray ES+ as ionization mode. The UV detection was set up at 220 and 254 nm.

- 30 Temperatures are given in degrees Celsius ($^{\circ}\text{C}$). The reactants used in the examples below may be obtained from commercial sources or they may be prepared from commercially available starting materials as described herein or by methods known in the art. All of the compounds of the invention are synthesized according to the Examples described herein. The progress of the reactions described herein were followed as appropriate by e.g. LC, GC or TLC, and as the skilled person will readily realise, reaction times and temperatures may be adjusted accordingly.

35

Chiral purification:Method A:

Instrument: Waters Prep SFC80

5 Stationary Phase: Chiralpak IC 5 μ m, 250 x 20mmMobile phase: CO₂ / (EtOH + 0.5% IPAm) 70/30

Flowrate: 50 mL/min

UV detection: 220 nm

Temperature: 40°C

10 Pressure: 100 bars

Method B:

Instrument: Waters Prep SFC80;

Stationary Phase: Chiralcel OJ-H 5 μ m, 250 x 20mm15 Mobile phase: CO₂ / (EtOH + 0.5% IPAm) 70/30

Flowrate: 50 mL/min

UV detection: λ =254 nm

Temperature: 40°C - Pressure: 100 bars

20

Abbreviations

In addition to the definitions above, the following abbreviations are used in the synthetic schemes above and the examples below. If an abbreviation used herein is not defined, it has its generally accepted meaning:

	Ac	Acetyl
	ACN	Acetonitrile
30	AcOH	Acetic acid
	BH ₃	Borane
	Boc	<i>tert</i> -butoxycarbonyl
	B(OiPr) ₃	Triisopropyl borate
	CMBP	Cyanomethylenetriisobutylphosphorane
35	Cs ₂ CO ₃	Cesium carbonate
	DAST	Diethylaminosulfur trifluoride
	DBU	1,8-Diazabicyclo(5.4.0)undec-7-ene


	DCM	Dichloromethane
	DIPEA	Diisopropylethylamine
	DMAP	4-Dimethylaminopyridine
	DMF	Dimethylformamide
5	DMSO	Dimethylsulfoxide
	Et	Ethyl
	EtOAc	Ethyl acetate
	Et ₃ N	Triethylamine
	EtOH	Ethanol
10	Et ₂ O	Diethyl ether
	h	hour
	H ₂ O	water
	HCl	Hydrochloric acid
	iPrOH	Isopropanol
15	K ₃ PO ₄	tripotassium phosphate
	KOAc	Potassium acetate
	KOH	Potassium hydroxide
	min	minutes
	Me	Methyl
20	MeCN	Acetonitrile
	MeO or OMe	Methoxy
	MeOH	Methanol
	MgSO ₄	Magnesium sulfate
	MS	Mass spectrometry
25	Ms	Mesyl
	NaOH	Sodium hydroxide
	Na ₂ SO ₄	Sodium sulfate
	NaHCO ₃	Sodium bicarbonate
	Na ₂ CO ₃	Sodium carbonate
30	nBuLi	n-Butyl Lithium
	NBS	N-Bromosuccinimide
	NH ₄ Cl	Ammonium chloride
	NH ₄ HCO ₃	Ammonium hydrogenocarbonate
	Pd(PPh ₃) ₄	tetrakis(triphenylphosphine) palladium
35	Pd(dppf)Cl ₂	bis(diphenylphosphino)ferrocene] dichloropalladium(II)
	Pd/C	Palladium on carbon
	Ph	Phenyl

rt	Room temperature (18 to 22 °C)
TBAF	tetrabutylammonium fluoride
TBDPSCI	tert-butyl-chlorodiphenylsilane
TFA	Trifluoroacetic acid
5 THF	Tetrahydrofuran
Xantphos	4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
XPhos	Dicyclohexyl[2',4',6'-tris(propan-2-yl)[1,1'-biphenyl]-2-yl]phosphane

10

Example 1 – Chemical Synthesis Routes**Scaffolds**15 **Dimethyl Scaffold Synthesis**


Synthesis of 4-bromo-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one



20

In a 250ml three-necked round bottom flask, 1 M lithium bis(trimethylsilyl)amide solution (33 mL, 33.4 mmol, 3.8 eq.) was added dropwise via an additional funnel to a solution of 4-bromo-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one (2.00 g, 8.92 mmol, 1 eq.) in anhydrous THF (44 mL, 0.2 N) at -78°C. The mixture was stirred at -78°C for 10 min. Then iodomethane (1.4 mL, 22.3 mmol, 2.5 eq.) was added. The reaction was allowed to warm up to room temperature and stirred at room temperature for 1h. Then NH₄Cl sat and ethyl acetate were added. The two phases were separated and the aqueous phase was extracted with ethyl acetate. Combined organic phases were dried over Na₂SO₄, filtered and evaporated to give crude product. The crude material was purified by flash chromatography on silica gel using a gradient of dichloromethane/ ethyl acetate. It was transferred via solid phase on dicalite. Relevant fractions were collected and concentrated under vacuum to afford 4-bromo-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one as a pale yellow powder (63% Yield). ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 11.26 (s, 1H), 7.95 (d, *J*=5.7 Hz, 1H), 7.19 (d, *J*=5.7 Hz, 1H), 1.39 (s, 6H); *m/z* = 241.2, 243.2 [M+H]⁺.


35 **Synthesis of 4-bromo-3,3-dimethyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one**



In a 20mL microwave vial, 3,4-dihydro-2H-pyran (0.68 mL, 7.47 mmol, 3 eq.) was added to a stirred solution of 4-bromo-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one (600 mg, 2.49 mmol) and p-toluene sulfonic acid hydrate (95 mg, 0.498 mmol, 0.2 eq.) in anhydrous toluene (12 mL, 0.2 N). The reaction was stirred at 90°C for 5h. The solvent was removed under vacuum to give crude material as an orange oil. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / ethyl acetate. Relevant fractions were collected and concentrated under vacuum to afford 4-bromo-3,3-dimethyl-1-(tetrahydropyran-2-yl)pyrrolo[2,3-b]pyridin-2-one (750mg, 93% Yield). ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 8.07 (d, *J*=5.6 Hz, 1H), 7.32 (d, *J*=5.6 Hz, 1H), 5.40 (dd, *J*=11.3, 2.1 Hz, 1H), 3.97 (d, *J*=10.8 Hz, 1H), 3.56 (qd, *J*=11.2, 10.8, 5.0 Hz, 1H), 2.85 (qd, *J*=13.7, 12.7, 3.8 Hz, 1H), 2.01 – 1.86 (m, 1H), 1.68 – 1.48 (m, 4H), 1.42 (s, 6H), *m/z* = 325.2, 327.0 [M+H]⁺.

15

Synthesis of 3,3-dimethyl-1-(tetrahydropyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one



20


A sealed vial was charged under nitrogen with 4-bromo-3,3-dimethyl-1-(tetrahydropyran-2-yl)pyrrolo[2,3-b]pyridin-2-one (0.75 g, 2.31mmol), bis(pinacolato)diboron (0.88 g, 3.46 mmol, 1.5 eq.), potassium acetate (715 mg, 6.92 mmol, 3 eq.) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (193 mg, 0.231 mmol, 0.1 eq.) in anhydrous dioxane (8 mL, 0.3 N). The vial was sealed and degassed with nitrogen. The reaction mixture was stirred at 100°C overnight. The reaction mixture was filtered through a pad of dicalite and the filtrate was evaporated to dryness to give crude material as a dark oil. The crude product was

25

purified by flash chromatography on silica gel using a gradient of heptane / ethyl acetate. Relevant fractions were collected and concentrated under vacuum to afford 3,3-dimethyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one (490mg, 57% Yield) as a yellow oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 8.19 (d, *J*=5.1 Hz, 1H), 7.24 (d, *J*=5.1 Hz, 1H), 5.42 (dd, *J*=11.3, 2.0 Hz, 1H), 3.96 (d, *J*=11.1 Hz, 1H), 3.64 – 3.44 (m, 1H), 2.89 (d, *J*=11.4 Hz, 1H), 1.91 (s, 1H), 1.73 – 1.46 (m, 4H), 1.40 (s, 6H), 1.35 (s, 12H). *m/z* = 373.4 [M+H]⁺.


Ethyl/Methyl Scaffold Synthesis

Synthesis of 3,4-dibromo-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one



To a stirred solution of 4-bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine (460 mg, 2.07 mmol) in tert-butanol (16 mL, 0.13 N) was added in small portions pyridinium bromide-perbromide (1.46 g, 4.56 mmol, 2.2 eq.) over 10 min. The reaction was stirred at room temperature overnight. t-Butanol was removed in vacuo. Water was added followed by ethyl acetate. The two phases were separated and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with water, dried over Na₂SO₄, concentrated under high vacuum to give 3,4-dibromo-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (660mg, 96% Yield) as a white solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 11.77 (s, 1H), 8.04 (d, *J*=5.7 Hz, 1H), 7.32 (d, *J*=5.7 Hz, 1H), 2.07 (s, 3H); (product not stable in LCMS)

Synthesis of 4-bromo-3-methyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one



In a 50mL round-bottomed flask, at room temperature, zinc powder (847 mg, 13.0 mmol, 2 eq.) was added in portions to a stirred suspension of 3,4-dibromo-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (2.00 g, 6.01 mmol) in a mixture of methanol (30 mL) and acetic acid (15 mL). The reaction was stirred at room temperature for 10 min. The mixture was neutralized with an aqueous solution of NaHCO₃ until pH=6. The solution was filtered and the aqueous phase was extracted

with EtOAc. Combined organic phases were washed with brine, dried over Na₂SO₄, filtered and evaporated to give 4-bromo-3-methyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one (1.08g, 76% Yield) as a white solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 11.22 (s, 1H), 7.95 (dd, *J*=5.7, 0.8 Hz, 1H), 7.18 (d, *J*=5.7 Hz, 1H), 3.66 – 3.49 (m, 1H), 1.43 (d, *J*=7.6 Hz, 3H); *m/z* = 227.1, 229.1 [M+H]⁺.

Synthesis of 4-bromo-3-ethyl-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one



At -78°C, under an argon stream, 1 M lithium [bis(trimethylsilyl)amide] solution (2.2 mL, 2.16 mmol, 2 eq.) was added dropwise to a solution of 4-bromo-3-methyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one (350 mg, 1.08 mmol) in anhydrous tetrahydrofuran (2.7 mL, 0.4 N). The reaction was stirred at -78°C for 10 min. Then iodoethane (0.087 mL, 1.08 mmol, 1 eq.) was added and the mixture was stirred at room temperature under argon stream for 1h. Then an aqueous solution of HCl 1N was added slowly to reach pH6-7 followed by ethyl acetate. The two phases were separated and the aqueous phase was extracted with ethyl acetate. Combined organic phases were dried using a phase separator and evaporated to give crude material as an orange solid. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / ethyl acetate. It was transferred via solid phase. Relevant fractions were collected and concentrated under vacuum to afford 4-bromo-3-ethyl-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (155mg, 56% Yield) as a beige powder. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.30 (s, 1H), 7.96 (d, *J* = 5.7 Hz, 1H), 7.21 (d, *J* = 5.7 Hz, 1H), 2.21 – 2.05 (m, 1H), 1.77 (dq, *J* = 14.7, 7.4 Hz, 1H), 1.38 (s, 3H), 0.50 (t, *J* = 7.4 Hz, 3H); *m/z* = 255.1, 257.1 [M+H]⁺.

The two enantiomers were obtained from chiral separation of the racemic mixture in SFC conditions.

Instrument: Novasep SFC Superprep

Stationary Phase: Chiralpak AD-H 20μm, 300 x 50mm

Mobile phase: CO₂ / MeOH 73/27

Flowrate: 1000 g/min UV detection: λ=295 nm

Temperature: 45°C

Pressure: 130 bars

Sample: dissolution in MeOH


rt (MeEt isomer 1) = 4.74 min and rt (MeEt isomer 2) = 7.06 min

The *S*-isomer has been arbitrarily assigned as MeEt isomer 1 and the *R*-isomer has been arbitrarily assigned as MeEt isomer 2. The same nomenclature has been used to describe all related derivatives.

5


The following protocols were the same for racemic mixture and the pure enantiomers. The synthesis of boronic esters is described with the racemic mixture.

10 Synthesis of 4-bromo-3-ethyl-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-*b*]pyridin-2-one



A 50 mL vial was charged with 4-bromo-3-ethyl-3-methyl-1H-pyrrolo[2,3-*b*]pyridin-2-one (2.14 g, 6.79 mmol), 3,4-dihydro-2H-pyran (1.9 mL, 20.4 mmol, 3 eq.), and *p*-toluene sulfonic acid hydrate (271 mg, 1.43 mmol, 0.2 eq) in anhydrous toluene (34 mL, 0.2 N). The reaction mixture was stirred at 80°C overnight. The reaction mixture was allowed to reach room temperature. Then water was added and the reaction mixture was extracted with EtOAc. Combined organic layers were dried using a phase separator and concentrated under vacuum to give crude material as an orange solid. The crude material was purified by flash chromatography on silica gel using a gradient of Cyclohexane/ EtOAc. It was transferred via solid phase on dicalite. Relevant fractions were collected and concentrated under vacuum to afford 4-bromo-3-ethyl-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-*b*]pyridin-2-one (1.45 g, 62.951% Yield) as a yellow oil. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.08 (d, *J* = 5.6 Hz, 1H), 7.33 (d, *J* = 5.7 Hz, 1H), 5.42 (dd, *J* = 11.4, 1.8 Hz, 1H), 3.97 (d, *J* = 10.9 Hz, 1H), 3.54 (tt, *J* = 11.2, 2.9 Hz, 1H), 2.86 (pd, *J* = 13.1, 3.9 Hz, 1H), 2.18 (ddh, *J* = 15.0, 7.5, 3.5 Hz, 1H), 1.93 (d, *J* = 10.8 Hz, 1H), 1.81 (dq, *J* = 14.7, 7.3, 1.7 Hz, 1H), 1.69 – 1.45 (m, 4H), 1.40 (d, *J* = 0.8 Hz, 3H), 0.45 (t, *J* = 7.4 Hz, 3H). *m/z* = 338.9, 340.8 [M+H]⁺.


Synthesis of 3-ethyl-3-methyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one



In a 20 mL microwave-vial were introduced bis(pinacolato)diboron (2.19 g, 8.61 mmol, 2 eq.), potassium acetate (1.33 g, 12.9 mmol, 3 eq.), 4-bromo-3-ethyl-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (1460 mg, 4.30 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (352 mg, 0.430 mmol, 0.1 eq.) in anhydrous dioxane (43 mL, 0.1 N). The mixture was degassed with nitrogen and then stirred at 100°C for 2h. The reaction mixture was allowed to reach room temperature and filtered through a dicalite pad. The dicalite was washed with EtOAc. Combined organic layers were concentrated under vacuum to give crude material as a brown oil. The crude material was purified by flash chromatography on silica gel using a gradient of Cyclohexane/ EtOAc. It was transferred via solid phase on dicalite. Relevant fractions were collected and concentrated under vacuum to afford 3-ethyl-3-methyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one (1.08 g, 52 % Yield) as a pale yellow oil. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 8.19 (d, *J*=5.2 Hz, 1H), 7.25 (d, *J*=5.1 Hz, 1H), 5.43 (dd, *J*=11.4, 2.0 Hz, 1H), 3.96 (d, *J*=11.1 Hz, 1H), 3.64 – 3.49 (m, 1H), 3.01 – 2.79 (m, 1H), 2.33 – 2.16 (m, 1H), 1.93 (d, *J*=11.0 Hz, 1H), 1.87 – 1.73 (m, 2H), 1.71 – 1.43 (m, 6H), 1.34 (s, 12 H), 0.38 (t, *J*=7.4 Hz, 3H); *m/z* = 387.0 [M+H]⁺.

20 Me/OH Scaffold Synthesis

Synthesis of 4-bromo-3-hydroxy-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one



25

A round bottom flask was charged with sodium hydride (60%, 203 mg, 5.09 mmol, 1.1 eq.) in THF (10 mL) under N₂. The mixture was cooled down to 0°C and 4-bromo-3-methyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one (1.05 g, 4.62 mmol) in THF (13 mL) was added dropwise. Then the reaction was opened and left to the air overnight at room temperature. Then an aqueous

solution of HCl 1N was added. The aqueous phase was extracted with ethyl acetate. Combined organic phases were dried over phase separator and evaporated to give crude material. The product was triturated in DCM to afford 4-bromo-3-hydroxy-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (697mg, 62% Yield) as a pale yellow solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 11.11 (s, 1H), 7.95 (d, *J*=5.7 Hz, 1H), 7.18 (d, *J*=5.7 Hz, 1H), 6.11 (s, 1H), 1.50 (s, 3H); *m/z* = 243.1, 245.1 [M+H]⁺.

The two enantiomers were obtained from chiral separation of the racemic mixture in SFC conditions:

10

Instrument: Waters prep SFC Supersep

Stationary Phase: Chiralpak AD-H 20μm, 250 x 50mm

Mobile phase: CO₂ / MeOH 87/13

Flowrate: 1000g/min UV detection: λ=290 nm

15

Temperature: 40°C

Pressure: 150 bars

Sample: dissolution in MeOH

rt (OHMe isomer 1) = 6.05 min and rt (OHMe isomer 2) = 8.34 min

20


The *S*-isomer has been arbitrarily assigned as OHMe isomer 1 and the *R*-isomer has been arbitrarily assigned as OHMe isomer 2. The same nomenclature has been used to describe all related derivatives.

25

The following protocols were the same for racemic mixture or the pure enantiomers. The boronic esters synthesis will be described for enantiomer 1.


Synthesis of (3*R*)-4-bromo-3-hydroxy-3-methyl-1-(tetrahydropyran-2-yl)-pyrrolo[2,3-*b*]pyridin-2-one

30



In a sealed vial, 3,4-dihydro-2H-pyran (3.0 mL, 32.9 mmol, 4 eq.) was added to a stirred solution of (3R)-4-bromo-3-hydroxy-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (2.00 g, 8.23 mmol) and p-toluene sulfonic acid hydrate (313 mg, 1.65 mmol, 0.2 eq.) in anhydrous toluene (27 mL, 0.3 N). The reaction was stirred at 90°C overnight. Then the mixture was cooled at 0°C and 4 M hydrogen chloride (4.1 mL, 16.5 mmol, 2 eq.) was added. The mixture was stirred for 2h at room temperature. The solution was concentrated under vacuum. Dichloromethane and an aqueous solution of NaHCO₃ aq were added. The aqueous phase was extracted by dichloromethane. The organic phase was dried on a phase separator and concentrated under vacuum. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / EtOAc. Relevant fractions were collected and evaporated to afford (3R)-4-bromo-3-hydroxy-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (1.02g, 36% Yield). ¹H NMR (DMSO-d₆, 400 MHz): δ (ppm) 8.07 (dd, J=5.6, 1.2 Hz, 1H), 7.31 (dd, J=5.7, 0.8 Hz, 1H), 6.28 (d, J=6.8 Hz, 1H), 5.37 (dd, J=11.3, 1.9 Hz, 1H), 4.02 – 3.90 (m, 1H), 3.54 (td, J=11.0, 10.6, 3.2 Hz, 1H), 2.90 – 2.73 (m, 1H), 1.93 (d, J=10.0 Hz, 1H), 1.69 – 1.44 (m, 7H); m/z = 327.0, 328.9 [M+H]⁺.

Synthesis of (3R)-3-hydroxy-3-methyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one




A vial was charged with *bis(pinacolato)diboron* (640 mg, 2.52 mmol, 1.5 eq.), potassium acetate (521 mg, 5.04 mmol, 3 eq.), (3R)-4-bromo-3-hydroxy-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (0.55 g, 1.68 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with *dichloromethane* (140 mg, 0.168 mmol, 0.1 eq.) in anhydrous dioxane (5.6 mL, 0.3N). The vial was sealed and degassed with nitrogen. The reaction mixture was stirred at 100°C for 2h. The reaction mixture was filtered through a pad of dicalite and the filtrate was evaporated to dryness to give crude material as a dark oil. The crude material was purified by flash chromatography on silica gel using a gradient of dichloromethane / ethyl acetate. It was transferred via solid phase on dicalite. Fractions were collected and concentrated under vacuum to afford (3R)-3-hydroxy-3-methyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-

dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one (211mg, 28% Yield) was obtained as a yellow gum.
¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 8.18 (d, *J*=5.0 Hz, 1H), 7.14 (d, *J*=5.1 Hz, 1H), 5.92 (d, *J*=6.4 Hz, 1H), 5.38 (d, *J*=9.9 Hz, 1H), 3.96 (d, *J*=11.0 Hz, 1H), 3.59 – 3.49 (m, 1H), 2.86 (q, *J*=13.4, 12.5 Hz, 1H), 1.92 (s, 1H), 1.70 – 1.41 (m, 7H), 1.33 (d, *J*=7.0 Hz, 12H); *m/z* = 293.2
 5 [M+H]⁺.


Me/OMe Scaffold Synthesis

10 Synthesis of (3R)-4-bromo-3-methoxy-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one



In a 50mL round-bottomed flask, at 0°C, under nitrogen, sodium hydride (60%, 378 mg, 9.44
 15 mmol, 1.5 eq.) was added to a stirred solution of (3R)-4-bromo-3-hydroxy-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (2.06 g, 6.30 mmol) in anhydrous DMF (32 mL, 0.2 N). The reaction was stirred at room temperature for 30mn. Then 2 M iodomethane in tert-butylmethyl ether (6.3 mL, 12.6 mmol, 2 eq.) was added dropwise at 0°C. The reaction was stirred at 0°C for 15 min and allowed to reach room temperature. After 45 min at room
 20 temperature, the reaction was quenched with water and EtOAc was added. The two phases were separated and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with water, dried using a phase separator and evaporated to give (3R)-4-bromo-3-methoxy-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one as an orange gum (1.49g, 63% Yield). ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 8.16 (d, *J*=5.6 Hz, 1H), 7.40 (dd, *J*=5.6, 0.8 Hz, 1H), 5.42 (dt, *J*=11.4, 2.6 Hz, 1H), 4.00 – 3.93 (m, 1H), 3.61 – 3.49 (m, 1H), 2.91 (s, 3H),
 25 2.87 – 2.75 (m, 1H), 1.94 (d, *J*=10.9 Hz, 1H), 1.70 – 1.41 (m, 7H); *m/z* = 341.1, 343.1 [M+H]⁺.


Synthesis of (3R)-3-methoxy-3-methyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one



A reacti-vial, under a nitrogen atmosphere, was charged with tricyclohexylphosphane (459 μ L, 0.290 mmol, 0.075 eq.), *bis*(pinacolato)diboron (1.96 g, 7.73 mmol, 4 eq.), (3R)-4-bromo-3-methoxy-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (1.45 g, 3.87 mmol) and anhydrous dioxane (19 mL, 0.2 N). Then potassium acetate (767 mg, 7.73 mmol, 4 eq.) and tris(dibenzylideneacetone)dipalladium(0) (186 mg, 0.193 mmol, 0.05 eq.) were added. The reaction was stirred at 100°C for 2 h. The solvent was evaporated. Then water and dichloromethane were added. The two phases were separated and the aqueous phase was extracted with dichloromethane. Combined organic phases were dried using a phase separator and evaporated to give crude material as an orange gum. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / ethyl acetate. It was transferred via solid phase. Relevant fractions were collected and concentrated under vacuum to afford (3R)-3-methoxy-3-methyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one (665 mg, 43% Yield) as an orange gum. ^1H NMR (DMSO- d_6 , 400 MHz): δ (ppm) 8.26 (d, $J=5.1$ Hz, 1H), 7.22 (dd, $J=5.1, 1.7$ Hz, 1H), 5.42 (ddd, $J=11.4, 5.4, 2.1$ Hz, 1H), 4.01 – 3.94 (m, 1H), 3.62 – 3.48 (m, 1H), 2.89 – 2.76 (m, 4H), 1.94 (d, $J=11.4$ Hz, 1H), 1.73 – 1.46 (m, 7H), 1.33 (d, $J=2.6$ Hz, 12H); m/z = 307.2 $[\text{M}+\text{H}]^+$ (acid form).

Et/OH Scaffold Synthesis

Synthesis of 3-bromo-4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-2-one



To a stirred solution of 4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridine hydrochloride (3.00 g, 13.8 mmol) in tert-butanol (106 mL, 0.13 N) was added in small portions pyridinium bromide-perbromide (11.05 g, 34.5 mmol). The reaction was stirred at room temperature during 3h. tert-

butanol was removed under vacuum. The product was triturated in water and filtered to afford 3-bromo-4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-2-one (2.95g, 77% Yield) as a beige solid. ^1H NMR(DMSO- d_6 , 400 MHz): δ (ppm) 11.89 (s, 1H), 8.18 (d, $J=5.7$ Hz, 1H), 7.21 (d, $J=5.7$ Hz, 1H), 2.84 – 2.56 (m, 1H), 2.47 – 2.23 (m, 1H), 0.62 (t, $J=7.4$ Hz, 3H)

5

Synthesis of 4-chloro-3-ethyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one




10

To a stirred suspension of 3-bromo-4-chloro-3-ethyl-1H-pyrrolo[2,3-b]pyridin-2-one (2.95 g, 10.7 mmol) in THF (33 mL, 0.3 N), at rt, was added zinc (1.05 g, 16.1 mmol) and then water (0.58 mL, 32.1 mmol) dropwise. The mixture was stirred at room temperature during 2h. Then the solution was filtered under Dicalite to remove all residue of zinc. The filtrate was concentrated under vacuum to afford 4-chloro-3-ethyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one (2.1g, 98% Yield) as a yellow solid; $m/z = 197.1, 199.1$ $[\text{M}+\text{H}]^+$.

15

Synthesis of 4-chloro-3-ethyl-3-hydroxy-1H-pyrrolo[2,3-b]pyridin-2-one



20

An aqueous solution of sodium hydroxide 10N (2.7 mL, 26.7 mmol) was added to a solution of 4-chloro-3-ethyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one (2.10 g, 10.7 mmol) in ethanol (49 mL, 0.2 N). The mixture was stirred at room temperature overnight. The mixture was concentrated under vacuum and a mixture of an aqueous solution of NH_4Cl and MeTHF was added. Phases were separated and the organic phase dried and concentrated under vacuum to afford 4-chloro-3-ethyl-3-hydroxy-1H-pyrrolo[2,3-b]pyridin-2-one (2.2 g, 94% Yield) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6) δ 8.07 (d, $J = 5.7$ Hz, 1H), 7.06 (d, $J = 5.7$ Hz, 1H), 6.19 (s, 1H), 2.13 (tt, $J = 14.3, 7.8$ Hz, 1H), 2.03 – 1.87 (m, 1H), 0.55 (t, $J = 7.5$ Hz, 3H); $m/z = 213.1, 215.1$ $[\text{M}+\text{H}]^+$.

25

30

The two enantiomers were obtained from chiral separation of the racemic mixture in SFC conditions:

Instrument: Waters prep SFC200

5 Stationary Phase: Chiralpak IC 5 μ m, 250 x 30mm

Mobile phase: CO₂ / MeOH 80/20

Flowrate: 100 mL/min UV detection: λ =210 nm

Temperature: 40°C

Pressure: 100 bars


10 Sample: dissolution in MeOH

rt (OHet isomer 1) = 4.82 min and rt (OHet isomer 2) = 6.74 min

The S-isomer has been arbitrarily assigned as OHet isomer 1 and the R-isomer has been arbitrarily assigned as OHet isomer 2. The same nomenclature has been used to describe all
15 related derivatives.

Et/OMe Scaffold Synthesis

20 Synthesis of 4-chloro-3-ethyl-3-hydroxy-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one




In a sealed vial, 3,4-dihydro-2H-pyran (0.79 mL, 8.67 mmol, 4 eq.) was added to a stirred solution of 4-chloro-3-ethyl-3-hydroxy-1H-pyrrolo[2,3-b]pyridin-2-one (614 mg, 2.89 mmol) and p-toluene
25 sulfonic acid hydrate (110 mg, 0.578 mmol) in anhydrous toluene (12 mL, 0.2 N). The reaction was stirred at 90°C overnight. Then the mixture was cooled at 0°C and 4 M hydrogen chloride (1.4 mL, 5.78 mmol, 2 eq.) was added. The mixture was stirred 3h at room temperature. The solution was concentrated under vacuum. Ethyl acetate and an aqueous solution of NaHCO₃ aq were added. The aqueous phase was extracted by ethyl acetate. The organic phase was dried
30 on a phase separator and concentrated under vacuum. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / EtOAc. Relevant fractions were collected and evaporated to afford 4-chloro-3-ethyl-3-hydroxy-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (446mg, 52% Yield) as a yellow oil. ¹H NMR(DMSO-d₆, 400 MHz): δ

(ppm) 8.19 (d, J=5.7 Hz, 1H), 7.18 (d, J=5.7 Hz, 1H), 6.34 (d, J=4.5 Hz, 1H), 5.39 (d, J=11.3 Hz, 1H), 3.97 (d, J=10.5 Hz, 1H), 3.55 (t, J=11.2 Hz, 1H), 2.92 – 2.73 (m, 1H), 2.17 (dtd, J=15.4, 7.7, 3.5 Hz, 1H), 1.99 – 1.88 (m, 2H), 1.64 – 1.44 (m, 4H), 0.50 (t, J=7.6 Hz, 3H); m/z = 297.1, 299.1 [M+H]⁺.

5


Synthesis of 4-chloro-3-ethyl-3-methoxy-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one



- 10 To a solution of 4-chloro-3-ethyl-3-hydroxy-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (220 mg, 0.741 mmol) in anhydrous DMF (3.7 mL, 0.2 N) was added sodium hydride (60%, 44 mg, 1.11 mmol) at 0°C under N₂. The resulting mixture was stirred 20 min at 0°C. Then iodomethane (0.092 mL, 1.48 mmol) was added dropwise at 0°C. The mixture was stirred 5 min at 0°C and allowed to reach RT. The resulting mixture was stirred 30min at RT under N₂. The
- 15 mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over phase separator and concentrated under vacuum to afford 4-chloro-3-ethyl-3-methoxy-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (213 mg, 90% Yield) as a yellow oil. ¹H NMR (DMSO-d₆, 400 MHz): δ (ppm) 8.29 (d, J=5.7 Hz, 1H), 7.29 (dd, J=5.7, 1.2 Hz, 1H), 5.43 (d, J=11.3 Hz, 1H), 3.98 (d, J=11.0 Hz, 1H), 3.55 (t, J=11.1 Hz, 1H),
- 20 3.28 (d, J=4.8 Hz, 1H), 2.95 (d, J=1.2 Hz, 3H), 2.81 (d, J=11.4 Hz, 1H), 2.18 (ddd, J=13.2, 7.7, 2.4 Hz, 1H), 1.98 (dd, J=13.3, 7.5 Hz, 1H), 1.57 (d, J=45.7 Hz, 4H), 0.55 (t, J=7.5 Hz, 3H), m/z = 311.2 - 313.2 [M+H]⁺.

Scaffold Me/NMe

Synthesis of 4-bromo-3-methyl-3-(methylamino)-1H-pyrrolo[2,3-b]pyridin-2-one



5


In a reactivial, a solution of methanamine in THF (6.0 mL, 8.04 mmol 1,34N) (cooled at -30°C) was added at -30°C to 3,4-dibromo-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (500 mg, 1.63 mmol). The mixture was allowed to reach 0°C and stirred 7h at 0°C. The solution was concentrated to dryness to give a yellow gum. The crude material was purified by flash chromatography on silica gel using a gradient of heptane /EtOAc. It was transferred via liquid injection in DCM on a 24g Redisep column. Relevant fractions were collected and concentrated under vacuum to afford 4-bromo-3-methyl-3-(methylamino)-1H-pyrrolo[2,3-b]pyridin-2-one as a white solid (179 mg, 43%); ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.23 (s, 1H), 7.96 (d, *J* = 5.7 Hz, 1H), 7.20 (d, *J* = 5.7 Hz, 1H), 1.90 (s, 3H), 1.41 (s, 3H); *m/z* = 256.0, 258.0 [*M*+*H*]⁺

15

Other Scaffolds

Synthesis of 7-bromo-1,3-dihydroimidazo[4,5-b]pyridin-2-one


20



4-bromopyridine-2,3-diamine (5.00 g, 25.3 mmol) and 1,1'-carbonyldiimidazole (8.19 g, 50.5 mmol) were introduced to a sealed vial. THF (140 mL) was added and the mixture was stirred at 60°C overnight. The flask was cooled with an ice-bath for 5min. The precipitate was filtered through a glass-frit and washed once with cold THF followed by water. The solid was dried under vacuum. 7-bromo-1,3-dihydroimidazo[4,5-b]pyridin-2-one was afforded as a brown powder (5.14g, 94%). ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 11.60 (s, 1H), 11.39 (s, 1H), 7.74 (d, *J*=5.7 Hz, 1H), 7.17 (d, *J*=5.7 Hz, 1H); *m/z* = 214.0, 216.0 [*M*+*H*]⁺.


30

Synthesis of 7-bromo-3-tetrahydropyran-2-yl-1H-imidazo[4,5-b]pyridin-2-one



To a solution of 7-bromo-1,3-dihydroimidazo[4,5-b]pyridin-2-one (500 mg, 2.34 mmol) in anhydrous THF (17.5 mL, 0.1 N) was added 3,4-dihydro-2H-pyran (0.64 mL, 7.01 mmol, 3 eq.) and p-toluene sulfonic acid hydrate (89 mg, 0.467 mmol, 0.2 eq.). The mixture was stirred at 75°C overnight. 3,4-dihydro-2H-pyran (0.64 mL, 7.01 mmol, 3 eq.) was added and the reaction mixture was stirred at 75°C for 3h. The reaction was allowed to reach room temperature and quenched with water. EtOAc was added and the two layers were separated. Aqueous layer was extracted with EtOAc. Combined organic layer was dried over Na₂SO₄, filtered and concentrated under vacuum to give crude material as a brown oil. The crude mixture was purified by flash chromatography using a gradient of cyclohexane/ EtOAc. It was transferred via solid deposit on dicalite. Relevant fractions were collected and concentrated under vacuum to afford 7-bromo-3-tetrahydropyran-2-yl-1H-imidazo[4,5-b]pyridin-2-one (452 mg, 65% Yield) as a yellow solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 11.77 (s, 1H), 7.84 (d, *J*=5.6 Hz, 1H), 7.28 (d, *J*=5.7 Hz, 1H), 5.41 (dd, *J*=11.3, 2.2 Hz, 1H), 4.02 – 3.92 (m, 1H), 3.58 (td, *J*=11.3, 3.4 Hz, 1H), 2.94 (qd, *J*=12.6, 4.1 Hz, 1H), 1.99 – 1.90 (m, 1H), 1.76 – 1.45 (m, 4H); *m/z* = 298.0; 300.0 [M+H]⁺.


Synthesis of 3-tetrahydropyran-2-yl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazo[4,5-b]pyridin-2-one



To a solution of 7-bromo-3-tetrahydropyran-2-yl-1H-imidazo[4,5-b]pyridin-2-one (300 mg, 1.01 mmol) in anhydrous dioxane (10 mL, 0.1 N) was added potassium acetate (420 mg, 4.02 mmol, 4 eq.) and bis(pinacolato)diboron (767 mg, 3.02 mmol, 3 eq.). The mixture was degassed with N₂ and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (78 mg, 0.101 mmol, 0.1 eq.) was added. The resulting mixture was stirred 2h at 95°C under N₂. The mixture was filtered on dicalite and concentrated to give 3-tetrahydropyran-2-yl-7-(4,4,5,5-tetramethyl-1,3,2-


dioxaborolan-2-yl)-1H-imidazo[4,5-b]pyridin-2-one (1.1g, 57% Yield) as a dark oil. The crude material was engaged in next steps without more purification. $m/z = 264.1$ $[M+H]^+$. (boronic acid).

5 Synthesis of 7-bromo-1-methyl-3-tetrahydropyran-2-yl-imidazo[4,5-b]pyridin-2-one



To a solution of 7-bromo-3-tetrahydropyran-2-yl-1H-imidazo[4,5-b]pyridin-2-one (502 mg, 1.63 mmol) in anhydrous DMF (8.3 mL, 0.1N) at 0°C was added sodium hydride (78 mg, 1.95 mmol, 1.2 eq., 60%). The mixture was stirred for 15 min and iodomethane (125 μ L, 2.01 mmol, 1.2 eq.) was added at the same temperature. The reaction mixture was stirred for 1h. Water was added and the resulting precipitate was filtered and washed with water. The solid was dried at 40°C under vacuum to afford 7-bromo-1-methyl-3-tetrahydropyran-2-yl-imidazo[4,5-b]pyridin-2-one (0.40 g, 77% Yield) as a pinkish solid. ^1H NMR (DMSO- d_6 , 400 MHz): δ (ppm) 7.86 (d, $J=5.6$ Hz, 1H), 7.32 (d, $J=5.6$ Hz, 1H), 5.49 (dd, $J=11.3$, 2.2 Hz, 1H), 3.97 (dd, $J=11.2$, 2.0 Hz, 1H), 3.59 (s, 4H), 2.92 (qd, $J=13.5$, 13.0, 4.4 Hz, 1H), 2.03 – 1.89 (m, 1H), 1.79 – 1.41 (m, 4H); $m/z = 312.1$, 314.1 $[M+H]^+$.

Synthesis of 7-bromo-3H-oxazolo[4,5-b]pyridin-2-one




2-amino-4-bromopyridin-3-ol (200 mg, 1.01 mmol) and 1,1'-carbonyldiimidazole (0.33 g, 2.01 mmol, 2 eq.) were introduced in a sealed vial. THF (6 mL, 0.2 N) was added and the mixture was stirred at 60°C overnight. The solution was evaporated under vacuum and the crude triturated in DCM. The solid obtained was filtered and dried under vacuum to obtain 7-bromo-3H-oxazolo[4,5-b]pyridin-2-one as a brown powder (140mg, 32% Yield). ^1H NMR (DMSO- d_6 , 400 MHz): δ (ppm) 7.85 (d, $J=5.8$ Hz, 1H), 7.25 (d, $J=5.8$ Hz, 1H).

Synthesis of 4-bromospiro[1H-pyrrolo[2,3-b]pyridine-3,1'-cyclopentane]-2-one



- 5 A solution of 4-bromo-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one (500 mg, 2.35 mmol) in anhydrous THF (7.8 mL, 0.3N) was cooled to -78 °C and 1 M lithium [bis(trimethylsilyl)amide] solution (8.2 mL, 8.21 mmol, 3.5 eq.) was added. After stirring for 30 minutes 1,4-diiodobutane (371 μ L, 2.82 mmol, 1.2 eq.) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched with a saturated aqueous
- 10 solution of NH_4Cl and extracted with EtOAc. The organic phase was dried using a phase separator and evaporated to give crude material as an oil. The crude material was purified by flash chromatography on silica gel using a gradient of heptane/EtOAc. It was transferred via solid phase on silica. Relevant fractions were collected and concentrated to give 4-bromospiro[1H-pyrrolo[2,3-b]pyridine-3,1'-cyclopentane]-2-one (258 mg, 41% yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.12 (s, 1H), 7.91 (d, $J = 5.7$ Hz, 1H), 7.19 (d, $J = 5.7$ Hz, 1H), 2.15 (dd, $J = 8.1, 5.5$ Hz, 2H), 2.08 – 1.82 (m, 6H); $m/z = 267.1, 269.1$ $[\text{M}+\text{H}]^+$.
- 15

Synthesis of 4'-bromo-1'-tetrahydropyran-2-yl-spiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridine]-2'-one




20

- 3,4-dihydro-2H-pyran (0.26 mL, 2.90 mmol, 3 eq.) was added to a stirred solution of 4-bromospiro[1H-pyrrolo[2,3-b]pyridine-3,1'-cyclopentane]-2-one (258 mg, 0.966 mmol) and p-toluene sulfonic acid hydrate (37 mg, 0.193 mmol, 0.2 eq.) in anhydrous toluene (4.8 mL, 0.2
- 25 N). The reaction was stirred at 90°C overnight. The solvent was removed under vacuum. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / ethyl acetate. Relevant fractions were collected and concentrated under vacuum to afford 4'-bromo-1'-tetrahydropyran-2-yl-spiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridine]-2'-one (238mg, 70% Yield). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.04 (d, $J = 5.6$ Hz, 1H), 7.32 (d, $J = 5.7$ Hz, 1H), 5.37


(dd, $J = 11.3, 2.1$ Hz, 1H), 3.96 (d, $J = 11.3$ Hz, 1H), 3.53 (td, $J = 11.2, 4.0$ Hz, 1H), 2.95 – 2.76 (m, 1H), 2.17 (dd, $J = 13.2, 5.9$ Hz, 2H), 2.04 – 1.87 (m, 7H), 1.69 – 1.50 (m, 4H); $m/z = 351.2$ – 353.2 $[M+H]^+$.

- 5 Synthesis of 1'-tetrahydropyran-2-yl-4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridine]-2'-one



- 10 A vial was charged with bis(pinacolato)diboron (258 mg, 1.02 mmol, 1.5 eq.), potassium acetate (210 mg, 2.03 mmol, 3 eq.), 4'-bromo-1'-tetrahydropyran-2-yl-spiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridine]-2'-one (238 mg, 0.68 mmol) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (57 mg, 0.068 mmol, 0.1 eq.) in anhydrous dioxane (2.2 mL, 0.3 N). The vial was sealed and degassed with nitrogen. The reaction mixture
- 15 was stirred at 100°C overnight. The reaction mixture was filtered through a pad of celite and the filtrate was evaporated to dryness to give crude material as a dark oil. The crude material was purified by flash chromatography on silica gel using a gradient of dichloromethane / ethyl acetate. It was transferred via solid phase on dicalite. Relevant fractions were collected and concentrated under vacuum to afford 1'-tetrahydropyran-2-yl-4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
- 20 yl)spiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridine]-2'-one (190 mg, 35 % Yield). ^1H NMR (Chloroform- d , 400 MHz): δ (ppm) 8.16 (d, $J = 5.2$ Hz, 1H), 7.28 (d, $J = 5.1$ Hz, 1H), 5.52 (dd, $J = 11.3, 2.2$ Hz, 1H), 4.21 – 4.10 (m, 1H), 3.69 (td, $J = 11.9, 2.2$ Hz, 1H), 3.00 (qd, $J = 13.1, 12.6, 4.1$ Hz, 1H), 2.29 – 1.95 (m, 9H), 1.85 – 1.60 (m, 4H), 1.35 (s, 12H); $m/z = 399.4$ $[M+H]^+$.

Synthesis of 4-bromo-5-chloro-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one




5

In a 50mL round-bottomed flask, at room temperature, N-chlorosuccinimide (133 mg, 0.996 mmol, 1.6 eq.) was added to a stirred suspension of 4-bromo-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one (150 mg, 0.622 mmol) and sodium acetate (26 mg, 0.311 mmol, 0.5 eq.) in acetic acid (0.8 mL, 0.8 N). The mixture was heated at 60°C for 2h. N-chlorosuccinimide (133 mg, 0.996 mmol, 1.6 eq.) was added and the solution was stirred at 80°C overnight. The reaction mixture was diluted with water and quenched with an aqueous solution of Na₂S₂O₃ 1M. The solid obtained was filtered through a glass-frit to give 4-bromo-5-chloro-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one (143mg, 82% Yield) as a yellow powder. The product was engaged in next step without further purification. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 11.41 (s, 1H), 8.27 (s, 1H), 1.41 (s, 6H); m/z = 275.0, 277.0 [M+H]⁺

15

Synthesis of 4-chloro-5-fluoro-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one



20


In a round-bottom flask, at 0°C, 1 M lithium [bis(trimethylsilyl)amide] solution (38 mL, 37.7 mmol, 3.7 eq.) was added dropwise to a stirred solution of 4-chloro-5-fluoro-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one (2.00 g, 10.2 mmol) in anhydrous 2-methyltetrahydrofuran (26 mL, 0.4 N). The mixture was stirred at 0°C for 10 min. Then iodomethane (1.6 mL, 25.5 mmol, 2.5 eq.) was added dropwise at 0°C and the mixture was stirred for 3h at this temperature. An aqueous solution of NH₄Cl_{sat} was added slowly. Water was added and the mixture was extracted with EtOAc. The combined organic layers were washed with water, brine, dried over phase separator and concentrated to afford a green solid. The crude product was taken in a mixture of diisopropylether / Et₂O (50/50) and filtered to afford 4-chloro-5-fluoro-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one

30

(1.8 g, 78% Yield) as a green solid. ^1H NMR (DMSO- d_6 , 400 MHz): δ (ppm) 11.32 (s, 1H), 8.24 (d, $J=2.2$ Hz, 1H), 1.41 (s, 6H). m/z = 215.2, 217.2 $[\text{M}+\text{H}]^+$

Synthesis of 4-chloro-5-fluoro-3,3-dimethyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one


5



A 20mL vial was successively charged with 4-chloro-5-fluoro-3,3-dimethyl-1H-pyrrolo[2,3-b]pyridin-2-one (830 mg, 3.87 mmol), anhydrous toluene (13 mL, 0.3 N), p-toluene sulfonic acid hydrate (147 mg, 0.773 mmol, 0.2 eq.) and 3,4-dihydro-2H-pyran (1.1 mL, 11.6 mmol, 3 eq). The reaction was stirred overnight at 90°C. Then 3,4-dihydro-2H-pyran (0.5ml) was added and the reaction was stirred at 90°C for another night. The solvent was evaporated to give crude material as a brown oil. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / ethyl acetate. It was transferred via solid phase. Relevant fractions were collected and concentrated under vacuum to afford 4-chloro-5-fluoro-3,3-dimethyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (785mg, 67% Yield) as an orange gum. ^1H NMR (400 MHz, DMSO- d_6) δ 8.37 (d, J = 2.0 Hz, 1H), 5.38 (dd, J = 11.3, 2.1 Hz, 1H), 3.97 (d, J = 10.7 Hz, 1H), 3.55 (td, J = 11.3, 4.0 Hz, 1H), 2.82 (qd, J = 13.7, 12.9, 4.1 Hz, 1H), 1.97 – 1.88 (m, 1H), 1.69 – 1.48 (m, 4H), 1.44 (s, 6H), m/z = 299.2, 301.2 $[\text{M}+\text{H}]^+$

20


Synthesis of 5-fluoro-3,3-dimethyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one



25

A reacti-vial, under nitrogen atmosphere, was charged with tricyclohexylphosphane (284 μ L, 0.180 mmol, 0.075 eq.), bis(pinacolato)diboron (1.22 g, 4.79 mmol, 2 eq.), 4-chloro-5-fluoro-3,3-dimethyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (715 mg, 2.39 mmol) and anhydrous dioxane (12 mL, 0.2 N). Then potassium acetate (475 mg, 4.79 mmol, 2 eq.) and tris(dibenzylideneacetone)dipalladium(0) (115 mg, 0.120 mmol, 0.05 eq.) were added. The reaction was stirred overnight at 100°C. The mixture was filtered on dicalite and concentrated to give crude material as a black oil. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / ethyl acetate. 5-fluoro-3,3-dimethyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one (670mg, 22% Yield) was obtained as a yellow solid (mixture of product and debrominated one). $m/z = 391.4$ $[M+H]^+$

Synthesis of 5-fluoro-3-methyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one;hydrochloride



15

4 M hydrogen chloride in dioxane (1.0 mL, 4.00 mmol, 5 eq.) was added to a solution of tert-butyl 5-fluoro-3-methyl-2-oxo-3H-pyrrolo[2,3-b]pyridine-1-carboxylate (210 mg, 0.752 mmol) in anhydrous dioxane (2 mL, 0.3 N). The vial was sealed and the reaction was stirred at 60°C for 1h. The solution was concentrated to dryness to give 5-fluoro-3-methyl-1,3-dihydropyrrolo[2,3-b]pyridin-2-one;hydrochloride (139 mg, 84% yield) as a white solid. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.01 (br s, 1H), 8.03 (t, $J=1.83$ Hz, 1H), 7.69 (dd, $J=2.20, 8.31$ Hz, 1H), 3.54-3.61 (m, 1H), 1.35 (d, $J=7.58$ Hz, 3H); $m/z = 167.1$ $[M+H]^+$


25 Synthesis of 3-ethyl-5-fluoro-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one



In a 2-5mL vial, at 0°C, 1 M lithium [bis(trimethylsilyl)amide] solution (1.7 mL, 1.71 mmol, 3.8 eq.) was added dropwise via syringe to a stirred suspension of 5-fluoro-3-methyl-1,3-


dihydropyrrolo[2,3-b]pyridin-2-one hydrochloride (98 mg, 0.445 mmol) in anhydrous 2-methyltetrahydrofuran (1.5 mL, 0.3 N). The reaction mixture was stirred at 0°C for 10min. iodoethane (0.065 mL, 0.813 mmol, 1.8 eq.) was added dropwise at 0°C and the reaction was stirred at room temperature over the weekend. Water was added and the mixture was acidified with an aqueous solution of HCl to pH=5. EtOAc was added. The two phases were separated and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with brine, dried using a phase separator and evaporated to give 3-ethyl-5-fluoro-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (104 mg, 90% yield) as an orange solid. ¹H NMR (400 MHz, DMSO-d₆) δ 11.05 (s, 1H), 8.05 (dd, J = 2.7, 1.9 Hz, 1H), 7.75 (dd, J = 8.3, 2.8 Hz, 1H), 1.86 – 1.69 (m, 2H), 1.28 (s, 3H), 0.57 (t, J = 7.4 Hz, 3H). m/z = 195.2 [M+H]⁺

Synthesis of 3-ethyl-5-fluoro-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one




A 2-5mL vial was charged with 3-ethyl-5-fluoro-3-methyl-1H-pyrrolo[2,3-b]pyridin-2-one (126 mg, 0.519 mmol), 3,4-dihydro-2H-pyran (0.14 mL, 1.56 mmol, 3 eq.) and p-toluene sulfonic acid hydrate (20 mg, 0.104 mmol, 0.2 N) in anhydrous toluene (1.7 mL, 0.3 N). The resulting mixture was stirred overnight at 95°C and concentrated to dryness. The crude material was purified by flash chromatography on silica gel using a gradient of Heptane/ EtOAc to afford 3-ethyl-5-fluoro-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (80 mg, 51% yield). ¹H NMR (DMSO-d₆, 600 MHz): δ (ppm) 8.17-8.18 (m, 1H), 7.85 (dd, J = 8.2, 2.8 Hz, 1H), 5.36 (d, J = 10.4 Hz, 1H), 3.95 (dt, J = 11.4, 2.0 Hz, 1H), 3.53 (tt, J = 11.4, 2.8 Hz, 1H), 2.79-2.94 (m, 1H), 1.89-1.95 (m, 1H), 1.74-1.86 (m, 2H), 1.53-1.65 (m, 2H), 1.45-1.55 (m, 2H), 1.29 (s, 3H), 0.51 (td, J = 7.4, 3.4 Hz, 3H) ; m/z = 279.2 [M+H]⁺.

Synthesis of 5-ethyl-3-fluoro-5-methyl-7-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7H-cyclopenta[b]pyridin-6-one



- 5 In a 2-5mL vial, sealed, at -60°C under N₂, 1 M lithium diisopropylamide solution (0.60 mL, 0.600 mmol, 2.3 eq.) was added dropwise to a stirred solution of 3-ethyl-5-fluoro-3-methyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (78 mg, 0.256 mmol) in anhydrous THF (2 mL, 0.1 N). The reaction was stirred at -60°C for 30mn. triisopropyl borate (0.15 mL, 0.650 mmol, 2.5 eq.) was added dropwise at -60°C. The reaction was stirred at -60°C for 30mn and the mixture
- 10 was allowed to warm to room temperature for 4h. 2,3-dimethylbutane-2,3-diol (0.60 mL, 0.512 mmol, 2 eq) was added to the mixture then after 10mn stirring, acetic acid (0.015 mL, 0.269 mmol, 1.05 eq) was added. The reaction was stirred at room temperature overnight. The mixture was filtered through dicalite. Solvent was partially evaporated under N₂ stream and the solution extracted by an aqueous solution of NaOH 5%. The resulting aqueous layer was collected and
- 15 acidified down to pH=6 at 0°C, by dropwise addition of 3N HCl, then extracted with EtOAc. Combined organic phases were washed with brine, dried using a phase separator and evaporated to give 5-ethyl-3-fluoro-5-methyl-7-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7H-cyclopenta[b]pyridin-6-one (50 mg, 26% yield) as a brown gum. m/z = 323.2 [M+H]⁺ (acid form) (impure)

Scaffold coupling - General Procedure (indole)

5

G = CMe_2 , CMeOH
 $n = 0, 1$

1. Mitsunobu reaction

- 10 To a stirred mixture of indole I (1.66 mmol) in anhydrous toluene (8 mL, 0.2 N), were added cyanomethylenetriphenylphosphorane (3.31 mmol, 2 eq.) and alcohol I' (2.48 mmol, 1.5 eq.). The reaction was stirred at 80°C overnight. Cyanomethylenetriphenylphosphorane (3.31 mmol, 2 eq.) and alcohol I' (2.48 mmol, 1.5 eq.) were added and the mixture stirred at 80°C for a further 4h. The reaction mixture was concentrated to dryness and the crude was purified by flash chromatography column with a gradient of EtOAc in cyclohexane. Relevant fractions were collected and concentrated under vacuum to afford expected products II.
- 15

Example: Synthesis of tert-butyl 4-indol-1-ylpiperidine-1-carboxylate (n=1, G=CMe₂)

White oil, yield 82%, ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 7.60 – 7.52 (m, 2H), 7.50 (d, *J*=3.2 Hz, 1H), 7.13 (t, *J*=7.8 Hz, 1H), 7.02 (t, *J*=7.4 Hz, 1H), 6.45 (d, *J*=3.2 Hz, 1H), 4.58 (ddt, *J*=11.7, 7.7, 3.8 Hz, 1H), 4.13 (d, *J*=12.2 Hz, 2H), 2.98 (s, 2H), 1.94 (d, *J*=10.4 Hz, 2H), 1.83 (qd, *J*=12.3, 4.3 Hz, 2H), 1.44 (s, 9H); *m/z* = 245.3 [M+H-tBu]⁺

2. Bromination

N-bromosuccinimide (1.45 mmol, 1.05 eq.) was added to a solution of substituted indole II (1.38 mmol) in anhydrous DMF (13.8 mL, 0.1 N). The resulting mixture was stirred 6h at room temperature under N₂. N-bromosuccinimide (1 eq.) was added and the reaction mixture was stirred at room temperature overnight under N₂. Water was added and the mixture was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over phase separator and concentrated under vacuum. The crude product was purified on silica gel column with a gradient of heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to give brominated products III.

Example: Synthesis of tert-butyl 4-(3-bromoindol-1-yl)piperidine-1-carboxylate (n=1, G=CMe₂)

White oil, yield 83%, ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 7.77 (s, 1H), 7.65 (d, *J*=8.3 Hz, 1H), 7.42 (d, *J*=7.9 Hz, 1H), 7.28 – 7.20 (m, 1H), 7.16 (t, *J*=7.4 Hz, 1H), 4.75 – 4.51 (m, 1H), 4.26 – 3.91 (m, 2H), 2.96 (s, 2H), 2.07 – 1.73 (m, 4H), 1.44 (s, 9H); *m/z* = 323.1, 325.1 [M+H-tBu]⁺

3. Boronic acid formation

To a solution of bromoindoles III (0.854 mmol) in anhydrous THF (4.3 mL, 0.2 N) was added dropwise 1.2 M butyllithium solution (1.1 mL, 1.28 mmol, 1.5 eq.) at -78°C. The resulting mixture was stirred for 20min at -78°C under N₂. Then triisopropyl borate (0.59 mL, 2.56 mmol, 3 eq.) was added and the solution stirred 4h30 while temperature was allowed to rise to room temperature. A mixture of Water/MeOH (1:1.3 mL) was added to quench the reaction. Water was added and the mixture was extracted with diethyl ether. The organic phase was washed with brine, dried over phase separator and concentrated to give expected boronic acids IV.

Example: Synthesis of [1-(1-tert-butoxycarbonyl-4-piperidyl)indol-3-yl]boronic acid (n=1, G=CMe₂) Green solid, yield 51%, *m/z* = 245.3 [M+H-Boc]⁺

4. Suzuki coupling

A reacti-vial was charged with boronic acid **IV** (0.218 mmol, 1.05 eq.), bromine scaffold **II'** (0.207 mmol), disodium carbonate (0.622 mmol, 3 eq.) in a mixture of DMF (1.5 mL) and water (0.5 mL).

- 5 The mixture was degassed and tetrakis(triphenyl)phosphine palladium (0.0207 mmol, 0.1 eq.) was added. The resulting mixture was stirred overnight at 90°C under N₂. The mixture was filtered on dicalite and evaporated under vacuum. Crude products were purified on silica gel column with a gradient of heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to afford Suzuki coupling products **V**.

10

Example: Synthesis of tert-butyl 4-[3-(3,3-dimethyl-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)indol-1-yl]piperidine-1-carboxylate (n=1, G= CMe₂)

Beige solid; Yield 20%; m/z = 461.4 [M+H]⁺

5. Deprotection

15

4 M hydrogen chloride solution in dioxane (0.16 mmol, 4 eq.) was added to a solution of Suzuki coupling compounds **V** (0.041 mmol) in anhydrous methanol (0.2 mL, 0.2 eq.). The reaction was stirred at room temperature overnight. Diisopropyl ether was added to the mixture and the precipitate was filtered to give a gum. The precipitate was diluted in MeOH and the solution

20

Example 7: Synthesis of 3,3-dimethyl-4-[1-(4-piperidyl)indol-3-yl]-1H-pyrrolo[2,3-b]pyridin-2-one dihydrochloride (n = 1, G= CMe₂)


Orange solid; yield 95%, ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.09 (s, 1H), 8.55-9.02 (m, 2H), 8.11 (d, J = 5.4 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.51 (s, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.26 (td, J = 7.6, 1.0 Hz, 1H), 7.10 (td, J = 7.3, 0.5 Hz, 1H), 6.92 (d, J = 5.4 Hz, 1H), 4.85 (tt, J = 11.5, 4.7 Hz, 1H), 3.48 (br d, J = 13.4 Hz, 3H), 3.10-3.23 (m, 2H), 2.17-2.29 (m, 4H), 1.13 (s, 6H); m/z = 361.1

25

Scaffold coupling – specific examples

30

The indole **I** was either obtained from commercial sources or synthesised by standard techniques according to the procedures that follow.

Scaffold coupling - Specific Procedure (specific indole 1)

5

1. Suzuki coupling

- 10 A reaction vial was successively charged with bromine scaffold I' (1.12 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1-carboxylate I (1.58 mmol, 1.4 eq.), disodium carbonate (3.35 mmol, 3 eq.), and tetrakis(triphenylphosphine) palladium (0.112 mmol, 0.1 eq.) in a mixture of DMF (9 mL) and water (1.9 mL). The vial was sealed, evacuated under vacuum and refilled with argon. The reaction was stirred at 100°C overnight. The reaction mixture was diluted with EtOAc, filtered, washed with water, dried over Na₂SO₄ and evaporated. The crude material was purified by flash chromatography on silica gel using a gradient of heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to afford expected Suzuki coupling products II.
- 15

Example: Synthesis of 4-(1H-indol-3-yl)-3,3-dimethyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one (G= CMe₂) Brown gum; yield 37%, ¹H NMR(DMSO-*d*₆, 400 MHz): δ (ppm) 11.47 (s, 1H), 8.21 (d, *J*=5.4 Hz, 1H), 7.51 (d, *J*=2.5 Hz, 1H), 7.48 (d, *J*=8.2 Hz, 1H), 7.30 (d, *J*=8.0 Hz, 1H), 7.22 – 7.11 (m, 1H), 7.06 – 6.97 (m, 2H), 5.48 (dd, *J*=11.3, 2.0 Hz, 1H), 3.99 (d, *J*=11.7 Hz, 1H), 3.65 – 3.51 (m, 1H), 3.08 – 2.87 (m, 1H), 1.95 (s, 1H), 1.71 – 1.45 (m, 4H), 1.14 (d, *J*=4.1 Hz, 6H); *m/z* = 362.1 [M+H]⁺

10 2. Michael reaction

A 4mL reacti-vial was successively charged with cyclobutylideneacetonitrile (0.387 mmol, 2 eq.), Suzuki coupling products II (0.194 mmol, 1 eq.) in anhydrous acetonitrile (0.95 mL, 0.2N) and DBU (0.387 mmol, 2 eq.). The reaction was stirred at 85°C overnight. Then 1 equivalent of cyclobutylideneacetonitrile was added and the reaction was stirred for 2h. The reaction mixture was filtered and the precipitate was washed with acetonitrile to give afforded products III.

Example: Synthesis of 2-[1-[3-(3,3-dimethyl-2-oxo-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-4-yl)]indol-1-yl]cyclobutyl]acetonitrile (G= CMe₂)

20 White powder; yield 29%, ¹H NMR(DMSO-*d*₆, 400 MHz): δ (ppm) 8.22 (d, *J*=5.4 Hz, 1H), 7.46 (s, 1H), 7.43 (d, *J*=8.3 Hz, 1H), 7.33 (d, *J*=7.8 Hz, 1H), 7.22 (t, *J*=7.7 Hz, 1H), 7.11 (t, *J*=7.2 Hz, 1H), 6.99 (d, *J*=5.3 Hz, 1H), 5.52 – 5.41 (m, 1H), 3.99 (d, *J*=10.9 Hz, 1H), 3.58 (t, *J*=11.1 Hz, 1H), 3.48 (s, 2H), 2.95 (d, *J*=11.4 Hz, 1H), 2.76 (t, *J*=11.2 Hz, 2H), 2.63 (t, *J*=9.2 Hz, 2H), 2.28 – 2.12 (m, 25 1H), 1.97 (d, *J*=11.4 Hz, 2H), 1.73 – 1.40 (m, 4H), 1.16 (d, *J*=3.7 Hz, 6H); *m/z* = 455.4 [M+H]⁺


3. Deprotection

30 4 M hydrogen chloride solution in dioxane (1.14 mmol, 20 eq.) was added to a solution of previous compounds III (0.057 mmol) in dioxane (0.2 mL, 0.3 N). The reaction was stirred at 45°C overnight. Then 4 M hydrogen chloride solution in dioxane (1.14 mmol, 20 eq.) was added and the mixture stirred at 50°C one more night. The solvent was evaporated. The crude material was purified via preparative HPLC under neutral conditions. Relevant fractions were combined and concentrated to give expected compounds IV.

35 Example 21: Synthesis of 2-[1-[3-(3,3-dimethyl-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)]indol-1-yl]cyclobutyl]acetonitrile (G= CMe₂) White powder; yield 37%, ¹H NMR (DMSO-*d*₆, 600 MHz): δ (ppm) 11.04 (s, 1H), 8.09 (d, *J* = 5.4 Hz, 1H), 7.43 (s, 1H), 7.42 (d, *J* = 8.4 Hz, 1H), 7.34 (d, *J* = 7.9 Hz, 1H), 7.21 (td, *J* = 7.7, 1.0 Hz, 1H), 7.07-7.12 (m, 1H), 6.89 (d, *J* = 5.3 Hz, 1H), 3.46 (s,

2H), 2.72-2.81 (m, 2H), 2.58-2.66 (m, 2H), 2.13-2.26 (m, 1H), 1.92-2.03 (m, 1H), 1.15 (s, 6H);
 $m/z = 371.0 [M+H]^+$.

5 Scaffold coupling - General Procedure (indazole 1)



G = CMe₂, CMeOH, CMeEt, CEtOH, COHOMe, CEtOMe
 L = H, THP
 R₁, R₄, R₅ = H, F
 R₃ = H, F, OCHF₂
 R₂ = H, F, CF₃
 n, m, p = 0, 1, 2

1. Mitsunobu reaction

- 20 A sealed-vial was successively charged with bromoindazole **I** (1.23 mmol), anhydrous toluene (4 mL, 0.3 M), hydroxypiperidine-1-carboxylate **I'** (2.46 mmol, 2 eq.) and cyanomethylenetriethylphosphorane (2.46 mmol, 2 eq.) under nitrogen atmosphere. The reaction was stirred at 90°C overnight. The solvent was evaporated to give crude material as a brown liquid. The crude material was purified by flash chromatography on silica gel using a gradient of heptane/ ethyl acetate. It was transferred via solid phase on dicalite. Fractions were collected and concentrated under vacuum. A mixture of 2 diastereoisomers **II** was obtained. The mixture was used in the next step.
- 25

Example: Synthesis of tert-butyl rac-(3R,4R)-4-(3-bromoindazol-1-yl)-3-fluoro-piperidine-1-carboxylate ($R_1 = R_2 = R_3 = R_5 = H$; $R_4 = F$; $n = 0$; $m = p = 1$)

Yellow oil; diastereoisomers, quantitative yield, ^1H NMR (400 MHz, DMSO- d_6) δ 7.81 (d, $J = 8.6$ Hz, 1H), 7.60 (d, $J = 8.2$ Hz, 1H), 7.57 – 7.50 (m, 1H), 7.32 – 7.26 (m, 1H), 5.09 (dd, $J = 18.2, 9.2$ Hz, 1H), 4.90 – 4.68 (m, 1H), 4.35 (s, 1H), 4.09 – 4.01 (m, 1H), 3.06 (s, 2H), 2.07 (qd, $J = 10.0, 3.8$ Hz, 2H), 1.45 (s, 9H); $m/z = 342.0, 344.0$ [M-tBu+H] $^+$

2. Boronic ester formation

10

In a 10 mL reacti-vial were introduced substituted bromoindazole II (0.753 mmol), bis(pinacolato)diboron (1.13 mmol, 1.5 eq) and bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.0753 mmol, 0.1 eq.) in anhydrous dioxane (2.5 mL, 0.3 N). The mixture was degassed with N_2 and stirred at 100°C overnight. The mixture was filtered on dicalite and concentrated under vacuum to give crude material as a dark oil. The crude material III was used in next step without further purification.

15

Example: Synthesis of tert-butyl rac-(3R,4R)-3-fluoro-4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-1-yl]piperidine-1-carboxylate ($R_1 = R_2 = R_3 = R_5 = H$; $R_4 = F$; $n = 0$; $m = p = 1$)

20

Black oil; $m/z = 364.0$ [M+H] $^+$ (boronic acid form)

3. Suzuki coupling

25

A 10mL vial was charged with bromine scaffold II' (0.332 mmol), boronic esters III (0.602 mmol, 1.8 eq.) and disodium carbonate (0.996 mmol, 3 eq.) in a mixture of DMF (3 mL) and water (0.6 mL). The mixture was degassed and tetrakis triphenylphosphine palladium (0.033 mmol, 0.1 eq.) was added. The reaction was heated at 100°C during 4h. Water was added. The product precipitated and was filtered. It was then solubilized in DCM and the organic phase dried on phase separator and concentrated under vacuum. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / EtOAc. Fractions were collected and concentrated under vacuum to afford expected Suzuki coupling compounds IV.

30

35

Example: Synthesis of tert-butyl rac-(3R,4R)-4-[3-(3,3-dimethyl-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)indazol-1-yl]-3-fluoro-piperidine-1-carboxylate ($R_1 = R_2 = R_3 = R_5 = H$; $R_4 = F$, $n = 0$; $m = p = 1$; $G = CMe_2$; $L = H$)

Beige powder; Yield 63%; ^1H NMR (DMSO- d_6 , 500 MHz): δ (ppm) 11.13 (s, 1H), 8.24 (d, J = 5.6 Hz, 1H), 7.80-7.90 (m, 2H), 7.47-7.57 (m, 1H), 7.36 (d, J = 5.4 Hz, 1H), 7.23-7.31 (m, 1H), 5.20-5.36 (m, 1H), 4.71-4.98 (m, 1H), 4.26-4.49 (m, 1H), 4.03-4.12 (m, 1H), 2.94-3.23 (m, 2H), 2.03-2.27 (m, 2H), 1.44 (s, 9H), 1.34 (d, J = 8.3 Hz, 6H); m/z = 480.2 $[\text{M}+\text{H}]^+$


5

4. Deprotection

4M hydrogen chloride in dioxane (1.04 mmol, 5 eq.) was added to a solution of Suzuki coupling products **IV** (0.21 mmol) in methanol (2 mL, 0.1 N). The mixture was stirred at room temperature overnight. The mixture was concentrated under vacuum. The product was triturated in diethyl ether and filtered. It was then dried under vacuum at 40°C to afford final expected products **V** under salt forms.

15 Racemate of Example 36: Synthesis of 3,3-dimethyl-4-[1-[rac-(3R,4R)-3-fluoro-4-piperidyl]indazol-3-yl]-1H-pyrrolo[2,3-b]pyridin-2-one;dihydrochloride ($\text{R}_1 = \text{R}_2 = \text{R}_3 = \text{R}_5 = \text{H}$; $\text{R}_4 = \text{F}$, $n = 0$; $m = p = 1$; $\text{G} = \text{CMe}_2$)

20 Yellow powder; yield 91%, ^1H NMR (500 MHz, DMSO- d_6) δ ppm 11.16 (s, 1 H); 8.97 - 10.01 (m, 2 H), 8.24 (d, J =5.38 Hz, 1 H); 7.84 (dd, J =8.31, 5.62 Hz, 2 H), 7.50 - 7.59 (m, 1 H), 7.34 (d, J =5.62 Hz, 1 H), 7.27 - 7.32 (m, 1 H), 5.37 - 5.48 (m, 1 H), 5.19 - 5.37 (m, 1 H); 3.85 (br s, 1 H); 3.46 - 3.54 (m, 1 H), 3.24 - 3.34 (m, 1 H), 3.13 - 3.24 (m, 1 H), 2.29 - 2.49 (m, 2 H), 1.36 (d, J =13.20 Hz, 6 H) ; m/z = 380.0

Scaffold coupling - General Procedure (indazole 2)

G = CMe₂, CMeEt
 R₁ = H, F
 R₄ = H, F
 R₃ = H, F, OCHF₂
 R₂ = H, F, Cl, CF₃
 n, m = 0, 1, 2

1. Mitsunobu

To a stirred mixture of bromoindazole I (1.97 mmol) in anhydrous toluene (8 mL, 0.25 N), were added cyanomethylenetriphenylphosphorane (5.91 mmol, 3 eq.) and hydroxypyrrolidine I' (3.94 mmol, 2 eq.). The reaction was stirred at 100°C overnight. The reaction mixture was concentrated to dryness and the crude was purified by flash chromatography column with a gradient of EtOAc in cyclohexane. Relevant fractions were collected and concentrated under vacuum to afford expected products II.

Example: Synthesis of tert-butyl (3S)-3-(3-(3-bromoindazol-1-yl)pyrrolidine-1-carboxylate (n=0, R₁ = R₂ = R₃ = R₄ = H)

Colorless oil, yield 44%, ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 7.80 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.52 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H), 7.20-7.33 (m, 1H), 5.35-5.60 (m, 1H),

3.69-3.83 (m, 1H), 3.55 (dd, $J = 11.0, 4.9$ Hz, 2H), 3.43 (br d, $J = 6.6$ Hz, 1H), 2.20-2.45 (m, 2H), 1.32-1.50 (m, 9H); $M/Z = 366.2-368.2$ $[M+H]^+$

2. Suzuki coupling

A 6-20mL reacti-vial was successively charged with substituted bromoindazole II (0.41 mmol), disodium carbonate (1.23 mmol, 3 eq.), boronic ester II' (0.491 mmol, 1.2 eq.) in a mixture of DMF (2.6 mL) and water (0.7 mL). The mixture was degassed and tetrakis triphenylphosphine palladium (0.0410 mmol, 0.01 eq.) was added. The reaction was stirred at 100°C overnight. The reaction mixture was poured in water. The precipitate was filtered. The filtrate was solubilized with dichloromethane. The organic phase was dried on a phase separator and evaporated to give crude material. It was then purified by flash chromatography on silica gel using a gradient of heptane / EtOAc. Relevant fractions were collected and concentrated under vacuum to afford expected products III.

Example: Synthesis of tert-butyl (3S)-3-[3-(3,3-dimethyl-2-oxo-1-tetrahydropyran-2-yl)pyrrolo[2,3-b]pyridin-4-yl]indazol-1-yl]pyrrolidine-1-carboxylate ($n=0$, $R_1 = R_2 = R_3 = R_4 = H$, $G = CMe_2$)

Beige foam; Yield 56%; ^1H NMR (400 MHz, DMSO- d_6) δ 8.35 (d, $J = 5.4$ Hz, 1H), 7.87 (dd, $J = 13.2, 8.4$ Hz, 2H), 7.54 (ddd, $J = 8.3, 6.9, 0.9$ Hz, 1H), 7.43 (d, $J = 5.4$ Hz, 1H), 7.32 – 7.27 (m, 1H), 5.62 (s, 1H), 5.51 – 5.47 (m, 1H), 4.00 (d, $J = 11.3$ Hz, 1H), 3.89 (s, 1H), 3.73 (d, $J = 10.6$ Hz, 1H), 3.62 – 3.46 (m, 3H), 2.94 (d, $J = 11.4$ Hz, 1H), 2.49-2.52 (m, 1H), 2.33 (s, 1H), 1.95 (s, 1H), 1.71 – 1.49 (m, 4H), 1.40 (d, $J = 5.2$ Hz, 9H), 1.37 (s, 3H), 1.31 (d, $J = 3.6$ Hz, 3H), $m/z = 532.4$ $[M+H]^+$

3. Deprotection

4 M hydrogen chloride solution in dioxane (9.18 mmol, 40 eq.) was added to a solution of Suzuki coupling compounds III (0.229 mmol) in anhydrous methanol (0.5 mL, 0.5 N). The reaction was stirred at 65°C overnight. The reaction mixture was filtered to give final compounds IV (60mg, 62% Yield) as hydrochlorhydric salts.


Example 16: Synthesis of 3,3-dimethyl-4-[1-[(3S)-pyrrolidin-3-yl]indazol-3-yl]-1H-pyrrolo[2,3-b]pyridin-2-one dihydrochloride ($R_1 = R_2 = R_3 = R_4 = H$, $G = CMe_2$)

White powder; yield 62%, ^1H NMR (DMSO- d_6 , 500 MHz): δ (ppm) 11.14 (br s, 1H), 8.23 (d, $J = 5.4$ Hz, 1H), 7.87 (d, $J = 8.6$ Hz, 1H), 7.82 (d, $J = 8.3$ Hz, 1H), 7.53 (t, $J = 7.7$ Hz, 1H), 7.28 (q, $J =$

4.8 Hz, 2H), 5.60 (s, 1H), 3.51-3.72 (m, 2H), 3.37 (br s, 4H), 2.44-2.48 (m, 1H), 2.33 (br d, J = 5.9 Hz, 1H), 1.91 (s, 1H), 1.36 (s, 3H), 1.31 (s, 3H); m/z = 348.0

Scaffold coupling - General Procedure (indazole 3)

5



10

15

1. Michael reaction

A 20mL biotage vial was successively charged with 3-bromo-1H-indazole **I** (2.46 mmol), reactant **I'** (2.46 mmol) and 1,8-diazabicyclo[5.4.0]undéc-7-ène (4.92 mmol, 2 eq.) in anhydrous acetonitrile (12 mL, 0.2 N). The mixture was stirred at 85°C overnight. The mixture was concentrated under vacuum. The crude material was purified on flash chromatography with a gradient of Heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to afford corresponding products **II**.

25

Example: Synthesis of 2-[1-(3-bromoindazol-1-yl)cyclobutyl]acetonitrile (Y=C-H, R₁ = H, Z=CH₂)

White solid, yield 83%, ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 7.60-7.64 (m, 2H), 7.47-7.52 (m, 1H), 7.26-7.32 (m, 1H), 3.38 (s, 2H), 2.80-2.94 (m, 2H), 2.52-2.61 (m, 2H), 2.17 (dquin, J = 11.3, 9.0 Hz, 1H), 1.95 (dt, J = 11.2, 9.8, 3.2 Hz, 1H); m/z = 290.1-292.1 [M+H]⁺

2. Suzuki coupling

In an 20mL biotage vial, substituted bromoindazole II (0.59 mmol, 1.1 éq.) was dissolved in a mixture of DMF (4 mL) and Water (1.3 mL), then boronic ester II' (0.53 mmol) and disodium carbonate (1.60 mmol, 3 eq.) were added. The solution was degassed with N₂ and tetrakis(triphenylphosphine) palladium (0.053 mmol, 0.01 eq.) was added. The mixture was heated to 75°C during 3h. The solution was cooled and water was added. The product was extracted several times with EtOAc. Organic phases were gathered, filtered on a phase separator and concentrated under vacuum, to afford crude material. It was then purified by flash chromatography with a gradient of Heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to afford expected compounds III.

Example: Synthesis of 2-[1-[3-(3-hydroxy-3-methyl-2-oxo-1-tetrahydropyran-2-yl)pyrrolo[2,3-b]pyridin-4-yl]indazol-1-yl]cyclobutyl]acetonitrile (Y=C-H, R₁ = H, G= COHMe, Z = CH₂)

Pale yellow solid; Yield 15%; ¹H NMR(DMSO-d₆, 400 MHz): δ (ppm) 8.40 (dd, J=5.5, 0.9 Hz, 1H), 8.09 (d, J=8.4 Hz, 1H), 7.72 (d, J=8.6 Hz, 1H), 7.61 (dd, J=5.5, 2.0 Hz, 1H), 7.58 – 7.51 (m, 1H), 7.40 – 7.34 (m, 1H), 6.11 (d, J=5.3 Hz, 1H), 5.47 (d, J=11.2 Hz, 1H), 4.00 (d, J=8.7 Hz, 1H), 3.54-3.62 (m, 1H), 3.50 (s, 2H), 3.28-3.31 (m, 1H), 3.05 – 2.81 (m, 3H), 2.71 – 2.58 (m, 2H), 2.31 – 2.17 (m, 1H), 1.94-2.06 (d, J=1.8 Hz, 1H), 1.59 (d, J=50.3 Hz, 4H), 1.51 (d, J=1.4 Hz, 3H); m/z = 458.4 [M+H]⁺


3. Deprotection

4 M hydrogen chloride solution in dioxane (1.5 mmol, 20 eq.) was added to a solution of Suzuki coupling compounds III (0.075 mmol) in anhydrous methanol (0.5 mL, 0.3N). The reaction was stirred at room temperature overnight then at 50°C one night more. The mixture was basified with an aqueous solution of NaHCO₃, extracted with DCM, and the solvent was evaporated to give crude material. It was then purified in reverse phase with a gradient of H₂O/Acetonitrile. Fractions containing the product were gathered and concentrated to give expected products IV.

Example 25: Synthesis of 2-[1-[3-(3-hydroxy-3-methyl-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)indazol-1-yl]cyclobutyl]acetonitrile (Y = C-H, R₁ = H, G = COHMe, Z = CH₂)

White powder; yield 26%, ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.09 (br s, 1H), 8.27 (d, J = 5.4 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H), 7.54 (ddd, J = 8.4, 7.2, 1.0 Hz, 1H), 7.51 (d, J = 5.6 Hz, 1H), 7.36 (dd, J = 7.8, 6.8 Hz, 1H), 5.98 (s, 1H), 3.49 (d, J = 2.2 Hz, 2H), 2.79-3.05 (m, 2H), 2.64 (ddd, J = 12.2, 8.9, 2.7 Hz, 2H), 1.93-2.30 (m, 2H), 1.48 (s, 3H); m/z = 374.2 [M+H]⁺

10 Scaffold coupling - General Procedure (indazole 4)



R₁ = H, F
R₂ = H, Me

1. Mitsunobu

In a 10 mL vial, at room temperature, cyanomethylenetriethylphosphorane (0.68 mL, 2.49 mmol, 2 eq.) was added to a stirred solution of bromoindazole I (1.24 mmol, 1 eq.) and alcohol (1.24 mmol, 1 eq.) in anhydrous toluene (3.7 mL, 0.3 N). The reaction mixture was stirred at 80°C for 5h. The reaction was allowed to reach room temperature, concentrated under vacuum to give crude material as a brown oil. The crude material was purified by flash chromatography on silica gel using a gradient of heptane/ EtOAc. It was transferred via liquid injection in DCM. Relevant fractions were collected and concentrated under vacuum to give expected compounds II.

Example: Synthesis of 4-benzyl-3-[(3-bromoindazol-2-yl)methyl]-3-methyl-morpholine (R₁ = H, R₂ = Me)

Colorless gum, 45% yield, ¹H NMR (400 MHz, DMSO-d₆) δ 7.82 (d, J = 8.6 Hz, 1H), 7.60 (d, J = 8.2 Hz, 1H), 7.54 – 7.41 (m, 1H), 7.40 – 7.16 (m, 6H), 4.83 (d, J = 14.7 Hz, 1H), 4.54 (d, J = 14.7 Hz, 1H), 3.93 – 3.79 (m, 1H), 3.75 (d, J = 13.9 Hz, 1H), 3.63 (dd, J = 9.8, 5.0 Hz, 1H), 3.51

(ddd, $J = 11.2, 8.2, 3.2$ Hz, 1H), 3.43 (d, $J = 11.3$ Hz, 1H), 3.26 (d, $J = 11.3$ Hz, 1H), 2.69 (ddd, $J = 11.7, 8.2, 3.3$ Hz, 1H), 2.43 – 2.28 (m, 1H), 1.06 (s, 3H); $m/z = 400.3, 402.3[M+H]^+$.

5 2. Suzuki coupling

A 6-20mL reacti-vial was successively charged with substituted bromoindazole II (0.532 mmol), 3,3-dimethyl-1-tetrahydropyran-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridin-2-one (0.532 mmol, 1 eq.), tripotassium phosphate (229 mg, 1.06 mmol, 3 eq.), Xphos (10 mg, 0.021 mmol, 0.04 eq.), tris(dibenzylideneacetone)dipalladium(0) (0.011 mmol, 0.02 eq.), dioxane (2.2 mL) and water (0.4 mL). The vial was sealed, evacuated under vacuum and refilled with argon. The reaction was stirred at 95°C overnight. Water and EtOAc were added. The two phases were separated and the aqueous phase was extracted with EtOAc. Combined organic phases were dried using a phase separator and evaporated to give crude material. The crude material was purified by flash chromatography on silica gel using a gradient of heptane/ EtOAc. It was transferred via liquid injection in DCM. Relevant fractions were collected and concentrated under vacuum to give expected products III.

Example: Synthesis of 4-[1-[(4-benzyl-3-methyl-morpholin-3-yl)methyl]indazol-3-yl]-3,3-dimethyl-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one ($R_1 = H, R_2 = Me$)

White foam; 67% yield; ^1H NMR (500 MHz, DMSO- d_6) δ 8.34 (d, $J=5.38$ Hz, 1H), 7.90 (d, $J=8.56$ Hz, 1H), 7.79 (d, $J=8.31$ Hz, 1H), 7.50 (t, $J=7.61$ Hz, 1H), 7.39 (d, $J=5.38$ Hz, 1H), 7.19-7.32 (m, 6H), 5.47-5.50 (m, 1H), 4.95 (d, $J=14.43$ Hz, 1H), 4.65 (d, $J=14.67$ Hz, 1H), 3.91-4.01 (m, 2H), 3.68-3.78 (m, 2H), 3.51-3.64 (m, 3H), 3.26-3.29 (m, 1H), 2.90-2.99 (m, 1H), 2.75 (br t, $J=8.80$ Hz, 1H), 2.37-2.42 (m, 1H), 1.96 (br d, $J=11.49$ Hz, 1H), 1.49-1.69 (m, 4H), 1.31-1.39 (m, 6H), 1.11 (s, 3H); $m/z = 566.5 [M+H]^+$

3. Deprotection of benzyl

Suzuki coupling product III (0.09 mmol) was dissolved in anhydrous methanol (2.2 mL, 0.04 N). Ammonium formate (0.62 mmol, 7 eq.) and Pd/C 10% Engelhard (0.09 mmol, 1 eq.) were added. The reacti-vial was sealed, evacuated under vacuum and refilled with argon. The suspension was stirred at 110 °C for 3h. The reaction mixture was filtered, washed with MeOH and concentrated, to give benzyl deprotected products.

Example: Synthesis of 3,3-dimethyl-4-[1-[(3-methylmorpholin-3-yl)methyl]indazol-3-yl]-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-2-one ($R_1 = H$, $R_2 = Me$)

Brown gum; 61% yield; ^1H NMR (600 MHz, DMSO- D_6 , 300 K) δ (ppm) = 8.33 (d, $J = 5.3$ Hz, 1H), 7.84 (d, $J = 8.5$ Hz, 1H), 7.78 (d, $J = 8.2$ Hz, 1H), 7.50 (ddd, $J = 0.9, 7.1, 8.3$ Hz, 1H), 7.38 (d, $J = 5.4$ Hz, 1H), 7.27 - 7.20 (m, 1H), 5.49 (dd, $J = 2.1, 11.4$ Hz, 1H), 4.69 (d, $J = 14.5$ Hz, 1H), 4.54 (d, $J = 14.5$ Hz, 1H), 3.99 (td, $J = 1.9, 11.4$ Hz, 1H), 3.65 (td, $J = 3.8, 11.0$ Hz, 1H), 3.61 - 3.46 (m, 3H), 3.13 - 3.06 (m, 1H), 3.04 - 2.83 (m, 1H), 2.78 - 2.70 (m, 1H), 2.37 - 2.14 (m, 1H), 1.96 (br dd, $J = 2.5, 10.0$ Hz, 1H), 1.72 - 1.44 (m, 5H), 1.37 (d, $J = 1.0$ Hz, 6H), 0.94 (s, 3H); $m/z = 476.5$ $[M+H]^+$

10

4. Deprotection of THP


4 M hydrogen chloride solution in dioxane (8 mmol, 8 eq.) was added to a solution of previous compounds (0.17 mmol) in anhydrous methanol (0.8 mL, 0.2 N). The reaction was stirred at 65°C overnight. After cooling, an aqueous solution of $NaHCO_3$ was added and the mixture was extracted with EtOAc. Combined organic phases were dried over Na_2SO_4 , filtered and evaporated to give expected compounds **IV** as hydrochloric salts.

Racemic precursor of Example 31: Synthesis of 3,3-dimethyl-4-[1-[(3-methylmorpholin-3-yl)methyl]indazol-3-yl]-1H-pyrrolo[2,3-b]pyridin-2-one ($R_1 = H$, $R_2 = Me$)

White powder; yield 62%, ^1H NMR (DMSO- d_6 , 600 MHz): δ (ppm) 11.10 (s, 1H), 8.21 (d, $J = 5.4$ Hz, 1H), 7.83 (d, $J = 8.7$ Hz, 1H), 7.80 (d, $J = 8.2$ Hz, 1H), 7.49 (ddd, $J = 8.3, 7.0, 1.0$ Hz, 1H), 7.29 (d, $J = 5.4$ Hz, 1H), 7.22-7.26 (m, 1H), 4.69 (d, $J = 14.5$ Hz, 1H), 4.53 (d, $J = 14.5$ Hz, 1H), 3.65 (dt, $J = 10.8, 3.8$ Hz, 1H), 3.58 (d, $J = 11.2$ Hz, 1H), 3.49 (ddd, $J = 10.8, 8.3, 2.9$ Hz, 1H), 3.28-3.30 (m, 1H), 3.10 (ddd, $J = 12.3, 8.6, 3.2$ Hz, 1H), 2.71-2.78 (m, 1H), 2.33 (br s, 1H), 1.36 (d, $J = 1.6$ Hz, 6H), 0.94 (s, 3H); $m/z = 392.1$ $[M+H]^+$

Enantiomeric compounds were obtained after chiral purification.

Example 63 was obtained as a secondary product during benzyl deprotection in methanol.

Scaffold coupling - General Procedure (indazole 5)

5

10

1. Synthesis of O1-tert-butyl O3-methyl 3-methylsulfonyloxypyrrolidine-1,3-dicarboxylate

At room temperature, methanesulfonyl chloride (1.2 mL, 14.9 mmol, 2 eq.) was added to a stirred suspension of triethylamine (2.1 mL, 14.9 mmol, 2 eq.) and 1-tert-butyl 3-methyl 3-hydroxypyrrolidine-1,3-dicarboxylate (1.90 g, 7.44 mmol, 2 eq.) in anhydrous dichloroethane (62 mL, 0.12 N). The reaction was stirred at 55°C overnight. Water was added and the mixture extracted with DCE. The organic phase was dried and concentrated under vacuum. The crude was purified by flash chromatography using a gradient of heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to afford O1-tert-butyl O3-methyl 3-methylsulfonyloxypyrrolidine-1,3-dicarboxylate (1.5 g, 63% Yield) as a yellow oil. ¹H NMR(Chloroform-d, 400 MHz): δ (ppm) 3.92 (t, J=14.9 Hz, 5H), 3.69 – 3.49 (m, 2H), 3.18 (s, 3H), 2.66 – 2.41 (m, 2H), 1.46 (s, 9H).

25

2. Substitution

A reacti-vial was charged with sodium hydride (1.99 mmol, 1.5 eq.) and anhydrous THF (0.05 mL). Then bromoindazole I (300 mg, 1.33 mmol) in anhydrous THF (0.1 mL) was added. O1-tert-

- butyl 3-methyl 3-methylsulfonyloxypyrrolidine-1,3-dicarboxylate (1.99 mmol, 2 eq.) in anhydrous THF (0.35 mL) was added dropwise at room temperature. The reaction was stirred at room temperature overnight. Sodium hydride (1.5 eq) was added and the reaction was stirred overnight at room temperature. The solvent was evaporated. This residue was solubilized in ethyl acetate and water was added. The two phases were separated. Combined aqueous phases were neutralized with an aqueous solution of HCl 1N and extracted with dichloromethane. Combined organic phases were dried using a phase separator and evaporated to give afforded products II.
- Example: Synthesis of 3-(3-bromo-6-fluoro-indazol-1-yl)-1-tert-butoxycarbonyl-pyrrolidine-3-carboxylic acid ($R_1 = F$)
- Colorless gum, 37% yield, ^1H NMR (400 MHz, DMSO- d_6) δ 13.72 (s, 1H), 7.69 (dd, $J = 8.9, 5.2$ Hz, 1H), 7.46 (s, 1H), 7.26 – 7.17 (m, 1H), 4.37 – 4.10 (m, 2H), 3.02 – 2.83 (m, 2H), 2.42 (s, 1H), 2.15 (s, 1H), 1.42 (s, 9H); $m/z = 400.3, 402.3 [M+H]^+$.

3. Reduction

- A 2mL reacti-vial was charged with substituted indazoles II (0.487 mmol) and a solution of 1 M borane tetrahydrofuran (0.974 mmol, 2 eq.) was added. The reaction was stirred at room temperature for 3h. The reaction mixture was poured in an aqueous solution of NH_4Cl sat. and extracted with dichloromethane. Combined organic phases were dried over phase separator and evaporated to give crude material as a brown solid. The crude material was purified by flash chromatography on silica gel using a gradient of dichloromethane/ ethyl acetate. It was transferred via solid phase on Isolute HM-N. Relevant fractions were collected and concentrated under vacuum to afford expected products III.

Example: Synthesis of tert-butyl 3-(3-bromo-6-fluoro-indazol-1-yl)-3-(hydroxymethyl)pyrrolidine-1-carboxylate ($R_1 = F$)

- White foam; 44% yield; $m/z = 358, 360 [M+H-tBu]^+$

4. Suzuki

- A 12mL reacti-vial was charged with previous compounds III (0.222 mmol), boronic ester I' (0.222 mmol, 1 eq.) and tetrakis(triphenyl)phosphine palladium (0.0222 mmol, 0.1 eq.) in a mixture of DMF (1.7 mL) and Water (0.6 mL). The mixture was degassed with N_2 , then disodium

carbonate (0.666 mmol, 3 eq.) was added. The mixture was once again degassed with N₂, then it is stirred at 90°C for 3h. Water was added to the cold mixture and the precipitate was filtered and washed with water, then dissolved in DCM. The organic phase was filtered on a phase separator and concentrated under vacuum. The crude product was purified with a gradient of
 5 heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to afford expected compounds **IV**.

Example: Synthesis of tert-butyl 3-[6-fluoro-3-(2'-oxo-1'-tetrahydropyran-2-yl)-spiro[cyclopentane-1,3'-pyrrolo[2,3-b]pyridine]-4'-yl]indazol-1-yl]-3-(hydroxymethyl)pyrrolidine-1-carboxylate (R₁ = F,
 10 G=CCyclopentyl)

Beige solid, 24% yield, m/z = 606.3 [M+H]⁺

5. Deprotection


15 4 M hydrogen chloride solution in dioxane (1.9 mmol, 40 eq.) was added to a solution of previous compounds **IV** (0.05 mmol) in anhydrous methanol (0.1 mL, 0.5 N). The reaction was stirred at 65°C overnight. The solution was concentrated. The product was dissolved in water and the impurities were extracted with EtOAc. The aqueous phase was concentrated under vacuum to afford expected compounds **IV** as hydrochloric salts.

20

Example 55: Synthesis of 4-[6-fluoro-1-[3-(hydroxymethyl)pyrrolidin-3-yl]indazol-3-yl]spiro[1H-pyrrolo[2,3-b]pyridine-3,1'-cyclopentane]-2-one dihydrochloride (R₁ = F, G=CCyclopentyl)

Yellow powder; 57% yield; ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.02 (s, 1H), 9.18-9.66 (m, 2H), 8.19 (d, J = 5.4 Hz, 1H), 7.65-7.84 (m, 2H), 7.17 (td, J = 9.0, 2.1 Hz, 1H), 7.11 (d, J = 5.4
 25 Hz, 1H), 4.10 (dt, J = 12.0, 6.0 Hz, 2H), 3.80-3.97 (m, 3H), 3.40-3.52 (m, 1H), 3.23-3.34 (m, 1H), 2.66-2.93 (m, 2H), 2.10-2.28 (m, 2H), 1.77-1.90 (m, 4H), 1.60 (br d, J = 2.7 Hz, 2H); m/z = 422.1 [M+H]⁺

30 *In order to obtain Example 77 one more step will be performed before deprotection:*



Synthesis of tert-butyl 3-[3-(3,3-dimethyl-2-oxo-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-4-yl)indazol-1-yl]-3-(fluoromethyl)pyrrolidine-1-carboxylate

5

In a 5mL reacti-vial at 0°C, DAST (0.019 mL, 0.142 mmol, 1.5 eq.) was added dropwise to a stirred solution of tert-butyl 3-[3-(3,3-dimethyl-2-oxo-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-4-yl)indazol-1-yl]-3-(hydroxymethyl)pyrrolidine-1-carboxylate (53 mg, 0.0944 mmol) in anhydrous DCM (1.2 mL, 0.08 N). The reaction mixture was allowed to reach room temperature and stirred


10

at room temperature overnight. DAST (0.019 mL, 0.142 mmol, 3eq.) was added and the reaction mixture was stirred at room temperature over weekend. The reaction mixture was quenched with an aqueous solution of NaOH 1M until pH=12, extracted with dichloromethane and dried over phase separator. The solvent was evaporated to give tert-butyl 3-[3-(3,3-dimethyl-2-oxo-1-tetrahydropyran-2-yl-pyrrolo[2,3-b]pyridin-4-yl)indazol-1-yl]-3-(fluoromethyl)pyrrolidine-1-

15

carboxylate (35.3 mg, 66% Yield) as a pale yellow gum. It was engaged in next step without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36 (d, J = 5.4 Hz, 1H), 7.94 – 7.77 (m, 2H), 7.58 – 7.48 (m, 1H), 7.41 (d, J = 6.3 Hz, 1H), 7.37 – 7.27 (m, 1H), 5.49 (d, J = 11.1 Hz, 1H), 5.10 – 4.78 (m, 2H), 4.09 – 3.95 (m, 1H), 3.57 (d, J = 10.2 Hz, 2H), 2.97 (dq, J = 13.7, 6.9 Hz, 3H), 2.75 (q, J = 7.2 Hz, 3H), 1.95 (s, 1H), 1.71 – 1.45 (m, 4H), 1.38 (d, J = 12.7 Hz, 6H), 1.07 (dt, J = 20.1, 7.2 Hz, 9H); m/z = 564.2 [M+H]⁺.

20

Scaffold coupling - Specific Procedure (specific indazole 1)

5

Step 1: Synthesis of tert-butyl-(1H-indazol-7-yloxy)-diphenyl-silane

To a solution of 7-hydroxy-1H-indazole (95%, 1.44 g, 10.2 mmol) in anhydrous DMF (14 mL, 0.5 N) was added tert-butyldichlorodiphenylsilane (6.8 mL, 25.5 mmol, 2.5 eq.) at room temperature. The resulting mixture was stirred at room temperature overnight. tert-butyl-chlorodiphenylsilane (6.8 mL, 25.5 mmol, 2.5 eq.) was added and the resulting mixture was stirred at 80°C overnight. The reaction was poured into an aqueous solution of NaHCO₃ and extracted with EtOAc. The two phases were separated and the organic phase was washed with water, dried over Na₂SO₄, filtered and evaporated. The crude material was purified by flash chromatography on silica gel using a gradient of heptane/EtOAc. It was transferred via liquid injection in DCM. Relevant fractions were collected and concentrated under vacuum to afford tert-butyl-(1H-indazol-7-yloxy)-diphenyl-silane (1.4 g, 37% yield) as a white foam. ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 13.36 (s, 1H), 8.07 (s, 1H), 7.71-7.74 (m, 4H), 7.40-7.51 (m, 6H), 7.23 (d, J = 8.1 Hz, 1H), 6.63 (t, J = 7.8 Hz, 1H), 6.13 (d, J = 7.3 Hz, 1H), 1.09 (s, 9H); m/z = 373.4 [M+H]⁺

Step 2: Synthesis of 4-[7-[tert-butyl(diphenyl)silyl]oxyindazol-1-yl]piperidine-1-carboxylate

To a stirred mixture of tert-butyl-(1H-indazol-7-yloxy)-diphenyl-silane (650 mg, 1.74 mmol) in anhydrous toluene (5 mL, 0.3 N), were added cyanomethylenetriphenylphosphorane (0.91 mL, 3.49 mmol, 2 eq.) and tert-butyl 4-hydroxypiperidine-1-carboxylate (0.70 g, 3.49 mmol, 2 eq.). The reaction was stirred at 85°C during 5h. tert-butyl 4-hydroxypiperidine-1-carboxylate (0.70 g, 3.49 mmol, 2 eq.) and cyanomethylenetriphenylphosphorane (0.91 mL, 3.49 mmol, 2 eq.) were added again and the reaction was stirred at 85°C overnight. The reaction mixture was concentrated to dryness and the crude was purified by flash chromatography column with a

gradient of EtOAc in Cyclohexane. Relevant fractions were collected and concentrated under vacuum to afford tert-butyl 4-[7-[tert-butyl(diphenyl)silyl]oxyindazol-1-yl]piperidine-1-carboxylate (180 mg, 18%). ¹H NMR (600 MHz, DMSO-d₆) Shift 8.09 (s, 1H), 7.71-7.76 (m, 4H), 7.38-7.52 (m, 6H), 7.23 (d, J=8.02 Hz, 1H), 6.64 (t, J=7.85 Hz, 1H), 6.21 (d, J=7.63 Hz, 1H), 5.57 (tt, J=5.28, 10.27 Hz, 1H), 4.14 (br d, J=12.03 Hz, 2H), 2.78 (br s, 2H), 2.02-2.11 (m, 4H), 1.38-1.45 (m, 9H), 1.11 (s, 9H); m/z = 556.4 [M+H]⁺.

Step 3: Synthesis of tert-butyl 4-(7-hydroxyindazol-1-yl)piperidine-1-carboxylate

In a 50 mL round-bottomed flask, at room temperature, 1 M tetrabutylammonium fluoride solution (0.49 mL, 0.486 mmol, 1.5 eq.) was added to a stirred solution of tert-butyl 4-[7-[tert-butyl(diphenyl)silyl]oxyindazol-1-yl]piperidine-1-carboxylate (180 mg, 0.324 mmol) in anhydrous THF (1.6 mL, 0.2 N). The reaction was stirred at room temperature for 1h. The reaction was quenched with brine, and EtOAc was added. The two phases were separated and the organic phase was washed with water and brine, dried over Na₂SO₄, and evaporated to dryness. The crude material was triturated in DCM. The solid was filtered and dried under high vacuum to give tert-butyl 4-(7-hydroxyindazol-1-yl)piperidine-1-carboxylate (70mg, 68% Yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.20 (s, 1H), 7.95 (s, 1H), 7.14 (dd, J = 8.0, 0.6 Hz, 1H), 6.96 – 6.82 (m, 1H), 6.69 (dd, J = 7.4, 0.6 Hz, 1H), 5.25 (p, J = 7.9, 7.4 Hz, 1H), 4.09 (d, J = 11.7 Hz, 2H), 2.93 (s, 2H), 2.02 – 1.87 (m, 4H), 1.43 (s, 9H); m/z = 318.1 [M+H]⁺

Step 4: Synthesis of tert-butyl 4-[7-(difluoromethoxy)indazol-1-yl]piperidine-1-carboxylate


In a 2-5mL sealed tube, at -78°C, diethyl [bromo(difluoro)methyl]phosphonate (0.080 mL, 0.429 mmol, 2 eq.) was added in one portion to a cooled solution of tert-butyl 4-(7-hydroxyindazol-1-yl)piperidine-1-carboxylate (68 mg, 0.214 mmol) and potassium hydroxide (240 mg, 4.29 mmol, 20 eq.) in a mixture of acetonitrile (1.1 mL) and water (1.1 mL). The reaction was allowed to warm to room temperature and stirred during 1h. The reaction mixture was diluted with EtOAc. The two phases were separated and the aqueous phase was extracted with EtOAc. Combined organic phases were washed with brine, water, dried over Na₂SO₄, and evaporated to give tert-butyl 4-[7-(difluoromethoxy)indazol-1-yl]piperidine-1-carboxylate as a brown gum. ¹H NMR (600 MHz, DMSO-d₆) δ ppm 8.17 (s, 1 H), 7.63 - 7.67 (m, 1 H), 7.27 - 7.53 (m, 1 H), 7.16 - 7.19 (m, 1 H), 7.11 - 7.15 (m, 1 H), 4.95 - 5.04 (m, 1 H), 4.03 - 4.18 (m, 2 H), 2.71 - 3.11 (m, 2 H), 1.83 - 2.06 (m, 4 H), 1.43 (s, 9 H); m/z = 312.2 [M+H]⁺

Step 5: Synthesis of tert-butyl 4-[3-bromo-7-(difluoromethoxy)indazol-1-yl]piperidine-1-carboxylate

N-bromosuccinimide (23 mg, 0.128 mmol, 1.05 eq.) was added to a solution of tert-butyl 4-[7-(difluoromethoxy)indazol-1-yl]piperidine-1-carboxylate (64 mg, 0.122 mmol) in acetonitrile (0.3 mL, 0.4 N). The mixture was stirred at room temperature overnight. The solvent was removed under vacuum, and the residue was dissolved in EtOAc. The organic solution was washed with an aqueous solution of NaOH, water, dried over Na₂SO₄, and concentrated under vacuum to give tert-butyl 4-[3-bromo-7-(difluoromethoxy)indazol-1-yl]piperidine-1-carboxylate (69 mg, 85% yield) as a purple gum. ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 7.15-7.71 (m, 4H), 4.89-5.07 (m, 1H), 3.99-4.19 (m, 2H), 2.75-3.10 (m, 2H), 1.72-2.15 (m, 4H), 1.36-1.46 (m, 9H); m/z = 390.2, 392.2 [M+H-tBu]⁺

The next steps were similar to general procedure - indazole 2.

Scaffold coupling - Specific Procedure (specific indazole 2)




A 6ml sealed-vial was successively charged with 3-bromo-1H-indazole (120 mg, 0.59 mmol), (tributyl-lambda~5-phosphanylidene)acetonitrile (0.31 mL, 1.18 mmol) and compound I' in anhydrous toluene (2 mL) under nitrogen atmosphere. The reaction was stirred at 80°C overnight. The solvent was evaporated to give crude material. It was purified by flash chromatography on silica gel using a gradient of heptane/ ethyl acetate. It was transferred via solid phase on Isolute HM-N on a 12g Redisep Gold column. Relevant fractions were collected and concentrated under vacuum to afford compounds II.

Example: Synthesis of tert-butyl N-[rac-(1R,2R,4R)-4-(3-bromoindazol-1-yl)-2-fluorocyclohexyl]carbamate (R₁ = F)

Beige solid, 58% yield, ¹H NMR (400 MHz, DMSO-d₆) δ 7.88 (d, J = 8.6 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.13 – 7.03 (m, 1H), 4.81 (s, 1H), 4.63 (s, 1H), 4.50 (s, 1H), 3.57 (s, 1H), 2.42 (d, J = 5.2 Hz, 1H), 2.21 – 2.08 (m, 1H), 1.91 (d, J = 7.3 Hz, 2H), 1.45 (d, J = 7.0 Hz, 2H), 1.42 (s, 9H).

Scaffold coupling - Specific Procedure (specific indazole 3)

5

**Step 1: Synthesis of 2-[1-(3-bromoindazol-1-yl)cyclobutyl]acetonitrile**

10

A 20ml biotage vial was successively charged with 3-bromo-1H-indazole (500 mg, 2.46 mmol), cyclobutylideneacetonitrile (0.25 mL, 2.46 mmol), 1,8-diazabicyclo[5.4.0]undéc-7-ène (0.73 mL, 4.92 mmol) in anhydrous acetonitrile (12 mL). The mixture was stirred at 85°C during 48h. The mixture was concentrated under vacuum. An orange oil was obtained and purified on a 12g silica gel column with a gradient of Heptane/EtOAc. Relevant fractions were collected and concentrated under vacuum to afford 2-[1-(3-bromoindazol-1-yl)cyclobutyl]acetonitrile (600mg, 83% Yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.63 (d, *J* = 9.1 Hz, 2H), 7.57 – 7.42 (m, 1H), 7.30 (dd, *J* = 8.7, 7.0 Hz, 1H), 3.39 (s, 2H), 2.87 (dt, *J* = 12.5, 9.7 Hz, 2H), 2.64 – 2.53 (m, 2H), 2.25 – 2.09 (m, 1H), 2.09 – 1.89 (m, 1H); *m/z* = 290.0, 292.0 [*M*+*H*]⁺

20

Step 2: Synthesis of 2-[1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-1-yl]cyclobutyl]acetonitrile



A vial was charged with bis(pinacol)diborane (1.5 g, 6.00 mmol), potassium acetate (589 mg, 6.00 mmol), 2-[1-(3-bromoindazol-1-yl)cyclobutyl]acetonitrile (580 mg, 2.00mmol), and bis(diphenylphosphino)ferrocene]dichloropalladium(II) (147 mg, 0.200 mmol) in anhydrous dioxane (20 mL). The vial was sealed, evacuated under vacuum and refilled with argon. The reaction mixture was stirred at 110°C for 2h then allowed to reach room temperature, filtered, washed with EtOAc, concentrated under vacuum to give crude material as a brown oil. The crude material was purified by flash chromatography on silica gel using a gradient of heptane /EtOAc. It was transferred via liquid injection in DCM on a 70g column. Relevant fractions were

collected and concentrated under vacuum to afford 2-[1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazol-1-yl]cyclobutyl]acetonitrile as an orange solid.

^1H NMR (400 MHz, DMSO- d_6) δ 7.96 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.41 – 7.36 (m, 1H), 7.26 – 7.21 (m, 1H), 3.42 (s, 2H), 2.90 (dt, J = 12.4, 9.8 Hz, 2H), 2.66 – 2.56 (m, 2H), 2.28 – 2.11 (m, 1H), 2.01 – 1.88 (m, 1H), 1.36 (s, 12H); m/z = 256.3 $[\text{M}+\text{H}]^+$

Scaffold coupling - General Procedure (pyrazole)

10



G = NH, CMe₂, CMeOH
 R = NBoc, CHNHBoc
 R₁ = NH, CHNH₂
 R₂ = H, CH₃
 X = OH, Br

15

First step: alkylation or Mitsunobu

20

1a. Alkylation (X = Br)

In a reactivial, cesium carbonate (532 mg, 1.63 mmol, 1.2 eq.) was added to a solution of 3-bromo-1H-pyrazole I (200 mg, 1.36 mmol) and tert-butyl 4-bromopiperidine-1-carboxylate (431 mg, 1.63 mmol, 1.2 eq.) in anhydrous DMF (14 mL, 0.1N). The mixture was heated to 70°C overnight. tert-butyl 4-bromopiperidine-1-carboxylate (431 mg, 1.63 mmol, 2 eq.) and cesium carbonate (532 mg, 1.63 mmol, 2 eq.) were added and the mixture heated to 80°C overnight. Tert-butyl 4-bromopiperidine-1-carboxylate (2 eq.) and cesium carbonate (2 eq.) were added

again and the mixture heated to 80°C for 4 hours more. Water was added and the mixture extracted with ethyl acetate. The organic phase was dried and concentrated under vacuum to afford crude material. The crude material was purified by flash chromatography on silica gel using a gradient of DCM / EtOAc. It was transferred via liquid injection in DCM. Relevant fractions were collected (not visible in UV) and concentrated under vacuum to afford tert-butyl 4-(3-bromopyrazol-1-yl)piperidine-1-carboxylate II (266mg, 54% yield) as a pale oil. ¹H NMR(DMSO-*d*₆, 400 MHz): δ (ppm) 7.83 (d, *J*=2.4 Hz, 1H), 6.38 (d, *J*=2.3 Hz, 1H), 4.35 (tt, *J*=11.5, 4.0 Hz, 1H), 4.03 (d, *J*=12.3 Hz, 2H), 2.88 (s, 2H), 2.04 – 1.92 (m, 2H), 1.73 (qd, *J*=12.4, 4.4 Hz, 2H), 1.42 (s, 9H); *m/z* = 276.1 [M+H]⁺

10 1b. Mitsunobu reaction (X= OH)

Cyanomethylenetriethylphosphorane (1.7 mL, 6.12 mmol, 3 eq.) was added to a solution of 3-bromo-1H-pyrazole I (300 mg, 2.04 mmol) and tert-butyl cis-4-hydroxycyclohexylcarbamate (1.32g, 6.12 mmol, 3 eq.) in anhydrous toluene (10 mL, 0.2 N). The reaction mixture was stirred at 90°C overnight. The solution was concentrated under vacuum. The crude material was purified by flash chromatography on silica gel using a gradient of heptane / EtOAc. Relevant fractions were collected and concentrated under vacuum to afford tert-butyl N-[4-(3-bromopyrazol-1-yl)cyclohexyl]carbamate II (288mg, 41% yield) as a yellow solid. ¹H NMR(DMSO-*d*₆, 400 MHz): δ (ppm) 7.79 (d, *J*=2.3 Hz, 1H), 6.80 (d, *J*=7.9 Hz, 1H), 6.34 (d, *J*=2.3 Hz, 1H), 4.09 (tt, *J*=11.9, 3.9 Hz, 1H), 3.22-3.30 (m, 1H), 2.04 – 1.65 (m, 6H), 1.51 – 1.20 (m, 11H), *m/z* = 288.1-290.1 [M+H-tBu]⁺

Same synthesis for following steps.

25 2. Boronic esters

In a reactival were introduced substituted bromopyrazoles II (0.806 mmol), bis(pinacolato)diboron (1.21 mmol, 1.5 eq.) and potassium acetate (2.42 mmol, 3 eq.) in anhydrous dioxane (2.7 mL, 0.3 N). The mixture was degassed with N₂ and bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.081 mmol, 0.1 eq.) was added. The reaction mixture was stirred at 100°C overnight. The mixture was filtered on dicalite and concentrated under vacuum to give crude material III. The crude material was used in next step without further purification.

Example: Synthesis of tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine-1-carboxylate (R=NHBoc, R₂=H)
Dark oil, *m/z* = 240.3 [M+H-tBu]⁺ (acid form)

3. Suzuki coupling

A reacti-vial was charged with boronic esters **III** (0.709 mmol, 2 eq.), bromine scaffold **I'** (0.332 mmol), disodium carbonate (0.996 mmol, 3 eq.) and tetrakis(triphenylphosphine) palladium (0.0332 mmol, 0.1 eq.) in a mixture of DMF (3.2 mL) and water (0.6 mL). The vial was degassed with nitrogen and stirred at 100°C during 4h. Water was added and the precipitate was filtered and solubilized in DCM. The organic phase was dried on a phase separator and concentrated under vacuum. The crude material was purified by flash chromatography on silica gel using a gradient of cyclohexane/ EtOAc. Relevant fractions were collected and concentrated under vacuum to afford Suzuki coupling products **IV**.

Example: Synthesis of tert-butyl 4-[3-(3,3-dimethyl-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]piperidine-1-carboxylate (R=NH₂Boc, R₂=H, G = CMe₂)


Yellow solid, 54% yield, ¹H NMR (DMSO-d₆, 400 MHz): δ (ppm) 11.01 (s, 1H), 8.07 (d, J=5.5 Hz, 1H), 7.95 (d, J=2.4 Hz, 1H), 7.24 (d, J=5.6 Hz, 1H), 6.83 (d, J=2.4 Hz, 1H), 4.49 (ddt, J=11.4, 7.9, 4.0 Hz, 1H), 4.13 – 3.99 (m, 2H), 2.91 (d, J=14.5 Hz, 2H), 2.06 (d, J=10.0 Hz, 2H), 1.86 (qd, J=12.4, 4.2 Hz, 2H), 1.45 (d, J=14.7 Hz, 15H); m/z = 412.4 [M+H]⁺

4. Deprotection

4 M hydrogen chloride solution in dioxane (0.73 mmol, 4 eq.) was added to a solution of Suzuki coupling compounds **IV** (0.18 mmol) in anhydrous methanol (0.16 mL, 0.1 N). The reaction was stirred at room temperature overnight. The solution was concentrated under vacuum. The product was triturated in DCM and dried under vacuum at 40°C overnight to give final compounds **IV** as hydrochloric salts.

Example: Synthesis of 3,3-dimethyl-4-[1-(4-piperidyl)pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridin-2-one dihydrochloride (R=NH₂, R₂=H, G = CMe₂)

White powder, 73% yield, ¹H NMR (DMSO-d₆, 500 MHz): δ (ppm) 11.06 (s, 1H), 8.62-9.21 (m, 2H), 8.08 (d, J = 5.6 Hz, 1H), 7.93 (d, J = 2.4 Hz, 1H), 7.25 (d, J = 5.6 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 4.59 (tt, J = 10.3, 5.0 Hz, 1H), 4.25 (br s, 1H), 3.43 (br d, J = 13.0 Hz, 2H), 3.02-3.14 (m, 2H), 2.13-2.29 (m, 4H), 1.48 (s, 6H); m/z = 312.1 [M+H]⁺

Scaffold coupling – General Procedure (pyrrole)

5

1. Mitsunobu reaction

A 10mL reacti-vial was charged with 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole (200 mg, 1.02 mmol) **I**, tert-butyl 4-hydroxypiperidine-1-carboxylate (409 mg, 2.03 mmol, 2 eq.), and anhydrous toluene (5 mL, 0.2 N). The vial was sealed and cyanomethylenetriphenylphosphorane (0.55 mL, 2.03 mmol, 2 eq.) was added. The reaction mixture was stirred at 110°C during 3h. tert-butyl 4-hydroxypiperidine-1-carboxylate (409 mg, 2.03 mmol, 2 eq.) and cyanomethylenetriphenylphosphorane (0.55 mL, 2.03 mmol, 2 eq.) were added and the reaction mixture was stirred at 110°C for 4h. Tert-butyl-4-hydroxypiperidine-1-carboxylate (2eq) and cyanomethylenetriphenylphosphorane (2eq) were added again and the reaction mixture was stirred at 110°C overnight. The reaction was stopped and the solvent was removed under vacuum. The crude material was purified by reverse chromatography in neutral conditions (MeCN/water). Relevant fractions were collected and concentrated under vacuum to afford tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrol-1-yl]piperidine-1-carboxylate (106 mg, 28%) as a white solid. ¹H NMR (DMSO-*d*₆, 400 MHz): δ (ppm) 7.14 (t, *J*=1.7 Hz, 1H), 6.88 (t, *J*=2.3 Hz, 1H), 6.21 – 6.17 (m, 1H), 4.16 – 3.95 (m, 3H), 2.82 (s, 2H), 1.91 (d, *J*=12.5 Hz, 2H), 1.76 – 1.59 (m, 2H), 1.42 (s, 9H), 1.23 (s, 12H); *m/z* = 377.3 [M+H]⁺

2. Suzuki coupling

A reacti-vial was charged with tert-butyl 4-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrol-1-yl]piperidine-1-carboxylate **II** (0.282 mmol, 1.1 eq.), bromine scaffold **I'** (0.256 mmol), disodium carbonate (81 mg, 0.768 mmol) and tetrakis(triphenylphosphine) palladium (30 mg, 0.0256 mmol, 0.1 eq.) in a mixture of DMF (2.5 mL) and water (0.5 mL). The vial was sealed, degassed with nitrogen and stirred at 100°C overnight. The reaction was stopped and the reaction mixture was filtered through a dicalite pad, then washed with DCM. The solvent was removed under vacuum to give crude material. The crude material was purified by flash chromatography on silica gel

using a gradient of cyclohexane/EtOAc followed by a gradient of toluene/acetone. Relevant fractions were collected and concentrated under vacuum to afford expected products **III**.

Example: Synthesis of tert-butyl 4-[3-(2-oxo-1,3-dihydroimidazo[4,5-b]pyridin-7-yl)pyrrol-1-yl]piperidine-1-carboxylate (G = NH)

White solid; Yield 13%; ¹H NMR(DMSO-*d*₆, 400 MHz): δ (ppm) 11.22 (s, 1H), 10.63 (s, 1H), 7.86 (dd, *J*=5.2, 1.4 Hz, 1H), 7.79 (d, *J*=5.6 Hz, 1H), 7.66 (s, 1H), 7.12 (d, *J*=5.6 Hz, 1H), 6.59 (s, 1H), 4.12 (s, 3H), 2.86 (s, 2H), 2.05 – 1.69 (m, 4H), 1.44 (s, 9H); *m/z* = 384.5 [M+H]⁺

3. Deprotection

4 M hydrogen chloride solution in dioxane (0.36 mmol, 10 eq.) was added to a solution of Suzuki coupling compounds **III** (0.032 mmol) in anhydrous methanol (0.16 mL, 0.2 N). The reaction was stirred at room temperature overnight. The reaction mixture was filtered and the product washed with pentane and dried under vacuum at 40°C to give final compounds as hydrochloric salts.

Example 6: Synthesis of 7-[1-(4-piperidyl)pyrrol-3-yl]-1,3-dihydroimidazo[4,5-b]pyridin-2-one; dihydrochloride (G = NH)

White powder; yield 50%, ¹H NMR (DMSO-*d*₆, 500 MHz): δ (ppm) 11.77 (br s, 1H), 10.97 (br s, 1H), 9.08 (br s, 1H), 8.89 (br s, 1H), 7.82 (d, *J* = 5.9 Hz, 1H), 7.64 (s, 1H), 7.22 (d, *J* = 5.9 Hz, 1H), 7.00 (t, *J* = 2.2 Hz, 1H), 6.70 (br s, 1H), 4.28 (tt, *J* = 11.4, 3.6 Hz, 1H), 3.53 (br s, 1H), 3.36-3.46 (m, 2H), 3.05 (q, *J* = 12.1 Hz, 2H), 2.23 (br d, *J* = 12.5 Hz, 2H), 2.06-2.18 (m, 2H); *m/z* = 284.2 [M+H]⁺

Example 2 – Biological Assays

PKC-theta and PKC-delta inhibition assay

PKC-theta and PKC-delta biochemical activities were measured using the PKC-theta HTRF KinEASEkit kit, according to manufacturer's instructions (Cisbio, catalogue number 61ST1PEJ). Briefly, the kinase buffer component of the kit was supplemented with 10 mM MgCl₂, 1 mM DTT and 0.1% Tween 20. For the PKC-theta assay, STK substrate and ATP were added to provide a final assay concentration of 525 nM and 6.5 μM, respectively. For the PKC-delta assay, STK substrate and ATP were added to provide a final assay concentration of 243 nM and 5.7 μM, respectively. The streptavidin_XL665 and STK antibody-cryptate detection

reagents were mixed according to the manufacturer's instructions. Test compounds were diluted in DMSO in a series of 10 semi-log step doses; 10 nL of each compound dose were dispensed in 384 well plates. Recombinant human PKC-theta (His-tagged 362-706) or PKC-delta (His-tagged 345-676) was diluted into kinase buffer to provide a final assay concentration of 10 ng/mL and added to the test compound for 30 minutes on ice. The reaction was started by addition of the substrate and ATP and incubated at 25°C for 30 minutes or 20 minutes for the PKC-theta and PKC-delta assays, respectively. The detection reagents were added, and the plate was incubated in the dark for 2 hours. Fluorescence was measured on an Envision 2103 plate reader with optical setup for excitation at 665 nM and emission at 620 nM in the HTRF mode. The ratio of acceptor and donor emission signals was calculated for each well. Percent inhibition values were calculated from the HTRF ratios at different doses and fitted to a 4-parameter logistic curve to determine IC₅₀ values (see Table 1).

Effector memory T cells IL-2 release assay

Test compound-mediated inhibition of NFκB signalling in T cells was assessed by quantification of the IL-2 secretion by human effector memory T cells (TEM) upon treatment and stimulation. Human TEM cells were isolated from buffy coats of healthy donors obtained from the French blood bank. First, peripheral blood mononuclear cells (PBMC) were purified from buffy coats diluted 1:1 with DPBS (Gibco, cat# 14190-094) by Pancoll (PAN BIOTECH, cat#P04-60500) density gradient centrifugation at 400 x g for 20 minutes. TEM cells were further enriched by negative immuno-magnetic cell sorting using a human CD4+ Effector Memory T Cell Isolation Kit (Miltenyi, cat#130-094-125) according to the manufacturer's instructions. Aliquots of 3 x 10⁶ purified TEM cells were kept frozen in Cryo-SFM medium (PromoCell, cat#C-29912) in gas phase nitrogen until used. Cell purity was verified by flow cytometry analysis of 200 000 PFA-fixed cells previously labelled with monoclonal antibodies anti-CD4-PerCP-Cy5.5 (BD Pharmigen, cat#332772), anti-CD8-V500 (BD Biosciences, cat#561617), anti-CD14-Pacific Blue (Biolegend, cat#325616), anti-CD45 RA-FITC (Biolegend, cat#304106) and anti-CCR7-APC (in CD4+ Effector Memory T Cell Isolation Kit, Miltenyi, cat#130-094-125).

TEM cells were resuspended in complete RPMI medium composed of: RPMI 1640 (Gibco, cat#31870-025), 10 % heat inactivated fetal bovine serum (Sigma, cat#F7524), 2 mM GlutaMAX (Gibco, cat#35050-038), 1 mM sodium pyruvate 100X (Gibco, cat#11360-039), 1 % MEM non-essential amino acids solution (Gibco, cat#11140-035) and 100 U/mL penicillin, 100 µg/mL streptomycin (Sigma-Aldrich, cat#11074440001). 5,000 cells per well were plated onto flat clear bottom 384 well plates (Corning, cat#3770). 5,000 Dynabeads Human T-Activator CD3/CD28

- (Gibco, cat#11132D) were added to each well for cell stimulation. Finally, 10 doses of test compound, originally prepared in DMSO by serial semi-log step dilution, were also added to cells in triplicate wells. Final DMSO concentration in wells was 0.1% in a total volume of 100 μ L complete medium. Plates were incubated for 24 h at 37°C in 5% CO₂ atmosphere. After incubation, cell suspensions were centrifuged at 400 x g and culture supernatants were recovered and stored at -80°C. Cell viability was assessed by flow cytometry after staining the cells with Fixable Viability Dye eFluor 780 (Invitrogen, cat# 65-0865-14). IL-2 levels were determined in cell supernatants using an HTRF human IL-2 detection kit (Cisbio, cat# 62HIL02PEH). IL-2 data at the different compound doses were fitted to a 4-parameter logistic curve to determine IC₅₀ values, corresponding to the compound concentration leading to 50% reduction of the maximal IL-2 levels observed in each experiment. Viability data were analysed similarly to exclude cytotoxicity as a cause of IL-2 decrease (see Table 1).

Example no.	PKC-theta HTRF pIC50	PKC-theta HTRF pIC50 (binned)	PKC-theta IL2 pIC50	PKC-theta IL2 pIC50 (binned)	PKC-theta/ PKC-delta selectivity	PKC-theta/ PKC-delta selectivity (binned)
1	6.1	G	5.5	G	1	G
2	5.1	H	5.0	G	0.2	G
3	6.7	F	5.2	G	1	F
4	6.0	H	5.4	G	2	F
5	7.1	E	6.9	E	1	F
6	7.4	E	6.2	F	3	F
7	7.4	E	6.3	F	6	E
8	8.1	C	6.9	E	5	E
9	8.7	B	7.4	D	15	D
10	7.4	E	6.2	F	12	D
11	7.2	E	5.8	G	4	F
12	8.1	C	6.7	E	11	D
13	7.4	E	6.2	F	4	F
14	8.5	C	7.3	D	3	F
15	8.6	B	7.4	D	14	D
16	8.3	C	7.2	D	18	D
17	8.0	D	6.4	F	7	E
18	7.9	D	6.5	F	11	D
19	8.4	C	7.3	D	9	E
20	7.8	D	6.7	E	13	D
21	7.3	E	6.0	G	9	E
22	8.0	C	6.5	F	15	D

23	9.3	A	7.5	C	11	D
24	8.4	C	7.2	D	9	E
25	9.3	A	7.7	C	6	E
26	8.5	C	7.1	D	11	D
27	7.3	E	5.8	G	5	E
28	8.7	B	7.5	C	15	D
29	9.4	A	7.4	D	24	C
30	8.9	B	7.3	D	14	D
31	8.9	B	7.4	D	22	C
32	8.1	C	7.0	E	13	D
33	8.5	B	7.2	D	22	C
34	8.8	B	7.4	D	12	D
35	8.5	C	7.0	D	11	D
36	8.3	C	6.9	E	14	D
37	8.6	B	7.6	C	19	D
38	8.9	B	7.7	C	16	D
39	9.7	A	8.0	B	10	E
40	9.7	A	7.8	C	17	D
41	9.4	A	7.8	C	14	D
42	7.6	D	6.4	F	N/D	N/D
43	8.1	C	6.5	F	11	D
44	7.5	E	6.6	E	14	D
45	7.4	E	6.0	G	15	D
46	8.2	C	6.8	E	3	F
47	9.2	A	7.6	C	12	D
48	6.5	F	6.1	F	33	B
49	8.2	C	6.5	E	3	F
50	9.1	A	7.7	C	11	D
51	9.3	A	7.8	C	11	D
52	8.4	C	7.4	D	8	E
53	8.3	C	7.0	D	13	D
54	8.6	B	7.1	D	22	C
55	8.2	C	6.8	E	4	F
56	8.7	B	7.3	D	15	D
57	8.9	B	7.3	D	14	D
58	9.3	A	8.0	C	18	D
59	9.2	A	7.7	C	11	D
60	8.4	C	7.0	E	8	E
61	8.7	B	7.3	D	16	D
62	9.5	A	8.8	A	3	F
63	7.5	D	5.9	G	17	D

64	8.6	B	7.1	D	28	C
65	7.3	E	6.4	F	28	C
66	8.4	C	7.0	D	21	C
67	7.5	E	6.4	F	9	E
68	9.6	A	8.0	C	12	D
69	7.0	E	5.9	G	9	E
70	8.1	C	6.9	E	20	C
71	8.1	C	6.9	E	22	C
72	7.9	D	6.7	E	20	D
73	7.5	D	6.2	F	10	D
74	6.5	F	6.2	F	33	B
75	8.7	B	7.3	D	19	D
76	8.5	B	7.0	D	22	C
77	9.0	A	7.9	C	11	D
78	9.0	A	7.3	D	10	D
79	8.9	B	7.3	D	15	D
80	9.1	A	7.7	C	9	E
81	7.5	E	6.1	F	20	C
82	9.1	A	7.3	D	12	D
83	8.8	B	7.2	D	13	D
84	7.5	E	5.9	G	14	D
85	7.3	E	5.9	G	10	E
86	7.5	D	5.9	G	26	C
87	9.0	A	7.3	D	38	B
88	8.4	C	6.7	E	14	D
89	8.6	B	7.1	D	32	B
90	9.0	A	7.8	C	11	D
91	8.1	C	6.9	E	19	D
92	7.9	D	6.8	E	15	D
93	8.4	C	7.3	D	10	E
94	8.4	C	6.9	E	23	C
95	9.9	A	8.8	A	25	C
96	8.7	B	7.6	C	17	D
97	8.6	B	7.4	D	23	C
98	7.5	D	6.0	G	57	A
99	7.0	E	6.4	F	105	A
100	8.1	C	7.0	D	29	C
101	7.6	D	6.2	F	42	B
102	8.2	C	N/D	N/D	46	B
103	8.6	B	7.2	D	22	C
104	9.1	A	7.9	C	17	D

105	7.9	D	6.4	F	33	B
106	9.1	A	7.9	C	15	D
107	7.7	D	6.2	F	23	C
108	8.5	B	7.3	D	17	D
109	7.7	D	6.3	F	11	D
110	7.6	D	6.0	G	29	C
111	8.0	D	6.4	F	7	E
112	8.5	B	7.2	D	22	C

Table 2: Biochemical data for representative compounds of the disclosure. In the columns indicated, the data has been binned in a category of A to H as indicated below dependent on the measured value.

5

For PKC- θ HTRF:

A means a measured pIC₅₀ of 9.0 and above;

B means a measured pIC₅₀ of between 8.5 and 9.0;

C means a measured pIC₅₀ of between 8.0 and 8.5;

10

D means a measured pIC₅₀ of between 7.5 and 8.0;

E means a measured pIC₅₀ of between 7.0 and 7.5;

F means a measured pIC₅₀ of between 6.5 and 7.0;

G means a measured pIC₅₀ of between 6.0 and 6.5;

H means a measured pIC₅₀ of <6.0.

15

For PKC- θ CD4Tc IL-2:

A means a measured pIC₅₀ of between 8.5 and 9.0;

B means a measured pIC₅₀ of between 8.0 and 8.5;

C means a measured pIC₅₀ of between 7.5 and 8.0;

20

D means a measured pIC₅₀ of between 7.0 and 7.5;

E means a measured pIC₅₀ of between 6.5 and 7.0;

F means a measured pIC₅₀ of between 6.0 and 6.5;

G means a measured pIC₅₀ of <6.0.

25 For PKC- θ /PKC- δ selectivity:

A means a ratio of between 50 and 120;

B means a ratio of between 30 and 50;

C means a ratio of between 20 and 30;

D means a ratio of between 10 and 20;

30

E means a ratio of between 5 and 10;


F means a ratio of between 1 and 5;

G means a ratio of between 0 and 1.

- 5 Modifications may be made to the above examples without departing from the scope of the present invention as defined in the accompanying claims.

CLAIMS

1. A compound having the structural Formula I:



I

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers, tautomer, or isotopic form, or pharmaceutically active metabolite thereof, or combinations thereof, wherein:

A is selected from the group consisting of: N, C-R^a, where R^a is selected from hydrogen, halogen, C1-3 alkyl and CN;

G is selected from the group consisting of: CR₁R₂; O and NR₁;

R₁ and R₂ are independently selected from the group consisting of: hydrogen, halogen, C1-3 alkyl; C3-7 cycloalkyl; C1-3 alkoxy; C2-6 cycloalkoxy; C2-6 alkyl alkoxy; hydroxyl, C1-3 alkyl hydroxyl; amino, C1-3 alkyl amino; C1-4 amino alkyl; C2-7 alkyl amino alkyl; and C1-3 haloalkyl; or

R₁ and R₂ together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring;


B is selected from the group consisting of: N; C-H and C-halogen;

D is selected from the group consisting of: N; and C-R₃;

R₃ is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 halo alkyl; C1-3 alkoxy; C2-5 alkyl alkoxy; and halogen;

R₄ is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 halo alkyl; OMe; and halogen; or

wherein when D is C-R₃, R₃ and R₄ together are joined to form an optionally substituted aryl or heteroaryl ring having the structure selected from the group consisting of:



wherein;

R7 is selected from the group consisting of: hydrogen; and halogen;

R8 is selected from the group consisting of: hydrogen; and halogen;

R9 is selected from the group consisting of: hydrogen; C1-3 halo alkyl; and halogen;


R10 is selected from the group consisting of: hydrogen; halogen; C1-3 halo alkyl; C1-3 haloalkoxy; and wherein:

n is selected from the group consisting of: 0; and 1;

E is selected from the group consisting of: C-H; and C-R^a, where R^a is selected from halogen; C1-3 alkyl; C1-3 alkyl hydroxy; C1-3 haloalkyl; C2-6 alkyl alkoxy and C1-3 alkyl nitrile;


R5 and R6 are joined together to form an optionally substituted, optionally bridged, 4-8-membered saturated carbocyclic or heterocyclic ring.

2. The compound of Claim 1, having the structural Formula II:




II

3. The compound of Claim 1 or Claim 2, having the structural Formula IIa:



IIa

wherein, R17 is selected from the group consisting of:



wherein

R11 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;

R12 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxyl; and C1-2 alkyl nitrile;

R13 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;

R14 is selected from the group consisting of: hydrogen and C1-2 alkyl;

R15 is selected from the group consisting of: hydrogen and C1-2 alkyl;

R16 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxy; and C1-3 alkyl alkoxy;

n is selected from the group consisting of: 0 and 1;

p is selected from the group consisting of: 1 and 2;

X is selected from the group consisting of: CH₂ and O;

Y is selected from the group consisting of: CH₂; O; NH and NMe.

4. The compound of Claim 3, wherein:

R1 is selected from the group consisting of: hydrogen, Me, Et, OMe, OEt, OH, NH₂, NHMe and NH₂Et;

R2 is selected from the group consisting of: hydrogen, Me and Et; or


R1 and R2 together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring; particularly a 4-5 membered optionally substituted carbocyclic or heterocyclic spiro ring; wherein in embodiments the carbocyclic or heterocyclic spiro ring is unsubstituted; wherein in alternative embodiments the carbocyclic or heterocyclic spiro ring is substituted with one or more

substituents selected from the group consisting of: C1-2 alkyl, halogen; C1-2 haloalkyl; hydroxyl; and C1-2 alkoxy;

A is selected from the group consisting of: C-H; C-F; C-Cl and C-Br;

B is selected from the group consisting of: N; C-H, C-F; C-Cl and C-Br;

R17 is selected from the group consisting of:



wherein:

R18 is selected from the group consisting of: hydrogen; and halogen;

R19 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxy;

m is selected from the group consisting of: 0 and 1;

R20 is selected from the group consisting of: hydrogen; halogen;


X is selected from the group consisting of: CH₂ and O;

R21 and R22 are each independently selected from the group consisting of: hydrogen and C1-3 alkyl;

Y is selected from the group consisting of: CH₂; O and NH;

R23 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl.

5. The compound of Claim 1, having the structural Formula III:



III


wherein;

D is selected from the group consisting of: N; C-H and C-R3;


R3 is selected from the group consisting of: C1-3 alkyl; C2-5 alkyl alkoxy; C1-3 haloalkyl and halogen;

R4 is selected from the group consisting of: hydrogen; C1-3 alkyl; C2-5 alkyl alkoxy; C1-3 haloalkyl and halogen.


6. The compound of Claim 5, having the structural Formula IIIa, IIIb or IIIc:



IIIa




IIIb



IIIc

wherein,

R17 is selected from the group consisting of:



wherein

R11 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;

R12 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxyl; and C1-2 alkyl nitrile;

R13 is selected from the group consisting of: hydrogen; halogen and C1-2 alkyl;

R14 is selected from the group consisting of: hydrogen and C1-2 alkyl;


R15 is selected from the group consisting of: hydrogen and C1-2 alkyl;

R16 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl hydroxyl; and C1-3 alkyl alkoxy;

n is selected from the group consisting of: 0 and 1;
 p is selected from the group consisting of: 1 and 2;
 X is selected from the group consisting of: CH₂ and O;
 Y is selected from the group consisting of: CH₂, O, NH and NMe.

7. The compound of Claim 6, wherein:

R1 is selected from the group consisting of: hydrogen, Me, Et, OMe, OH, NH₂, and NHMe;
 R2 is selected from the group consisting of: hydrogen; Me; and Et; or
 R1 and R2 together form a 3-5 membered optionally substituted spiro carbocyclic or heterocyclic ring;
 A is selected from the group consisting of: C-H, C-F, C-Cl and C-Br;
 R17 is selected from the group consisting of:



wherein:

R18 is selected from the group consisting of: hydrogen and halogen;
 R19 is selected from the group consisting of: hydrogen; C1-3 alkyl; C1-3 haloalkyl; C1-3 alkyl and hydroxyl;
 m is selected from the group consisting of: 0 and 1;
 R20 is selected from the group consisting of: hydrogen and halogen;
 X is selected from the group consisting of: CH₂; and O;
 R21 and R22 are each independently selected from the group consisting of: hydrogen and C1-3 alkyl;
 Y is selected from the group consisting of: CH₂; O and NH;
 R23 is selected from the group consisting of: hydrogen; C1-3 alkyl; and C1-3 haloalkyl.

8. A compound according to Table 1, or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers, tautomer, isotopic form, or pharmaceutically active metabolite thereof, or combinations thereof.
9. A pharmaceutical composition comprising a compound of any of Claims 1 to 8 or a pharmaceutically acceptable salt, solvate, stereoisomer or mixture of stereoisomers, tautomer, or isotopic form, or pharmaceutically active metabolite thereof, or combinations thereof, and one or more pharmaceutically acceptable carrier.
10. The compound of any of Claim 1 to 8 or the pharmaceutical composition of Claim 9 for use in the treatment of a disorder or disease selected from autoimmune disorders and/or inflammatory diseases and/or oncologic disease and/or cancers and/or HIV infection and replication.
11. The compound or pharmaceutical composition for use according to Claim 10, wherein the disorder or disease is selected from the group consisting of: rheumatoid arthritis, multiple sclerosis, psoriasis, atopic dermatitis.
12. The compound or pharmaceutical composition for use according to Claim 10 or Claim 11, wherein the compound is an inhibitor of PKC-theta.
13. The compound or pharmaceutical composition for use according to any of Claims 10 to 12, wherein the use is in a method comprising administering the compound orally, topically, by inhalation, by intranasal administration, or systemically by intravenous, intraperitoneal, subcutaneous, or intramuscular injection.
14. The compound or pharmaceutical composition for use according to any of Claims 10 to 13, wherein the use is in a method comprising administering the compound according to any one of Claims 1 to 8 in combination with one or more additional therapeutic agent.
15. The compound or pharmaceutical composition for use according to Claims 14, wherein the administering comprises administering the compound according to any one of Claims 1 to 8 simultaneously, sequentially or separately from the one or more additional therapeutic agents.
16. The compound or pharmaceutical composition for use according to any of Claims 10 to 15, which comprises administering to a subject an effective amount of the compound according to any one of Claims 1 to 8, wherein the effective amount is between about 5 nM and about 10 μ M in the blood of the subject.